NZ725576B2 - Method of treating lung adenocarcinoma - Google Patents
Method of treating lung adenocarcinoma Download PDFInfo
- Publication number
- NZ725576B2 NZ725576B2 NZ725576A NZ72557615A NZ725576B2 NZ 725576 B2 NZ725576 B2 NZ 725576B2 NZ 725576 A NZ725576 A NZ 725576A NZ 72557615 A NZ72557615 A NZ 72557615A NZ 725576 B2 NZ725576 B2 NZ 725576B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- ros1
- fusion
- compound
- slc34a2
- protein
- Prior art date
Links
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 title claims abstract description 40
- 201000005249 lung adenocarcinoma Diseases 0.000 title claims abstract description 40
- 102100002050 ROS1 Human genes 0.000 claims abstract description 404
- 101710027587 ROS1 Proteins 0.000 claims abstract description 350
- 101700054115 ROS1A Proteins 0.000 claims abstract description 350
- 230000004927 fusion Effects 0.000 claims abstract description 328
- 150000001875 compounds Chemical class 0.000 claims abstract description 274
- 239000011780 sodium chloride Substances 0.000 claims abstract description 124
- 150000003839 salts Chemical class 0.000 claims abstract description 117
- 150000004701 malic acid derivatives Chemical class 0.000 claims description 44
- 239000002146 L01XE16 - Crizotinib Substances 0.000 claims description 43
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 27
- 229960005277 gemcitabine Drugs 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 23
- 210000004072 Lung Anatomy 0.000 claims description 20
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 13
- 229960003668 docetaxel Drugs 0.000 claims description 13
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 claims description 12
- 229960004562 Carboplatin Drugs 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000000546 pharmaceutic aid Substances 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 125000001475 halogen functional group Chemical group 0.000 claims 4
- 201000011510 cancer Diseases 0.000 abstract description 89
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 abstract description 84
- 108009000071 Non-small cell lung cancer Proteins 0.000 abstract description 79
- 230000002401 inhibitory effect Effects 0.000 abstract description 51
- 239000003112 inhibitor Substances 0.000 abstract description 30
- 102100013180 KDR Human genes 0.000 abstract description 2
- 101710030888 KDR Proteins 0.000 abstract description 2
- 108020001507 fusion proteins Proteins 0.000 description 172
- 102000037240 fusion proteins Human genes 0.000 description 172
- 229920000023 polynucleotide Polymers 0.000 description 150
- 239000002157 polynucleotide Substances 0.000 description 150
- 239000000523 sample Substances 0.000 description 141
- 210000004027 cells Anatomy 0.000 description 88
- 229920001184 polypeptide Polymers 0.000 description 88
- 102100005556 SLC34A2 Human genes 0.000 description 87
- 108091006491 SLC34A2 Proteins 0.000 description 86
- 239000000203 mixture Substances 0.000 description 76
- 150000007523 nucleic acids Chemical class 0.000 description 69
- 108020004707 nucleic acids Proteins 0.000 description 60
- 102100018480 GOPC Human genes 0.000 description 50
- 101700071882 GOPC Proteins 0.000 description 50
- -1 L-malate salt Chemical class 0.000 description 48
- 108090001123 antibodies Proteins 0.000 description 48
- 102000004965 antibodies Human genes 0.000 description 48
- 235000001014 amino acid Nutrition 0.000 description 46
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 46
- 108091000081 Phosphotransferases Proteins 0.000 description 44
- 102000001253 Protein Kinases Human genes 0.000 description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 44
- 102000004169 proteins and genes Human genes 0.000 description 43
- 108090000623 proteins and genes Proteins 0.000 description 43
- 150000001413 amino acids Chemical class 0.000 description 41
- 230000002759 chromosomal Effects 0.000 description 41
- 238000001514 detection method Methods 0.000 description 40
- 235000018102 proteins Nutrition 0.000 description 40
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 39
- 229920000665 Exon Polymers 0.000 description 38
- 201000005202 lung cancer Diseases 0.000 description 38
- 239000000243 solution Substances 0.000 description 36
- 230000000694 effects Effects 0.000 description 35
- KTEIFNKAUNYNJU-GFCCVEGCSA-N Crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 32
- 239000002585 base Substances 0.000 description 32
- 229960005061 crizotinib Drugs 0.000 description 32
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 31
- 239000003826 tablet Substances 0.000 description 29
- 239000012458 free base Substances 0.000 description 27
- 239000002253 acid Substances 0.000 description 26
- 238000002360 preparation method Methods 0.000 description 26
- 239000002775 capsule Substances 0.000 description 23
- 125000003275 alpha amino acid group Chemical group 0.000 description 22
- 201000010099 disease Diseases 0.000 description 22
- 238000000034 method Methods 0.000 description 22
- 230000000295 complement Effects 0.000 description 21
- 238000009396 hybridization Methods 0.000 description 21
- 230000035772 mutation Effects 0.000 description 21
- 239000000047 product Substances 0.000 description 20
- 239000000126 substance Substances 0.000 description 20
- 229920001405 Coding region Polymers 0.000 description 19
- 229920001850 Nucleic acid sequence Polymers 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 19
- 238000007901 in situ hybridization Methods 0.000 description 19
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 18
- 108020004999 Messenger RNA Proteins 0.000 description 17
- 230000014509 gene expression Effects 0.000 description 17
- 229920002106 messenger RNA Polymers 0.000 description 17
- 239000002773 nucleotide Substances 0.000 description 17
- 125000003729 nucleotide group Chemical group 0.000 description 17
- 238000004166 bioassay Methods 0.000 description 16
- 239000007787 solid Substances 0.000 description 15
- UZMWMNNHLOWIKU-UHFFFAOYSA-N FC1=CC=C(C=C1)NC(=O)C1(CC1)C(=O)NC1=CC=C(C=C1)OC1=NC2=CC(=C(C=C2C=C1)OC)OC Chemical compound FC1=CC=C(C=C1)NC(=O)C1(CC1)C(=O)NC1=CC=C(C=C1)OC1=NC2=CC(=C(C=C2C=C1)OC)OC UZMWMNNHLOWIKU-UHFFFAOYSA-N 0.000 description 14
- 230000003321 amplification Effects 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 210000001519 tissues Anatomy 0.000 description 14
- 238000007792 addition Methods 0.000 description 13
- 238000003199 nucleic acid amplification method Methods 0.000 description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- XHXFXVLFKHQFAL-UHFFFAOYSA-N Phosphoryl chloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 12
- 230000010261 cell growth Effects 0.000 description 12
- 238000002509 fluorescent in situ hybridization Methods 0.000 description 12
- 239000008194 pharmaceutical composition Substances 0.000 description 12
- 210000000349 Chromosomes Anatomy 0.000 description 11
- 210000003917 Chromosomes, Human Anatomy 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- 230000002159 abnormal effect Effects 0.000 description 11
- 125000005843 halogen group Chemical group 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 10
- 229920002676 Complementary DNA Polymers 0.000 description 10
- 230000000692 anti-sense Effects 0.000 description 10
- 239000002299 complementary DNA Substances 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 10
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- 241000124008 Mammalia Species 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 9
- 239000002246 antineoplastic agent Substances 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
- 239000000969 carrier Substances 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 150000002500 ions Chemical class 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 201000010874 syndrome Diseases 0.000 description 9
- 241000282412 Homo Species 0.000 description 8
- 229920000272 Oligonucleotide Polymers 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 239000001257 hydrogen Substances 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 8
- 229940121358 tyrosine kinase inhibitors Drugs 0.000 description 8
- FXHOOIRPVKKKFG-UHFFFAOYSA-N DMA Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 7
- 238000001574 biopsy Methods 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- 229940079593 drugs Drugs 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 7
- 238000011144 upstream manufacturing Methods 0.000 description 7
- 238000005292 vacuum distillation Methods 0.000 description 7
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-Aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 6
- 206010069754 Acquired gene mutation Diseases 0.000 description 6
- 208000009956 Adenocarcinoma Diseases 0.000 description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 6
- 229940035295 Ting Drugs 0.000 description 6
- 230000003213 activating Effects 0.000 description 6
- 239000012472 biological sample Substances 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000001404 mediated Effects 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 5
- JQWTVIFNRAALHM-UHFFFAOYSA-N 1-[(4-fluorophenyl)carbamoyl]cyclopropane-1-carbonyl chloride Chemical compound C1=CC(F)=CC=C1NC(=O)C1(C(Cl)=O)CC1 JQWTVIFNRAALHM-UHFFFAOYSA-N 0.000 description 5
- NWNVXBNGKWBZGF-UHFFFAOYSA-N 4-(6,7-dimethoxyquinolin-2-yl)oxyaniline Chemical compound N1=C2C=C(OC)C(OC)=CC2=CC=C1OC1=CC=C(N)C=C1 NWNVXBNGKWBZGF-UHFFFAOYSA-N 0.000 description 5
- WOVKYSAHUYNSMH-RRKCRQDMSA-N Bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 229940116298 L- MALIC ACID Drugs 0.000 description 5
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 description 5
- 229910019213 POCl3 Inorganic materials 0.000 description 5
- 101000428716 ROS1 Proteins 0.000 description 5
- 102100003571 SDC4 Human genes 0.000 description 5
- 150000001408 amides Chemical group 0.000 description 5
- 125000004429 atoms Chemical group 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 229960001292 cabozantinib Drugs 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 230000003247 decreasing Effects 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 239000007850 fluorescent dye Substances 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 102000024256 human ROS1 protein Human genes 0.000 description 5
- 238000003364 immunohistochemistry Methods 0.000 description 5
- 235000011090 malic acid Nutrition 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 235000015320 potassium carbonate Nutrition 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- WRVHQEYBCDPZEU-UHFFFAOYSA-N 4-chloro-6,7-dimethoxyquinoline Chemical compound C1=CC(Cl)=C2C=C(OC)C(OC)=CC2=N1 WRVHQEYBCDPZEU-UHFFFAOYSA-N 0.000 description 4
- 229920002395 Aptamer Polymers 0.000 description 4
- 230000036912 Bioavailability Effects 0.000 description 4
- 210000004369 Blood Anatomy 0.000 description 4
- 229960001681 Croscarmellose Sodium Drugs 0.000 description 4
- 229920002785 Croscarmellose sodium Polymers 0.000 description 4
- 230000004544 DNA amplification Effects 0.000 description 4
- 102100010782 EGFR Human genes 0.000 description 4
- 101700039191 EGFR Proteins 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N MeOtBu Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N Oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 4
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 4
- 102100006051 RET Human genes 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N Thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 230000001594 aberrant Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- 230000035514 bioavailability Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000000875 corresponding Effects 0.000 description 4
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 4
- FDKLLWKMYAMLIF-UHFFFAOYSA-N cyclopropane-1,1-dicarboxylic acid Chemical compound OC(=O)C1(C(O)=O)CC1 FDKLLWKMYAMLIF-UHFFFAOYSA-N 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 230000002068 genetic Effects 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000002609 media Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000001105 regulatory Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 230000001225 therapeutic Effects 0.000 description 4
- PFMAFXYUHZDKPY-UHFFFAOYSA-N 1-[(4-fluorophenyl)carbamoyl]cyclopropane-1-carboxylic acid Chemical compound C=1C=C(F)C=CC=1NC(=O)C1(C(=O)O)CC1 PFMAFXYUHZDKPY-UHFFFAOYSA-N 0.000 description 3
- ONIQOQHATWINJY-UHFFFAOYSA-N Cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 description 3
- 102100015167 EZR Human genes 0.000 description 3
- FUZZWVXGSFPDMH-UHFFFAOYSA-N Hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 241000229754 Iva xanthiifolia Species 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 3
- 206010061289 Metastatic neoplasm Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N P-Toluenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 229940072417 Peroxidase Drugs 0.000 description 3
- 108090000437 Peroxidases Proteins 0.000 description 3
- 102000003992 Peroxidases Human genes 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 239000007759 RPMI Media 1640 Substances 0.000 description 3
- 101700072640 SDC4 Proteins 0.000 description 3
- 210000002966 Serum Anatomy 0.000 description 3
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 description 3
- 108020004459 Small Interfering RNA Proteins 0.000 description 3
- 206010041067 Small cell lung cancer Diseases 0.000 description 3
- 102100009301 TPM3 Human genes 0.000 description 3
- 101700003022 TPM3 Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000000240 adjuvant Effects 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 230000000903 blocking Effects 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 230000001394 metastastic Effects 0.000 description 3
- 238000010208 microarray analysis Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000001184 potassium carbonate Substances 0.000 description 3
- OFPTZWGZSRJCOT-MSPNRCMCSA-M potassium;2-[(1S,2S,3R,4S,5S,6R)-3-(diaminomethylideneamino)-4-[(2R,3R,4R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine;(2S,5R,6R)-3,3-d Chemical compound [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O OFPTZWGZSRJCOT-MSPNRCMCSA-M 0.000 description 3
- 230000003389 potentiating Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrugs Drugs 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 102000027656 receptor tyrosine kinases Human genes 0.000 description 3
- 108091007921 receptor tyrosine kinases Proteins 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 239000002924 silencing RNA Substances 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N (E)-but-2-enedioate;hydron Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-Lutidine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 2
- YQEMORVAKMFKLG-UHFFFAOYSA-N 2-stearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- KRZCOLNOCZKSDF-UHFFFAOYSA-N 4-fluoroaniline Chemical compound NC1=CC=C(F)C=C1 KRZCOLNOCZKSDF-UHFFFAOYSA-N 0.000 description 2
- YCIOUNSWHDKEBM-UHFFFAOYSA-N 6,7-dimethoxy-1H-quinolin-2-one Chemical compound C1=CC(=O)NC2=C1C=C(OC)C(OC)=C2 YCIOUNSWHDKEBM-UHFFFAOYSA-N 0.000 description 2
- 230000035533 AUC Effects 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N Benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 210000001124 Body Fluids Anatomy 0.000 description 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
- 102100004099 CD74 Human genes 0.000 description 2
- 101710007476 CD74 Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 208000006990 Cholangiocarcinoma Diseases 0.000 description 2
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 2
- 229940034568 Cometriq Drugs 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N DATI Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 238000000018 DNA microarray Methods 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 102100016662 ERBB2 Human genes 0.000 description 2
- 101700025368 ERBB2 Proteins 0.000 description 2
- 229940088598 Enzyme Drugs 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 230000036826 Excretion Effects 0.000 description 2
- FJXZHNKTSLZODE-UHFFFAOYSA-N FC1=CC=C(C=C1)[NH-] Chemical compound FC1=CC=C(C=C1)[NH-] FJXZHNKTSLZODE-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- 208000005017 Glioblastoma Diseases 0.000 description 2
- 229920002277 Glycol nucleic acid Polymers 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N L-serine Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 102100003884 LRIG3 Human genes 0.000 description 2
- 101700041876 LRIG3 Proteins 0.000 description 2
- 230000036650 Metabolic stability Effects 0.000 description 2
- TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Natural products OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 2
- 229960005190 Phenylalanine Drugs 0.000 description 2
- 102000003993 Phosphatidylinositol 3-Kinases Human genes 0.000 description 2
- 108090000430 Phosphatidylinositol 3-Kinases Proteins 0.000 description 2
- 229940068917 Polyethylene Glycols Drugs 0.000 description 2
- WFIZEGIEIOHZCP-UHFFFAOYSA-M Potassium formate Chemical compound [K+].[O-]C=O WFIZEGIEIOHZCP-UHFFFAOYSA-M 0.000 description 2
- 208000006265 Renal Cell Carcinoma Diseases 0.000 description 2
- 101000195212 SLC34A2 Proteins 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-CTQIIAAMSA-N Sorbitan Chemical compound OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 108010055215 Syndecan-4 Proteins 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 229940116362 Tragacanth Drugs 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- HWKQNAWCHQMZHK-UHFFFAOYSA-N Trolnitrate Chemical compound [O-][N+](=O)OCCN(CCO[N+]([O-])=O)CCO[N+]([O-])=O HWKQNAWCHQMZHK-UHFFFAOYSA-N 0.000 description 2
- 229940049068 Xalkori Drugs 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 230000002378 acidificating Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000003139 buffering Effects 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- HFCFMRYTXDINDK-WNQIDUERSA-N cabozantinib malate Chemical compound OC(=O)[C@@H](O)CC(O)=O.C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 HFCFMRYTXDINDK-WNQIDUERSA-N 0.000 description 2
- 101700018328 ccdB Proteins 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229960004106 citric acid Drugs 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 230000002255 enzymatic Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 102000038540 human SLC34A2 protein Human genes 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 230000002055 immunohistochemical Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229940011051 isopropyl acetate Drugs 0.000 description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-M isovalerate Chemical compound CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 2
- 230000003902 lesions Effects 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 201000005244 lung non-small cell carcinoma Diseases 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 208000009018 medullary Thyroid cancer Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 230000000051 modifying Effects 0.000 description 2
- 108010045030 monoclonal antibodies Proteins 0.000 description 2
- 102000005614 monoclonal antibodies Human genes 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N n-butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- OIPZNTLJVJGRCI-UHFFFAOYSA-M octadecanoyloxyaluminum;dihydrate Chemical compound O.O.CCCCCCCCCCCCCCCCCC(=O)O[Al] OIPZNTLJVJGRCI-UHFFFAOYSA-M 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 125000003431 oxalo group Chemical group 0.000 description 2
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 230000002335 preservative Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 238000001711 protein immunostaining Methods 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 2
- 229920002033 ribozyme Polymers 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- CGRKYEALWSRNJS-UHFFFAOYSA-N sodium;2-methylbutan-2-olate Chemical compound [Na+].CCC(C)(C)[O-] CGRKYEALWSRNJS-UHFFFAOYSA-N 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 230000000392 somatic Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cells Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- GXMBHQRROXQUJS-UHFFFAOYSA-N (2-hept-2-ynylsulfanylphenyl) acetate Chemical compound CCCCC#CCSC1=CC=CC=C1OC(C)=O GXMBHQRROXQUJS-UHFFFAOYSA-N 0.000 description 1
- KWMLJOLKUYYJFJ-AIECOIEWSA-N (2R,3R,4R,5S,6R)-2,3,4,5,6,7-hexahydroxyheptanoic acid Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-AIECOIEWSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N (2S)-2-acetamido-N-[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-4-methylpentanamide Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- PSLCKQYQNVNTQI-BHFSHLQUSA-N (2S)-2-aminobutanedioic acid;(2S)-2-aminopentanedioic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O.OC(=O)[C@@H](N)CCC(O)=O PSLCKQYQNVNTQI-BHFSHLQUSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UWTATZPHSA-L (R)-malate(2-) Chemical class [O-]C(=O)[C@H](O)CC([O-])=O BJEPYKJPYRNKOW-UWTATZPHSA-L 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2R,4S,5R)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 1
- AZGGNLGPTXHLRL-UHFFFAOYSA-N 1-pyrazol-1-ylpiperidine Chemical compound C1CCCCN1N1N=CC=C1 AZGGNLGPTXHLRL-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- XLZYKTYMLBOINK-UHFFFAOYSA-N 3-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C(=O)C=2C=CC(O)=CC=2)=C1 XLZYKTYMLBOINK-UHFFFAOYSA-N 0.000 description 1
- VXEQRXJATQUJSN-UHFFFAOYSA-N 4-(6,7-dimethoxyquinolin-4-yl)oxyaniline Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC1=CC=C(N)C=C1 VXEQRXJATQUJSN-UHFFFAOYSA-N 0.000 description 1
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-Aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-Nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- RJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 description 1
- YJISHJVIRFPGGN-UHFFFAOYSA-N 5-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy-6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)O)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 YJISHJVIRFPGGN-UHFFFAOYSA-N 0.000 description 1
- IRECQXWRHWPICF-UHFFFAOYSA-N 6,7-dimethyl-4-(4-nitrophenoxy)quinoline Chemical compound C=12C=C(C)C(C)=CC2=NC=CC=1OC1=CC=C([N+]([O-])=O)C=C1 IRECQXWRHWPICF-UHFFFAOYSA-N 0.000 description 1
- 101710026772 66 Proteins 0.000 description 1
- 102100011141 ALK Human genes 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N Aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 108010005474 Anaplastic Lymphoma Kinase Proteins 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 229960000686 Benzalkonium Chloride Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N Benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N Bis-tris methane Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000033243 CDKN2A Human genes 0.000 description 1
- 241000220450 Cajanus cajan Species 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L Calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N Camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- OSASVXMJTNOKOY-UHFFFAOYSA-N Chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 1
- 229960004926 Chlorobutanol Drugs 0.000 description 1
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N Cypionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N DCM Dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- UZZWBUYVTBPQIV-UHFFFAOYSA-N DME dimethoxyethane Chemical compound COCCOC.COCCOC UZZWBUYVTBPQIV-UHFFFAOYSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N DMSO dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 108020001019 DNA Primers Proteins 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K Dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- RCJVRSBWZCNNQT-UHFFFAOYSA-N Dichlorine monoxide Chemical compound ClOCl RCJVRSBWZCNNQT-UHFFFAOYSA-N 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 101700045840 ECT Proteins 0.000 description 1
- 101710040068 EZR Proteins 0.000 description 1
- 241000083551 Ena Species 0.000 description 1
- 229960001433 Erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N Erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N Ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N Ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N Ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 101000071506 GOPC Proteins 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N Gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229960002989 Glutamic Acid Drugs 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229940093915 Gynecological Organic acids Drugs 0.000 description 1
- 229940031574 HYDROXYMETHYL CELLULOSE Drugs 0.000 description 1
- 206010073071 Hepatocellular carcinoma Diseases 0.000 description 1
- 210000000987 Immune System Anatomy 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N Iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 229940036571 Iodine therapy Drugs 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N Isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 102000010638 Kinesin Human genes 0.000 description 1
- 108010063296 Kinesin Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 229920002521 Macromolecule Polymers 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N Malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108020004388 MicroRNAs Proteins 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- WVKNBCACIPKHEW-UHFFFAOYSA-N N,N-diethylethanamine;N,N-dimethylformamide Chemical compound CN(C)C=O.CCN(CC)CC WVKNBCACIPKHEW-UHFFFAOYSA-N 0.000 description 1
- OHLUUHNLEMFGTQ-UHFFFAOYSA-N N-methylacetamide Chemical compound CNC(C)=O OHLUUHNLEMFGTQ-UHFFFAOYSA-N 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229910020700 Na3VO4 Inorganic materials 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091005503 Nucleic proteins Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 206010025310 Other lymphomas Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N PMSF Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N Pepstatin Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 229920002224 Peptide nucleic acid Polymers 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N Phenylpropanoic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 102000016462 Phosphate Transport Proteins Human genes 0.000 description 1
- 108010092528 Phosphate Transport Proteins Proteins 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N Pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229960000502 Poloxamer Drugs 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene (PE) Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 229960004063 Propylene glycol Drugs 0.000 description 1
- 229940107700 Pyruvic Acid Drugs 0.000 description 1
- 101700019476 REV1 Proteins 0.000 description 1
- 230000025458 RNA interference Effects 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N Rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102220448974 SDC2 E34R Human genes 0.000 description 1
- 101710035379 SLC34A2 Proteins 0.000 description 1
- 229910006024 SO2Cl2 Inorganic materials 0.000 description 1
- 102100019667 STAT3 Human genes 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N Silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 229920001891 Small hairpin RNA Polymers 0.000 description 1
- 229940005550 Sodium alginate Drugs 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N Sodium orthovanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- MFRIHAYPQRLWNB-UHFFFAOYSA-N Sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 1
- 102000013996 Sodium-dependent phosphate transport protein 2B Human genes 0.000 description 1
- 108050003877 Sodium-dependent phosphate transport protein 2B Proteins 0.000 description 1
- 240000001016 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229940075582 Sorbic Acid Drugs 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 210000003802 Sputum Anatomy 0.000 description 1
- 229940032147 Starch Drugs 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N Sulfuryl chloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 102100019730 TP53 Human genes 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J Tetrasodium pyrophosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- YTBSYETUWUMLBZ-QWWZWVQMSA-N Threose Chemical compound OC[C@@H](O)[C@H](O)C=O YTBSYETUWUMLBZ-QWWZWVQMSA-N 0.000 description 1
- 108010010691 Trastuzumab Proteins 0.000 description 1
- 229940117013 Triethanolamine oleate Drugs 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 210000002700 Urine Anatomy 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- ZBKFYXZXZJPWNQ-UHFFFAOYSA-N [N-]=C=S Chemical compound [N-]=C=S ZBKFYXZXZJPWNQ-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive Effects 0.000 description 1
- 230000001464 adherent Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940027983 antiseptics and disinfectants Quaternary ammonium compounds Drugs 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 108010062796 arginyllysine Proteins 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- PUPZLCDOIYMWBV-UHFFFAOYSA-N butylene glycol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 230000000973 chemotherapeutic Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 108091006028 chimera Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 238000003200 chromosome mapping Methods 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 201000011231 colorectal cancer Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005824 corn Nutrition 0.000 description 1
- 230000002596 correlated Effects 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 230000003111 delayed Effects 0.000 description 1
- 230000002939 deleterious Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 230000001809 detectable Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000001079 digestive Effects 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 230000000447 dimerizing Effects 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide DMF Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical group CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000001804 emulsifying Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000001747 exhibiting Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 108010055671 ezrin Proteins 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 201000002406 genetic disease Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 102000036249 human GOPC protein Human genes 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 238000003317 immunochromatography Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000000977 initiatory Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000009114 investigational therapy Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000004901 leucine-rich repeat Anatomy 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 201000009546 lung large cell carcinoma Diseases 0.000 description 1
- 210000004880 lymph fluids Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000001465 metallisation Methods 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 229920001239 microRNA Polymers 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 108010029942 microperoxidase Proteins 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 230000027405 negative regulation of phosphorylation Effects 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic Effects 0.000 description 1
- 230000004650 oncogenic pathway Effects 0.000 description 1
- 102000025475 oncoproteins Human genes 0.000 description 1
- 108091008124 oncoproteins Proteins 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N palmityl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000865 phosphorylative Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920003255 poly(phenylsilsesquioxane) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000011528 polyamide (building material) Substances 0.000 description 1
- 108091008117 polyclonal antibodies Proteins 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 150000003140 primary amides Chemical class 0.000 description 1
- 230000000750 progressive Effects 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 201000003454 pulmonary alveolar microlithiasis Diseases 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
- 230000002285 radioactive Effects 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 239000003638 reducing agent Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 1
- 230000000717 retained Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- MSXHSNHNTORCAW-UHFFFAOYSA-M sodium 3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].OC1OC(C([O-])=O)C(O)C(O)C1O MSXHSNHNTORCAW-UHFFFAOYSA-M 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 239000001187 sodium carbonate Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Inorganic materials [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- KEAYESYHFKHZAL-OUBTZVSYSA-N sodium-24 Chemical compound [24Na] KEAYESYHFKHZAL-OUBTZVSYSA-N 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- WSWCOQWTEOXDQX-UHFFFAOYSA-N sorbic acid Chemical compound CC=CC=CC(O)=O WSWCOQWTEOXDQX-UHFFFAOYSA-N 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000003595 spectral Effects 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran THF Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 102000027575 transmembrane receptors Human genes 0.000 description 1
- 108091007901 transmembrane receptors Proteins 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 125000002306 tributylsilyl group Chemical group C(CCC)[Si](CCCC)(CCCC)* 0.000 description 1
- 239000011778 trisodium citrate Substances 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 238000004450 types of analysis Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Abstract
This invention is directed to the treatment of cancer in a patient, particularly a patient with lung adenocarcinoma, and more particularly a patient with SLC34A2-ROS1, CD74-ROS1, or FIG-ROSl fusion-positive non-small cell lung cancer, with an inhibitor of MET, VEGFR2, and ROS1 which is a compound of Formula (I): or a pharmaceutically acceptable salt thereof. Formula (I): or a pharmaceutically acceptable salt thereof.
Description
Method of Treating Lung Adenocarcinoma
Cross Reference to Related Applications
This PCT application claims the benefit of U.S. Provisional Application Serial No.
61/984,599, filed April 25, 2014, the disclosure of which is hereby incorporated by reference
in its entirety.
Sequence Listing
This application incorporates by reference in its entirety the Sequence Listing entitled
“EX14-003C-PC_2015_04_20_SEQUENCE_LISTING_ST25.txt,” created on April 27,
2015, at 12:54 pm, that is 26 KB, and filed electronically herewith.
Field of the Invention
This invention is directed to the detection, diagnosis and treatment of cancer,
particularly lung adenocarcinoma, using an inhibitor of receptor tyrosine kinases.
Background of the Invention
Lung cancer is the leading cause of cancer-related mortality worldwide. Recent
developments in ed therapies have led to a treatment gm shift in non-small-cell
lung cancer (NSCLC). Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N,
Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ,
Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M. Gefitinib or
carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009 Sep
3;361(10):947-57.Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H,
Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori
K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, ra K, Morita S,
Nukiwa T; North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell
lung cancer with mutated EGFR. N Engl J Med. 2010 Jun 24;362(25):2380-8. Epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), nib and erlotinib, and
the stic lymphoma kinase (ALK) TKI, crizotinib, have shown al ty in
NSCLC patients with EGFR mutations or ALK gene rearrangements. Kwak EL, Bang YJ,
e DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB,
Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan
W, Gandhi L, Mino-Kenudson M, Wei GC, e SM, Ratain MJ, Settleman J,
Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, e AJ. Anaplastic
lymphoma kinase inhibition in non-small-cell lung . N Engl J Med. 2010 Oct
28;363(18):1693-703. Shaw AT, Camidge, Engelman JA, Solomon BJ, Kwak EL, Clark JW,
Salgia R, Shapiro, Bang YJ, Tan W, Tye L, Wilner KD, Stephenson P, Varella-Garcia M,
Bergethon K, Iafrate AJ, Ou SH. Clinical activity of crizotinib in advanced non-small cell
lung cancer ) harboring ROS1 gene rearrangement. J Clin Oncol. 2012 30 (suppl;
abstr 7508). Fusion of the KIF5B (the kinesin family 5B) gene and the RET oncogene has
been recently reported as a driver mutation in 1–2% of NSCLC ts and are a focus as a
therapeutic target. Kohno T, Ichikawa H, Totoki Y, Yasuda K, Hiramoto M, Nammo T,
Sakamoto H, Tsuta K, Furuta K, Shimada Y, Iwakawa R, Ogiwara H, Oike T, Enari M,
Schetter AJ, Okayama H, Haugen A, Skaug V, Chiku S, Yamanaka I, Arai Y, Watanabe S,
Sekine I, Ogawa S, Harris CC, Tsuda H, Yoshida T, Yokota J, Shibata T. KIF5B-RET
fusions in lung adenocarcinoma. Nat Med. 2012 Feb 12;18(3):375-7. Takeuchi K, Soda M,
Togashi Y, Suzuki R, Sakata S, Hatano S, Asaka R, Hamanaka W, ya H, Uehara H,
Lim Choi Y, Satoh Y, a S, Nakagawa K, Mano H, Ishikawa Y. RET, ROS1 and
ALK fusions in lung cancer. Nat Med. 2012 Feb 3):378-81. Lipson D, Capelletti M,
Yelensky R, Otto G, Parker A, Jarosz M, Curran JA, Balasubramanian S, Bloom T, Brennan
KW, Donahue A, Downing SR, Frampton GM, Garcia L, Juhn F, ll KC, White E,
White J, Zwirko Z, Peretz T, Nechushtan H, Soussan-Gutman L, Kim J, Sasaki H, Kim HR,
Park SI, Ercan D, Sheehan CE, Ross JS, Cronin MT, Jänne PA, Stephens PJ. Identification
of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med. 2012
Feb 12;18(3):382-4. Thus, it is ng more important to identify key driver genes in
NSCLC and to develop therapies for each genomic subset of patients.
[0004a] In this specification where reference has been made to patent specifications, other
external documents, or other sources of information, this is generally for the purpose of
ing a context for discussing the features of the invention. Unless specifically stated
otherwise, reference to such external documents is not to be construed as an admission that
such nts, or such sources of information, in any jurisdiction, are prior art, or form part
of the common general knowledge in the art.
y of the ion
These and other needs are met, and/or the public at least provided with a useful choice
by the present invention. Described herein is a method for treating lung adenocarcinoma
using an inhibitor of tyrosine kinase activity, specifically, ROS1 kinase activity. The method
comprises stering a therapeutically effective amount of a compound or a
pharmaceutically acceptable salt thereof that modulates ROS1 kinase and/or a ROS1 fusion
protein to a patient in need of such treatment. In one ment, the lung adenocarcinoma
is non-small cell lung cancer (NSCLC). More particularly, the lung adenocarcinoma is most
ntly SLC34A2-ROS1 fusion-positive NSCLC, CD74-ROS1 fusion positive NSCLC,
FIG-ROS1 fusion positive NSCLC, (e.g. CD74-ROS1, FIG-ROS1, FIG-ROS1(L), FIGROS1
(S), and S1(VL)) and NSCLC harboring other known ROS1 fusions proteins.
ROS1 kinase is encoded by the ROS1 gene on chromosome 6 in humans (6q22).
[0005a] More specifically, in a first aspect, the present invention provides use of a compound
of Formula I:
Formula I
or a pharmaceutically acceptable salt thereof, wherein:
R1 is halo;
R2 is halo;
R3 is (C1-C6)alkyl;
R4 is (C1-C6)alkyl; and
Q is CH or N,
in the manufacture of a medicament for the treatment of lung adenocarcinoma, wherein the
lung adenocarcinoma is SLC34A2-ROS1, CD74-ROS1, or FIG-ROS1 fusion-positive nonsmall
cell lung cancer.
] In a second aspect, the present invention provides use of compound 1
H H
N N
O O
CH3 O F
H3C O N
nd 1
or a pharmaceutically acceptable salt thereof,
in the manufacture of a medicament for the treatment of ROS1 fusion-positive non-small cell
lung cancer.
Described herein is a method for treating NSCLC in a patient in need of such
treatment, comprising administering a therapeutically effective amount of a compound or a
pharmaceutically acceptable salt thereof that simultaneously tes ROS1 and/or a ROS1
fusion protein, to the patient.
In one embodiment, the ROS1 kinase inhibitor or ROS1 fusion kinase inhibitor is a
compound of Formula I:
or a pharmaceutically acceptable salt thereof, wherein:
R1 is halo;
R2 is halo;
R3 is (C1-C6)alkyl;
R4 is (C1-C6)alkyl; and
Q is CH or N.
In another embodiment, the compound of Formula I is a compound of Formula Ia
Formula Ia
or a pharmaceutically able salt f, n:
R1 is halo;
R2 is halo; and
Q is CH or N.
In another embodiment, the compound of Formula I is compound 1:
H H
N N
O O
CH3 O F
H3C O N
compound 1
or a pharmaceutically acceptable salt thereof. compound 1 is known as N-(4-{[6,7-
bis(methyloxy)quinolinyl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-
dicarboxamide and by the name Cabozantinib. On November 29, 2012, the S-malate salt
(i.e., L-malate salt) of (6,7-dimethoxyquinolinyl)oxy]phenyl}-N′-(4-fluorophenyl)
cyclopropane-1,1-dicarboxamide (also known as cabozantinib or COMETRIQ®) was
approved by the United States Food and Drug Administration for the treatment of
progressive, metastatic medullary thyroid cancer (MTC). In December 2013, the European
Committee for Medicinal ts for Human Use (CHMP), issued a positive opinion on the
Marketing ization Application (MAA), submitted to the European Medicines Agency,
or EMA, for COMETRIQ for the proposed indication of ssive, unresectable, locally
advanced, or metastatic MTC. Cabozantinib is being evaluated in a broad development
program, including ongoing phase 3 pivotal trials in metastatic renal cell cancer (RCC), and
advanced cellular cancer (HCC).
Compound 1 is a potent inhibitor of c-MET, RET, and VEGFR2. Yakes FM, Chen J,
Tan J, Yamaguchi K, Shi Y, Yu P, Qian F, Chu F, Bentzien F, Cancilla B, Orf J, You A,
Laird AD, Engst S, Lee L, Lesch J, Chou YC, Joly AH. Cabozantinib (XL184), a novel MET
and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor
growth. Mol Cancer Ther. 2011 Dec;10(12):2298-308; Bentzien, F., Zuzow, M., Heald, N.,
Gibson, A., Shi, Y., Goon, L., Yu, P., Engst, S., Zhang, W., Huang, S., Zhao, L., kaia,
V., Chu, F., Bautista, R., Cancilla, B., Lamb, P., Joly, A. and Yakes, M. In vitro and in vivo
activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of
medullary thyroid cancer. d, 2013 (23) 577. In nical studies, compound
1-mediated tion of kinase activity produced rapid and robust regression of tumor
vasculature, reduced, tumor invasiveness and metastasis, and prolonged survival. Sennino
B., ro-Oonuma T, Wei Y, Naylor RM, Williamson CW, Bhagwandin V, Tabruyn SP,
You WK, Chapman HA, Christensen JG, Aftab DT, McDonald DM. (2012), “Suppression of
tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in
pancreatic neuroendocrine tumors.”, Cancer Discovery, 2(3):270-87 (Epublished,
2012).
In another ment, the compound of Formula I, Ia, compound 1, or a
pharmaceutically acceptable salt f, is administered as a pharmaceutical composition
comprising a pharmaceutically able additive, diluent, or excipient.
In one embodiment, the compound of a I, Ia, or compound 1, or a
pharmaceutically acceptable salt thereof, is administered as a pharmaceutical composition
comprising a pharmaceutically acceptable additive, diluent, or excipient is administered to
inhibit oncogenic fusion kinases involving the orphan receptor tyrosine kinase ROS1
resulting from chromosomal rearrangements that lead to constitutive tion of the ROS1
kinase activity. These ROS1 fusion kinases are targeted for tion using the compound of
Formula I, Ia, or compound 1or a pharmaceutically acceptable salt thereof. These
compounds can be administered as a pharmaceutical composition comprising a
pharmaceutically acceptable additive, diluent, or excipient to treat lung adenocarcinoma, for
example, non-small cell lung carcinoma harboring one or more oncogenic ROS1 fusion
kinases.
Described herein is a method for inhibiting a ROS1 kinase and/or ROS1 fusion kinase
activity in one or more non-small cell lung cancers or NSCLC cell lines, comprising
administering a therapeutically effective amount of a pharmaceutical composition comprising
a compound of Formula I or the malate salt of a compound of Formula I or another
pharmaceutically acceptable salt of a compound of Formula I to said non-small cell lung
cancers or NSCLC cell lines harboring a ROS1 kinase and/or a ROS1 fusion polypeptide.
Described herein is a method for detecting, diagnosing and treating a ROS1 fusion
positive NSCLC, for example, a SLC34A2-ROS1 fusion-positive NSCLC, and other known
ROS1 fusion ve NSCLC, ing ROS1 fusions CD74-ROS1, S1, FIGROS1
(L), FIG-ROS1(S), and FIG-ROS1(VL), and other ROS1 fusion proteins d by
the ROS1 gene on chromosome 6 in humans (See: Bergethon K, Shaw AT, Ou SH,
Katayama R, Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R,
Mark EJ, Batten JM, Chen H, Wilner KD, Kwak EL, Clark JW, Carbone DP, Ji H, Engelman
JA, Mino-Kenudson M, Pao W, Iafrate AJ. ROS1 rearrangements define a unique molecular
class of lung cancers. J Clin Oncol. 2012 Mar 10;30(8):863-70) comprising stering a
therapeutically effective amount of a pharmaceutical composition comprising a compound of
Formula I or the malate salt of a compound of Formula I or another pharmaceutically
acceptable salt of a compound of Formula I, to a t in need of such treatment. In a
specific embodiment, the compound of Formula I is compound 1 or the malate salt of
compound 1, particularly the S-malate salt of compound 1.
Described herein is a method for treating a lung adenocarcinoma which is SLC34A2-
ROS1 fusion positive non-small cell lung cancer in a patient in need of such treatment,
comprising administering to the patient an effective amount of nd 1:
H H
N N
O O
CH3 O F
H3C O N
Compound 1
or a pharmaceutically acceptable salt f.
Described herein is a method for ng a lung adenocarcinoma which is CD74-
ROS1 fusion positive non-small cell lung cancer in a patient in need of such treatment,
sing administering to the patient an effective amount of compound 1:
H H
N N
O O
CH3 O F
H3C O N
Compound 1
or a ceutically acceptable salt thereof.
Described herein is a method for treating a lung adenocarcinoma which is FIG-ROS1
fusion positive non-small cell lung cancer in a patient in need of such treatment, comprising
administering to the patient an effective amount of compound 1:
H H
N N
O O
CH3 O F
H3C O N
Compound 1
or a pharmaceutically acceptable salt thereof.
Described herein is a method for inhibiting ROS1 fusion kinase activity in a NSCLC
cell, the method comprising contacting said cell with an effective amount of a compound of
Formula I:
or a pharmaceutically acceptable salt thereof, wherein:
R1 is halo;
R2 is halo;
R3 is (C1-C6)alkyl;
R4 is (C1-C6)alkyl; and
Q is CH or N.
In the ption in this specification reference may be made to subject matter which
is not within the scope of the appended claims. That subject matter should be readily
identifiable by a person d in the art and may assist in putting into practice the invention
as defined in the appended claims.
Brief Description of the Figures
Figure 1 s a graphical representation of ROS1 fusion proteins known to exist in
Non-Small Cell Lung Carcinoma (NSCLC) tumor samples. ROS1 rearrangements in
NSCLC, glioblastoma, and cholangiocarcinoma. CD74(L)/(S), r of differentiation 74,
long/short isoforms; EZR, ezrin; FIG, fused in glioblastoma; LRIG3, leucine-rich repeats and
globulin-like domains 3; ROS1 TK, ROS1 tyrosine kinase domain with fusion
partners; SDC4, syndecan-4; SLC34A2(L)/(S), solute carrier family 34 (sodium phosphate),
member 2, hort isoforms; SDC4, syndecan-4; TPM3, tropomyosin 3. Exon numbers
E32, E34, E35, or E36 indicate break points of ROS1. Red box denotes the transmembrane
domain retained in ROS1.
Figure 2 depicts inhibition of phosphorylation of SLC34A2-ROS1 fusion in vitro in
HCC-78 NSCLC cells that were stered single escalating doses of compound 1, or 3-
[(1R)(2,6-dichlorofluorophenyl)ethoxy](1-piperidinylpyrazolyl)pyridin
amine (Crizotinib; XALKORI®).
Figure 3 is the amino acid sequence of an exemplary human ROS1 protein denoted
herein as SEQ ID NO:1.
Figure 4 is an exemplary amino acid sequence of human ROS1 kinase domain
denoted herein as SEQ ID NO: 2.
Detailed Description of the ion
iations and Definitions
The following abbreviations and terms have the indicated meanings throughout this
ation.
Abbreviation Meaning
Ac Acetyl
Br Broad
°C Degrees Celsius
c- Cyclo
CBZ CarboBenZoxy = benzyloxycarbonyl
d Doublet
dd Doublet of doublet
dt Doublet of triplet
DCM Dichloromethane
DME 1,2-dimethoxyethane
DMF N,N-Dimethylformamide
DMSO dimethyl sulfoxide
EI Electron Impact ionization
G Gram(s)
h or hr Hour(s)
HPLC High pressure liquid tography
L Liter(s)
M Molar or molarity
m Multiplet
Mg Milligram(s)
MHz Megahertz (frequency)
Abbreviation Meaning
Min Minute(s)
mL Milliliter(s)
µL Microliter(s)
µM Micromole(s) or micromolar
mM Millimolar
Mmol Millimole(s)
Mol Mole(s)
MS Mass spectral analysis
N Normal or normality
nM Nanomolar
NMR Nuclear magnetic resonance spectroscopy
q Quartet
RT Room temperature
s Singlet
t or tr Triplet
TFA oroacetic acid
THF Tetrahydrofuran
TLC Thin layer chromatography
[0024a] The term “comprising” as used in this specification and claims means “consisting at
least in part of”. When interpreting statements in this specification and claims which include
the term “comprising”, other features besides the features prefaced by this term in each
statement can also be present. Related terms such as “comprise”, “comprises”, and
“comprised” are to be interpreted in similar manner.
The symbol “-” means a single bond, “=” means a double bond.
When chemical structures are depicted or described, unless explicitly stated
ise, all carbons are assumed to have hydrogen substitution to conform to a valence of
four. For example, in the ure on the and side of the schematic below there are nine
ens implied. The nine ens are depicted in the hand structure. Sometimes a
particular atom in a structure is described in textual formula as having a hydrogen or
hydrogens as substitution (expressly defined hydrogen), for example, -CH2CH2-. It is
understood by one of ordinary skill in the art that the aforementioned descriptive techniques
are common in the chemical arts to provide brevity and simplicity to ption of otherwise
complex structures.
H H H
Br Br
H H
If a group “R” is depicted as “floating” on a ring system, as for e in the
then, unless otherwise defined, a substituent “R” may reside on any atom of the ring system,
assuming replacement of a depicted, implied, or expressly defined hydrogen from one of the
ring atoms, so long as a stable structure is formed.
If a group “R” is depicted as floating on a fused ring system, as for example in the
formulae:
R H
N Z
H , or , or R
then, unless otherwise d, a substituent “R” may reside on any atom of the fused ring
, assuming replacement of a depicted hydrogen (for example the -NH- in the formula
above), implied hydrogen (for example as in the formula above, where the hydrogens are not
shown but understood to be present), or expressly defined hydrogen (for example where in
the formula above, “Z” equals =CH-) from one of the ring atoms, so long as a stable structure
is formed. In the example depicted, the “R” group may reside on either the 5-membered or
the 6-membered ring of the fused ring system. When a group “R” is depicted as ng on a
ring system containing saturated carbons, as for example in the formula:
(R)y
where, in this example, “y” can be more than one, assuming each replaces a tly
depicted, implied, or expressly defined hydrogen on the ring; then, unless otherwise defined,
where the resulting structure is stable, two “R’s” may reside on the same . A simple
example is when R is a methyl group; there can exist a geminal dimethyl on a carbon of the
depicted ring (an “annular” carbon). In another example, two R’s on the same carbon,
including that carbon, may form a ring, thus ng a yclic ring (a “spirocyclyl”
group) ure with the depicted ring as for example in the formula:
“Halogen” or “halo” refers to fluorine, chlorine, bromine or iodine.
As used herein, “ROS1” protein or polypeptide includes mammalian ROS1, for
example, human ROS1 kinase protein (encoded by the ROS1 gene) which is a 2347 amino
acid long receptor tyrosine kinase that is prone to aberrant expression g to cancer. A
description of full length human ROS1 kinase (with the amino acid sequence of the human
ROS1 protein) can be found at UniProt Accession No. P08922. Additionally, there are
multiple known lly-occurring variants of ROS1 (see, e.g., Greenman et al., Nature 446:
153-158, 2007). The tide and amino acid sequences of murine full-length ROS1 are
known (see, e.g., UniProt Accession No. Q78DX7). Using routine experimentation, the
ordinarily skilled biologist would be readily able to determine corresponding sequences in
non-human mammalian ROS1 homologues.
By "wild-type" ROS1 is meant the full length ROS1 kinase (i.e., for human ROS1, the
2347 amino acid long polypeptide (SEQ ID NO:1) or 2320 amino acid long ptide
(mature sequence) following removal of the signal peptide ce) in healthy (or normal)
tissue (e.g., non-cancerous tissue) of a normal individual (e.g., a normal individual who is not
suffering from cancer). ROS1 kinase (full length or truncated) does not appear to be
expressed in normal lung tissue in humans. However, using the methods bed below, the
inventors have made the surprising discovery of specific inhibition of ROS1 kinase in lung
cancer cells using the compounds described . Such expression in an atypical cell (in
this case a cancerous cell) where no expression is seen in a typical cell (e.g., a non-cancerous
lung cell) is aberrant.
Aberrantly expressed ROS1 kinase, in the form of a fusion with another protein, for
example, SLC34A2, CD74 or FIG, has been reported in glioblastoma (see Charest et al.,
Charest et al., Genes Chromosomes Cancer 37: 58-71, 2003; Charest et al., Proc. Natl. Acad.
Sci. USA 100: 916-921, 2003) in liver cancer (see, e.g., PCT Publication No.
WO2010/093928) in bile duct cancer (see Gu et al., PLOS one 2011 Jan 6;6(1):e15640. doi:
.1371/journal.pone.0015640) and in NSCLC adenocarcinoma (See Kurtis D. Davies et al.
Identifying and Targeting ROS1 Gene Fusions in all Cell Lung Cancer, Clin Cancer
Res. 2012 September 1; 18(17): 4570–4579).
As used , the term "ROS1 fusion" refers to a portion of the ROS1 polypeptide
comprising the kinase domain of the ROS1 protein (or polynucleotide encoding the same)
fused to all or a portion of r polypeptide (or polynucleotide encoding the same), where
the name of that second polypeptide or polynucleotide is named in the fusion. (The term
"fusion" simply means all or a portion of a polypeptide or polynucleotide from first gene
fused to all or a portion of a polypeptide or a polynucleotide from a second gene). For
example, an SLC34A2-ROS1 fusion is a fusion between a portion of the SLC34A2
polypeptide (or polynucleotide encoding the same) and a portion of the ROS1 polypeptide (or
polynucleotide encoding the same) comprising the kinase domain ROS1. An ROS1 fusion
often results from a chromosomal ocation or inversion. There are numerous known
ROS1 fusions, all of which are ROS1 fusions of the present disclosure and e, without
limitation, the SLC34A2-ROS1 fusion ns whose members include SLC34A2-
ROS1(VS), SLC34A2-ROS1(S), SLC34A2-ROS1(L) (see U.S. Patent ation No.
20100143918), CD74-ROS1 (see U.S. Patent Publication No. 20100221737) and the FIGROS1
fusion proteins whose members include FIG-ROS1(S), FIG-ROS1(L), and FIGROS1
(XL) (see PCT Publication No. WO2010/093928), the disclosures of which are each
incorporated herein in their entireties. The designation of (L), (S), (VS), (VL) (XS) or (XL)
following a ROS1 polypeptide or ROS1 fusion, generally refers to long, short, very short,
very long, extra short, and extra-long ROS1polypeptide or polynucleotide tively.
All of the known ROS1 fusion proteins comprise the full kinase domain of full length
ROS1. Thus, as used herein, by a "polypeptide with ROS1 kinase activity" (or "polypeptide
having ROS1 kinase activity") is meant a protein (or polypeptide) that includes the full kinase
domain of full length ROS1 protein and, thus, retains ROS1 kinase activity. miting
examples of ns with ROS1 kinase activity include, without limitation, full length ROS1
protein, the SLC34A2-ROS1 fusion proteins, whose members e 2-ROS1(VS),
SLC34A2-ROS1(S), SLC34A2-ROS1(L) (see U.S. Patent Publication No. 43918),
CD74-ROS1 (see U.S. Patent Publication No. 21737) and the FIG-ROS1 fusion
proteins whose members include FIG-ROS1(S), FIG-ROS1(L), and FIG-ROS1(XL) (see
PCT Publication No. WO2010/093928), and any truncated or mutated form of ROS1 kinase
that retains the kinase domain of full-length ROS1 kinase n. An exemplary kinase
domain of ROS1 is set forth in SEQ ID NO: 2, a "polypeptide with ROS1 kinase activity" is
one whose amino acid sequence comprises SEQ ID NO: 2, or a kinase active portion thereof.
As used herein, "polypeptide" (or "amino acid sequence" or "protein") refers to a
polymer formed from the linking, in a defined order, of preferably, a-amino acids, D-, L-
amino acids, and combinations thereof. The link between one amino acid residue and the next
is referred to as an amide bond or a peptide bond. Non-limiting examples of polypeptides
include refers to an oligopeptide, peptide, polypeptide, or protein sequence, and fragments or
ns thereof, and to naturally occurring or synthetic molecules. Polypeptides also include
derivatized les such as glycoproteins and lipoproteins as well as lower molecular
weight polypeptides. "Amino acid sequence" and like terms, such as "polypeptide" or
in", are not meant to limit the ted amino acid sequence to the complete, native
amino acid sequence associated with the recited protein molecule.
It will be recognized in the art that some amino acid ces of a polypeptide of the
t disclosure can be varied without significant effect of the structure or function of the
mutant protein. If such differences in sequence are contemplated, it should be remembered
that there will be critical areas on the protein which determine activity (e.g. the kinase
domain of ROS1). In general, it is possible to replace residues that form the tertiary structure,
provided that residues performing a r function are used. In other instances, the type of
residue may be tely unimportant if the tion occurs at a itical region of the
protein.
Thus, a polypeptide with ROS1 activity of the present disclosure further includes
variants of the full length ROS1 protein or the various ROS1 fusion polypeptides described
herein that shows substantial ROS1 kinase activity. Some non-limiting vative
substitutions include the exchange, one for another, among the aliphatic amino acids Ala,
Val, Leu and Ile; exchange of the hydroxyl residues Ser and Thr; exchange of the acidic
residues Asp and Glu; exchange of the amide residues Asn and Gln; exchange of the basic
residues Lys and Arg; and exchange of the aromatic residues Phe and Tyr. Further examples
of conservative amino acid substitutions known to those skilled in the art are: Aromatic:
phenylalanine phan tyrosine (e.g., a tryptophan residue is replaced with a
phenylalanine); Hydrophobic: leucine cine valine; Polar: glutamine asparagines; Basic:
arginine lysine histidine; Acidic: aspartic acid glutamic acid; Small: alanine serine threonine
methionine glycine. As indicated in detail above, further guidance concerning which amino
acid changes are likely to be phenotypically silent (i.e., are not likely to have a significant
deleterious effect on a function) can be found in Bowie et al., Science 247, supra.
“SLC34A2” may refer to the sodium-dependent phosphate transport protein 2B
encoded by the human SLC34A2 gene protein, or the SLC34A2 gene. The human SLC34A2
protein (isoform A, which has an NCBI ion number NP_001171469) is a 689 amino
acid protein. SLC34A2 is further described herein.
CD74 is also referred to as the HLA class II histocompatibility antigen gamma chain
also known as HLA-DR antigens-associated invariant chain or CD74 (Cluster of
Differentiation 74), is a protein that in humans is encoded by the CD74 gene. An illustrative
human CD74 protein has an NCBI accession number of NP_001020329 and an mRNA
accession number of NM_001025158. CD74 has 160 amino acids and is encoded by the
CD74 gene located on chromosome 5 . CD74 has 9 exons. CD74 is further described
herein.
FIG (Fused in Glioblastoma) is also referred to as “Golgi-associated PDZ and coiled-
coil motif containing” or “GOPC” protein, is encoded by a gene located on chromosome 6 at
6q21. This protein in human has 462 amino acids. FIG has 3 isoforms produced by
alternative ng. An exemplary human FIG protein referred to in the present disclosure
has a UniProtKB identifier of Q9HD26-1.
“SLC34A2-ROS1 fusion protein or gene” refers to somatic gene fusions of the
partners 2 and ROS1. In some embodiments, the SLC34A2-ROS1 fusion protein
including N-terminal domain of a fusion partner, such as 2 and the C-terminal kinase
domain of ROS1 n. The N-terminal domain of a fusion partner may be positioned at N-
terminus of the fusion protein, and the inal kinase domain of ROS1 protein may be
positioned at the C-terminus of the fusion protein. The fusion partner may be a N-terminal
domain of SLC34A2 protein, which is positioned at N-terminus of the fusion protein. In this
case, the fusion protein may be represented as SLC34A2-ROS1 protein which includes N-
terminal domain of SLC34A2 protein at inus and C-terminal kinase domain of ROS1
protein at C-terminus. Another embodiment provides a fusion gene encoding the fusion
n, where a gene encoding the N-terminal domain of the fusion partner positions at 5'
end and a gene encoding the C-terminal kinase domain of the ROS1 protein positions at 3'
end. In some ments, portions of the SLC34A2 protein is fused in frame to ns of
the ROS1 protein comprising a functional kinase domain as a result of an aberrant
chromosomal ocation yielding a ROS1 chromosomal ngement with SLC34A2. In
some embodiments, SLC34A2-ROS1 fusion protein can include the fusion SLC34A2 exon 4-
ROS1 exon 32. In some embodiments, SLC34A2-ROS1 fusion protein can include the
fusion SLC34A2 exon 4-ROS1 exon 34 SLC34A2-ROS1 fusion protein or gene having a
functional ROS1 kinase domain as used in the t disclosure may contain other
breakpoints involving the two translocation partners SLC34A2 and ROS1. Exemplary
SLC34A2-ROS1 fusion proteins can be found in COSMIC-Catalogue of somatic mutations
in cancer database v.68 at cancer.sanger.ac.uk/cancergenome/projects/cosmic/ the contents of
which are incorporated herein by reference in its entirety.
ROS1 fusion protein or gene” refers to c gene fusions of the partners
CD74 and ROS1. Exemplary CD74-ROS1 fusion proteins can be found in COSMICCatalogue
of somatic mutations in cancer se v.68 at
cancer.sanger.ac.uk/cancergenome/projects/cosmic/ the contents of which are incorporated
herein by reference in its entirety.
“FIG-ROS1 fusion protein or gene” refers to somatic gene fusions of the partners FIG
and ROS1. In some embodiments, an intra-chromosomal homozygous deletion of 240
kilobases on human some 6, at position 6q21 is responsible for the formation of the
FIG-ROS1 locus. In some embodiments, the FIG-ROS1 transcript is encoded by 7 FIG exons
and 9 ROS1-derived exons. In some embodiments, the FIG-ROS1 gene encodes for an inframe
fusion protein with a constitutively active and onal ROS1 kinase domain.
Exemplary FIG-ROS1 fusion proteins can be found in -Catalogue of somatic
mutations in cancer database v.68 at cancer.sanger.ac.uk/cancergenome/projects/cosmic/ the
contents of which are incorporated herein by nce in its entirety.
“Patient” for the purposes of the present sure includes humans and other
animals, particularly mammals, and other organisms. Thus the methods are applicable to both
human therapy and veterinary applications. In r embodiment the patient is a mammal,
and in another embodiment the patient is human.
“Pharmaceutically acceptable salt” of a compound means a salt that is
pharmaceutically acceptable and that possesses the desired pharmacological ty of the
parent compound. It is understood that the pharmaceutically acceptable salts are non-toxic.
Additional information on suitable pharmaceutically acceptable salts can be found in
Remington’s Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, PA,
1985, which is incorporated herein by reference or S. M. Berge, et al., “Pharmaceutical
Salts,” J. Pharm. Sci., 1977;66:1-19 both of which are incorporated herein by reference.
Examples of pharmaceutically acceptable acid addition salts include those formed
with inorganic acids such as hloric acid, romic acid, sulfuric acid, nitric acid,
phosphoric acid, and the like; as well as organic acids such as acetic acid, trifluoroacetic acid,
propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic
acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, malic
acid, citric acid, benzoic acid, cinnamic acid, 3-(4-hydroxybenzoyl)benzoic acid, ic
acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid,
2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid,
2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, glucoheptonic
acid, 4,4’-methylenebis-(3-hydroxyenecarboxylic acid), 3-phenylpropionic acid,
trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, ic acid, glutamic
acid, hydroxynaphthoic acid, lic acid, stearic acid, muconic acid, p-toluenesulfonic
acid, and salicylic acid and the like.
“Prodrug” refers to compounds that are transformed (typically rapidly) in vivo to yield
the parent compound of the above formulae, for example, by hydrolysis in blood. Common
es include, but are not limited to, ester and amide forms of a compound having an
active form bearing a ylic acid moiety. Examples of pharmaceutically acceptable esters
of the compounds of this invention include, but are not limited to, alkyl esters (for example
with between about one and about six carbons) the alkyl group is a straight or branched
chain. Acceptable esters also e cycloalkyl esters and arylalkyl esters such as, but not
limited to benzyl. es of pharmaceutically acceptable amides of the compounds of this
invention include, but are not limited to, primary amides, and secondary and tertiary alkyl
amides (for example with between about one and about six carbons). Amides and esters of
the compounds of the present invention may be ed according to conventional methods.
A thorough discussion of prodrugs is provided in T. Higuchi and V. Stella, “Pro-drugs as
Novel ry s,” Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible
Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and
Pergamon Press, 1987, both of which are incorporated herein by reference for all purposes.
“ROS1” or the “ROS1 protein” is a transmembrane receptor tyrosine kinase, and is
further bed .
“Therapeutically effective ” is an amount of a compound of the invention, that
when administered to a patient, ameliorates a m of the disease. A therapeutically
effective amount is intended to include an amount of a compound alone or in combination
with other active ingredients effective to modulate c-Met, and/or VEGFR2, or ive to
treat or prevent cancer. The amount of a compound of the invention which constitutes a
“therapeutically ive amount” will vary depending on the compound, the disease state
and its severity, the age of the patient to be treated, and the like. The therapeutically effective
amount can be determined by one of ordinary skill in the art having regard to their knowledge
and to this disclosure.
“Treating” or “treatment” of a disease, disorder, or syndrome, as used herein, includes
(i) preventing the disease, disorder, or syndrome from occurring in a human, i.e. causing the
clinical symptoms of the disease, disorder, or syndrome not to develop in an animal that may
be exposed to or predisposed to the disease, disorder, or syndrome but does not yet
experience or display symptoms of the disease, disorder, or syndrome; (ii) reversing or
ting the disease, disorder, or syndrome, i.e., arresting its development; and (iii)
relieving the disease, disorder, or syndrome, i.e., causing regression of the e, disorder,
or syndrome. As is known in the art, adjustments for systemic versus localized delivery, age,
body weight, l health, sex, diet, time of administration, drug interaction and the
severity of the condition may be ary, and will be ascertainable with routine experience.
“Yield” for each of the reactions bed herein is expressed as a percentage of the
theoretical yield.
Embodiments
In one embodiment the compound of Formula I is the compound of Formula Ia:
Formula Ia
or a pharmaceutically acceptable salt thereof, wherein:
R1 is halo;
R2 is halo; and
Q is CH or N.
In another embodiment, the compound of Formula I is compound 1:
H H
N N
O O
CH3 O F
H3C O N
Compound 1
or a pharmaceutically acceptable salt thereof. As indicated previously, compound 1 is
referred to herein as N-(4-{[6,7-bis(methyloxy)quinolinyl]oxy}phenyl)-N'-(4-
fluorophenyl)cyclopropane-1,1-dicarboxamide. , which is incorporated
herein by reference in its entirety, discloses compound 1 and describes how it is made (WO
2005/030140, Example 12, 37, 38, and 48) and also discloses the therapeutic activity of this
compound to t, regulate and/or modulate the signal transduction of kinases, (WO
2005/030140, Assays, Table 4, entry 289). Example 48 is on paragraph [0353] in WO
2005/030140.
In other embodiments, the compound of Formula I, Ia, or compound 1, or a
pharmaceutically acceptable salt thereof, is administered as a pharmaceutical composition,
wherein the pharmaceutical ition additionally comprises a ceutically
acceptable carrier, excipient, or diluent. In a specific embodiment, the compound of Formula
I is compound 1.
The nd of Formula I, Formula Ia and compound I, as described herein,
es both the recited compounds as well as individual isomers and es of isomers.
In each instance, the compound of Formula I includes the pharmaceutically acceptable salts,
hydrates, and/or solvates of the recited compounds and any individual s or mixture of
isomers thereof.
In other embodiments, the compound of Formula I, Ia, or compound 1 can be the (L)-
malate salt. The malate salt of the compound of Formula I and of compound 1 is disclosed in
and USSN 095, both of which are incorporated herein by
nce in their entireties.
In other embodiments, the compound of Formula I is the (D)-malate salt, which is
also ed to as the R-malate salt.
In other ments, the compound of Formula Ia is the malate salt.
In other embodiments, the compound of Formula Ia is the (L)-malate salt, which is
also referred to as the S-malate salt.
In other embodiments, compound 1 is the (D)-malate salt, which is also referred to as
the S-malate salt.
In other embodiments, compound 1 is the malate salt.
In other ments, compound 1 is the (L)-malate salt, which is also referred to as
the S-malate salt.
In another embodiment, the malate salt is in the crystalline N-1 form or the N-2 form
of the (L) malate salt and/or the (D) malate salt of compound 1 as disclosed in United States
patent Application Ser. No. 61/325095. Also see , incorporated by
nce in its ty, for the properties of lline enantiomers, including the N-1
and/or the N-2 crystalline forms of the malate salt of nd 1. Methods of making and
characterizing such forms are fully described in PCT/US10/021194, which is incorporated
herein by reference in its entirety.
Described herein is a method for reversing or inhibiting NSCLC, comprising
administering to a patient in need of such treatment a therapeutically ive amount of a
compound of Formula I or a pharmaceutically acceptable salt thereof, in any of the
embodiments disclosed herein. In a specific ment, the compound of Formula I is
compound 1, or a pharmaceutically acceptable salt thereof.
bed herein is a method for reversing or inhibiting SLC34A2-ROS1fusion-
positive NSCLC, comprising administering to a patient in need of such treatment a
therapeutically ive amount of a compound of Formula I or a pharmaceutically
acceptable salt thereof, in any of the embodiments disclosed herein. In a specific
embodiment, the compound of Formula I is compound 1 or a pharmaceutically able
salt thereof.
Described herein is a method for reversing or inhibiting CD74-ROS1fusion-positive
NSCLC, comprising stering to a patient in need of such treatment a therapeutically
effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof,
in any of the embodiments disclosed herein. In a specific embodiment, the compound of
Formula I is compound 1 or a pharmaceutically able salt thereof.
Described herein is a method for reversing or inhibiting S1fusion-positive
NSCLC, comprising administering to a patient in need of such treatment a therapeutically
effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof,
in any of the embodiments disclosed . In a specific embodiment, the compound of
Formula I is compound 1 or a pharmaceutically acceptable salt thereof.
In another embodiment, the compound of Formula I, or a pharmaceutically acceptable
salt thereof, is stered before, concurrently, or subsequent to one or more other
treatments. In another embodiment, the compound of Formula I, or a pharmaceutically
acceptable salt thereof, is administered subsequent to one or more treatments. “Treatment”
means any of the treatment options are available to the skilled n, including surgery,
chemotherapeutic agents, hormone therapies, antibodies, immunotherapies, radioactive iodine
therapy, and radiation. In particular, “treatment’ means another chemotherapeutic agent or
antibody.
Thus, in another embodiment, the compound of Formula I, or a pharmaceutically
acceptable salt thereof, is administered post-cisplatin and/or gemcitabine ent.
In another embodiment, the compound of Formula I, or a pharmaceutically acceptable
salt thereof, is administered post-docetaxel treatment.
In another embodiment, the compound of Formula I, or a pharmaceutically acceptable
salt thereof, is stered post HER-2 antibody treatment. In another ment, the
HER-2 antibody is trastuzumab.
In another ment, the compound of Formula I, or a pharmaceutically acceptable
salt thereof, is administered post-cisplatin and/or gemcitabine and/or docetaxel treatment.
In another embodiment, the compound of Formula I, Ia, or compound 1, or a
pharmaceutically acceptable salt thereof, is administered orally once daily as a tablet or
capsule. In these and other embodiments, the compound of a I, or a pharmaceutically
acceptable salt thereof, is compound 1, or a ceutically acceptable salt thereof.
In another embodiment, compound 1 is administered orally as its free base or the
malate salt as a capsule or tablet.
In another ment, compound 1 is stered orally once daily as its free base
or as the malate salt as a capsule or tablet containing up to 100 mg of compound 1.
In another embodiment, compound 1 is administered orally once daily as its free base
or as the malate salt as a capsule or tablet containing 100 mg of compound 1.
In another embodiment, compound 1 is administered orally once daily as its free base
or as the malate salt as a e or tablet containing 95 mg of compound 1.
In another embodiment, compound 1 is administered orally once daily as its free base
or as the malate salt as a capsule or tablet containing 90 mg of compound 1.
In another embodiment, nd 1 is stered orally once daily as its free base
or as the malate salt as a capsule or tablet containing 85 mg of compound 1.
In another embodiment, compound 1 is administered orally once daily as its free base
or as the malate salt as a capsule or tablet containing 80 mg of compound 1.
In another ment, nd 1 is stered orally once daily as its free base
or as the malate salt as a capsule or tablet containing 75 mg of compound 1.
In another embodiment, compound 1 is administered orally once daily as its free base
or as the malate salt as a e or tablet containing 70 mg of compound 1.
In another embodiment, compound 1 is stered orally once daily as its free base
or as the malate salt as a e or tablet containing 65 mg of compound 1.
In another embodiment, compound 1 is administered orally once daily as its free base
or as the malate salt as a capsule or tablet containing 60 mg of compound 1.
In another embodiment, compound 1 is administered orally once daily as its free base
or as the malate salt as a capsule or tablet containing 55 mg of compound 1.
In another embodiment, compound 1 is administered orally once daily as its free base
or as the malate salt as a capsule or tablet containing 50 mg of compound 1.
In another embodiment, compound 1 is administered orally once daily as its free base
or as the malate salt as a capsule or tablet containing 45 mg of compound 1.
In another ment, compound 1 is stered orally once daily as its free base
or as the malate salt as a capsule or tablet containing 40 mg of compound 1.
In another embodiment, compound 1 is administered orally once daily as its free base
or as the malate salt as a capsule or tablet containing 35 mg of compound 1.
In another embodiment, compound 1 is administered orally once daily as its free base
or as the malate salt as a capsule or tablet containing 30 mg of compound 1.
In another embodiment, compound 1 is administered orally once daily as its free base
or as the malate salt as a capsule or tablet containing 25 mg of compound 1.
In another embodiment, compound 1 is administered orally once daily as its free base
or as the malate salt as a capsule or tablet containing 20 mg of compound 1.
In another embodiment, compound 1 is stered orally once daily as its free base
or as the malate salt as a e or tablet containing 15 mg of compound 1.
In another embodiment, compound 1 is administered orally once daily as its free base
or as the malate salt as a capsule or tablet ning 10 mg of compound 1.
In another embodiment, compound 1 is administered orally once daily as its free base
or as the malate salt as a capsule or tablet containing 5 mg of compound 1.
In another embodiment, compound 1 is administered as its free base or malate salt
orally once daily as a tablet as provided in the following table.
Ingredient (% w/w)
Compound 1 31.68
Microcrystalline Cellulose 38.85
Lactose anhydrous 19.42
Hydroxypropyl Cellulose 3.00
Croscarmellose Sodium 3.00
Total Intra-granular 95.95
Silicon dioxide, Colloidal 0.30
Croscarmellose Sodium 3.00
Magnesium Stearate 0.75
Total 100.00
In another embodiment, compound 1 is administered orally as its free base or malate
salt once daily as a tablet as provided in the following table.
Ingredient (% w/w)
Compound 1 25.0-33.3
Microcrystalline Cellulose q.s
Hydroxypropyl Cellulose 3
Poloxamer 0-3
rmellose Sodium 6.0
Colloidal n Dioxide 0.5
Magnesium te 0.5-1.0
Total 100
In another embodiment, compound 1 is administered orally as its free base or malate
salt once daily as a tablet as provided in the following table.
Ingredient Theoretical
Quantity (mg/unit
dose)
Compound 1 100.0
Microcrystalline Cellulose PH- 155.4
Lactose Anhydrous 60M 77.7
Hydroxypropyl Cellulose, EXF 12.0
Croscarmellose Sodium 24
dal Silicon Dioxide 1.2
Magnesium Stearate (Non- 3.0
Bovine)
Opadry Yellow 16.0
Total 416
Any of the tablet formulations provided above can be adjusted ing to the dose
of compound 1, or a pharmaceutically acceptable salt thereof desired. Thus, the amount of
each of the formulation ingredients can be proportionally adjusted to provide a table
formulation containing various amounts of compound 1 as provided in the previous
aphs. In another embodiment, the formulations can n 20, 40, 60, or 80 mg of
compound 1, or a pharmaceutically acceptable salt thereof.
bed herein is a method for ting or reversing the progress of
abnormal cell growth in a mammal, comprising administering a compound of Formula I, or a
pharmaceutically acceptable salt thereof, wherein the abnormal cell growth is cancer
mediated by a ROS1 fusion protein, for example, SLC34A2-ROS1 fusion protein, CD74-
ROS1 fusion protein, FIG-ROS1 fusion protein, FIG-ROS1(L) fusion protein, S1(S)
fusion protein, and FIG-ROS1(VL) fusion n, and other ROS1 fusion proteins
comprising a functional C-terminal ROS1 kinase domain as encoded by the ROS1 gene on
chromosome 6 in humans (6q22). In one embodiment, the cancer is lung adenocarcinoma. In
another, the lung adenocarcinoma is non-small cell lung cancer. In another embodiment, the
lung adenocarcinoma is SLC34A2-ROS1 fusion-positive all cell lung cancer. In
another embodiment, the lung adenocarcinoma is CD74-ROS1 fusion-positive non-small cell
lung cancer. In another embodiment, the lung adenocarcinoma is FIG-ROS1 fusion-positive
non-small cell lung cancer. In another embodiment, the lung adenocarcinoma is a ROS1
fusion-positive non-small cell lung . In r ment, a nd of Formula
I, or a pharmaceutically acceptable salt thereof is administered as a pharmaceutical
composition comprising a compound of Formula I, or a ceutically acceptable salt
thereof and at least one pharmaceutically acceptable carrier. In another ment, the
compound of Formula I is administered subsequent to another form of treatment. In another
embodiment, a compound of Formula I, or a pharmaceutically acceptable salt thereof, is
administered post-cisplatin and/or gemcitabine treatment. In another embodiment, a
compound of Formula I or a pharmaceutically acceptable salt thereof, is administered postcarboplatin
and/or abine treatment. In another embodiment, a nd of Formula I
is administered post-crizotinib treatment. In another embodiment, a compound of Formula I,
or a pharmaceutically acceptable salt thereof, is administered post-crizotinib and/or
gemcitabine treatment. In another embodiment, a nd of Formula I or a
pharmaceutically acceptable salt f, is administered post-docetaxel treatment. In another
embodiment, a compound of Formula I is administered post-carboplatin treatment. In
another embodiment, a compound of Formula I or a pharmaceutically acceptable salt thereof,
is stered post-cisplatin and/or gemcitabine and/or docetaxel ent. In another
embodiment, a compound of a I or a pharmaceutically acceptable salt thereof, is
administered post-carboplatin and/or gemcitabine and/or docetaxel treatment. In another
ment, a compound of Formula I or a ceutically acceptable salt thereof, is
administered post-crizotinib and/or gemcitabine and/or docetaxel treatment.
Described herein is a method for inhibiting or ing the progress of
abnormal cell growth in a mammal, comprising stering a compound of a Ia, or
a pharmaceutically acceptable salt thereof, wherein the abnormal cell growth is cancer
mediated by a ROS1 fusion protein, for example, SLC34A2-ROS1 fusion n, CD74-
ROS1 fusion protein, FIG-ROS1 fusion protein, FIG-ROS1(L) fusion protein, FIG-ROS1(S)
fusion protein, and FIG-ROS1(VL) fusion protein, and other ROS1 fusion proteins
comprising a functional C-terminal ROS1 kinase domain as encoded by the ROS1 gene on
chromosome 6 in humans (6q22). In one embodiment, the cancer is lung adenocarcinoma. In
r, the lung adenocarcinoma is non-small cell lung cancer. In another embodiment, the
lung adenocarcinoma is SLC34A2-ROS1 fusion-positive non-small cell lung cancer. In
another embodiment, the lung adenocarcinoma is CD74-ROS1 fusion-positive non-small cell
lung cancer. In another embodiment, the lung adenocarcinoma is FIG-ROS1 fusion-positive
non-small cell lung cancer. In another embodiment, the lung adenocarcinoma is a ROS1
fusion-positive all cell lung . In another embodiment, a compound of Formula
Ia, or a pharmaceutically acceptable salt thereof is administered as a pharmaceutical
composition comprising a compound of Formula Ia, or a pharmaceutically acceptable salt
thereof and at least one pharmaceutically acceptable carrier. In another embodiment, the
compound of Formula Ia is administered subsequent to another form of treatment. In another
embodiment, a compound of Formula Ia, or a pharmaceutically acceptable salt thereof, is
administered post-cisplatin and/or gemcitabine treatment. In another embodiment, a
compound of Formula Ia, or a pharmaceutically acceptable salt thereof, is administered postdocetaxel
treatment. In another embodiment, a compound of Formula Ia, or a
pharmaceutically acceptable salt thereof, is stered post-cisplatin and/or gemcitabine
and/or docetaxel treatment. In another ment, a nd of a Ia or a
pharmaceutically acceptable salt thereof, is administered post-carboplatin and/or gemcitabine
treatment. In another embodiment, a compound of Formula Ia, or a pharmaceutically
able salt thereof, is administered post-crizotinib ent. In another embodiment, a
compound of Formula Ia, or a pharmaceutically acceptable salt thereof, is administered postcrizotinib
and/or gemcitabine treatment. In another embodiment, a nd of Formula Ia
or a pharmaceutically able salt thereof, is administered post-docetaxel treatment. In
another embodiment, a compound of Formula Ia is administered post-carboplatin treatment.
In another embodiment, a compound of Formula Ia or a pharmaceutically acceptable salt
thereof, is administered post-cisplatin and/or gemcitabine and/or docetaxel treatment. In
another embodiment, a nd of Formula Ia or a pharmaceutically acceptable salt
thereof, is administered arboplatin and/or abine and/or xel treatment. In
r embodiment, a compound of Formula Ia or a pharmaceutically acceptable salt
thereof, is administered post-crizotinib and/or gemcitabine and/or docetaxel treatment.
Described herein is a method for inhibiting or reversing the progress of
abnormal cell growth in a , comprising administering compound 1 or a
pharmaceutically acceptable salt thereof, wherein the abnormal cell growth is cancer
mediated by a ROS1 fusion protein, for example, SLC34A2-ROS1 fusion protein, CD74-
ROS1 fusion protein, FIG-ROS1 fusion protein, FIG-ROS1(L) fusion protein, FIG-ROS1(S)
fusion n, and FIG-ROS1(VL) fusion protein, and other ROS1 fusion proteins
sing a functional C-terminal ROS1 kinase domain as encoded by the ROS1 gene on
chromosome 6 in humans (6q22). In one ment, the cancer is lung adenocarcinoma. In
r, the lung adenocarcinoma is all cell lung cancer. In another embodiment, the
lung adenocarcinoma is SLC34A2-ROS1 fusion-positive non-small cell lung cancer. In
another embodiment, the lung arcinoma is CD74-ROS1 fusion-positive non-small cell
lung cancer. In another embodiment, the lung adenocarcinoma is FIG-ROS1 fusion-positive
non-small cell lung cancer. In another embodiment, the lung adenocarcinoma is a ROS1
fusion-positive non-small cell lung cancer. In another embodiment, compound 1 or a
pharmaceutically acceptable salt thereof is administered as a pharmaceutical ition
comprising nd 1 or a pharmaceutically acceptable salt thereof and at least one
pharmaceutically acceptable carrier. In another embodiment, compound 1 is administered
subsequent to another form of ent. In another embodiment, compound 1, or a
pharmaceutically acceptable salt thereof, is administered post-cisplatin and/or gemcitabine
treatment. In another embodiment, compound 1, or a pharmaceutically acceptable salt
thereof, is administered post-docetaxel treatment. In another embodiment, compound 1, or a
pharmaceutically acceptable salt thereof, is administered post-cisplatin and/or gemcitabine
and/or docetaxel ent. In another embodiment, compound 1 or a pharmaceutically
acceptable salt thereof, is administered post-carboplatin and/or gemcitabine ent. In
another embodiment, compound 1 or a pharmaceutically acceptable salt thereof is
administered post-crizotinib treatment. In another embodiment, compound 1, or a
pharmaceutically acceptable salt thereof, is administered post-crizotinib and/or gemcitabine
treatment. In another embodiment, compound 1, or a pharmaceutically acceptable salt
thereof, is administered post-docetaxel treatment. In another embodiment, compound 1, or a
pharmaceutically acceptable salt thereof, is administered post-carboplatin treatment. In
another embodiment, compound 1, or a ceutically acceptable salt thereof, is
administered post-cisplatin and/or gemcitabine and/or docetaxel treatment. In another
embodiment, compound 1, or a ceutically acceptable salt thereof, is administered
arboplatin and/or gemcitabine and/or docetaxel ent. In another embodiment,
compound 1, or a pharmaceutically acceptable salt thereof, is administered post-crizotinib
and/or gemcitabine and/or docetaxel treatment. In another embodiment, compound 1, or a
pharmaceutically acceptable salt thereof, is administered post-crizotinib and/or carboplatin
ent.
] Described herein is a method for preventing, treating, inhibiting or reversing
the progress of abnormal cell growth in a mammal, comprising stering nd 1, or
a pharmaceutically acceptable salt thereof, wherein the abnormal cell growth is a cancer
ed by a ROS1 fusion protein, for e, SLC34A2-ROS1 fusion protein, CD74-
ROS1 fusion n, FIG-ROS1 fusion protein, FIG-ROS1(L) fusion protein, FIG-ROS1(S)
fusion protein, FIG-ROS1(VL) fusion protein, or other ROS1 fusion proteins, wherein the
cancer has been previously treated with a eutic regimen of crizotinib, and/or
carboplatin and is resistant to crizotinib, and/or carboplatin. In some embodiments, the
cancer that is resistant to crizotinib, and/or carboplatin, harbors one or more ROS1 fusion
proteins selected from: SLC34A2-ROS1 fusion protein, CD74-ROS1 fusion protein, FIGROS1
fusion protein, FIG-ROS1(L) fusion protein, FIG-ROS1(S) fusion protein, and FIGROS1
(VL) fusion protein, and/or contains a mutation in the ROS1 kinase domain of the
SLC34A2-ROS1 fusion protein, CD74-ROS1 fusion protein, FIG-ROS1 fusion protein, 1
(L) fusion protein, FIG-ROS1(S) fusion protein, or S1(VL) fusion protein. In
one embodiment, the crizotinib and/or carboplatin resistant cancer is a cancer having a
mutation in the ROS1 kinase domain of a CD74-ROS1 fusion protein. In a related
embodiment, the cancer is a crizotinib refractory CD74-ROS1 fusion positive lung
adenocarcinoma, for e, a crizotinib tory CD74-ROS1 fusion positive NSCLC,
harboring a mutation in the ROS1 kinase domain. In another embodiment, the crizotinib
and/or carboplatin resistant cancer is a cancer, for example, a inib resistant lung
adenocarcinoma, for example, a crizotinib resistant NSCLC, ing a mutation selected
from E1990G, G2032R, L2026M, L1951R, M2128V, K2003I, and combinations f in
the ROS1 kinase domain of a CD74-ROS1fusion protein.
Described herein is a method for preventing, treating, inhibiting or reversing
the progress of abnormal cell growth in a mammal, for e, a cancer, the method
comprising administering a compound of Formula I, or a pharmaceutically acceptable salt
thereof, wherein the abnormal cell growth is a cancer mediated by a ROS1 fusion protein, for
example, SLC34A2-ROS1 fusion protein, CD74-ROS1 fusion protein, FIG-ROS1 fusion
protein, FIG-ROS1(L) fusion protein, FIG-ROS1(S) fusion protein, S1(VL) fusion
n, or other ROS1 fusion proteins, wherein the cancer has been previously treated with a
therapeutic regimen of crizotinib, and/or carboplatin and is resistant to crizotinib, and/or
carboplatin. In some embodiments, the cancer that is ant to crizotinib, and/or
carboplatin, harbors one or more ROS1 fusion proteins selected from: SLC34A2-ROS1
fusion protein, CD74-ROS1 fusion protein, FIG-ROS1 fusion protein, FIG-ROS1(L) fusion
n, FIG-ROS1(S) fusion protein, and FIG-ROS1(VL) fusion protein, and/or contains a
mutation in the ROS1 kinase domain of the SLC34A2-ROS1 fusion protein, OS1
fusion protein, FIG-ROS1 fusion protein, FIG-ROS1(L) fusion protein, FIG-ROS1(S) fusion
protein, or FIG-ROS1(VL) fusion protein. In one embodiment, the crizotinib ant
cancer is a cancer having a mutation in the ROS1 kinase domain of a CD74-ROS1 fusion
protein. In a related embodiment, the cancer is a crizotinib refractory CD74-ROS1 fusion
positive lung adenocarcinoma, for example, a crizotinib refractory CD74-ROS1 fusion
positive NSCLC, harboring a on in the ROS1 kinase domain. In another embodiment,
the crizotinib resistant cancer is a cancer, for example, a crizotinib resistant lung
adenocarcinoma, for example, a crizotinib resistant NSCLC, harboring a on selected
from E1990G, G2032R, L2026M, , M2128V, K2003I, and combinations thereof in
the ROS1 kinase domain of a CD74-ROS1fusion protein. In various embodiments described
above, a method for preventing, treating, inhibiting or reversing the progress of al cell
growth in a mammal, comprises administering a compound of Formula I, or a compound of
Formula Ia, or compound 1, or a pharmaceutically acceptable salt thereof, in an ary
therapeutically effective dose ranging from about 0.01mg/kg to about 100 mg/kg, or from
about 0.1 mg/kg to about 75 mg/kg, or from about 0.1 mg/kg to about 50 mg/kg, or from
about 0.1 mg/kg to about 40 mg/kg, or from about 0.1 mg/kg to about 30 mg/kg, or from
about 0.1 mg/kg to about 20 mg/kg, or from about 0.1 mg/kg to about 15 mg/kg, or from
about 0.1 mg/kg to about 10 mg/kg or from about 0.1 mg/kg to about 5 mg/kg, or from about
0.1 mg/kg to about 1 mg/kg to a patient in need thereof, n the abnormal cell growth is
a cancer mediated by a ROS1 fusion protein, for example, SLC34A2-ROS1 fusion n,
CD74-ROS1 fusion protein, FIG-ROS1 fusion protein, S1(L) fusion protein, FIGROS1
(S) fusion protein, FIG-ROS1(VL) fusion protein, or other ROS1 fusion protein; or a
cancer ing one or more mutations in a ROS1 fusion protein, for example, a mutation in
a ROS1 kinase domain in a SLC34A2-ROS1 fusion protein, CD74-ROS1 fusion protein,
FIG-ROS1 fusion protein, FIG-ROS1(L) fusion protein, FIG-ROS1(S) fusion protein, FIGROS1
(VL) fusion protein, or other ROS1 fusion proteins, including in some embodiments, a
cancer that has been previously treated with a eutic regimen of crizotinib, and/or
carboplatin and is ant to crizotinib, and/or carboplatin, for example, a crizotinib resistant
cancer, for example, a crizotinib resistant lung arcinoma, for example, a crizotinib
resistant NSCLC.
Administration
Administration of the compound of Formula I, Formula Ia, or compound 1, or
a pharmaceutically acceptable salt f, in pure form or in an appropriate pharmaceutical
composition, can be carried out via any of the accepted modes of administration or agents for
g similar utilities. Thus, administration can be, for example, , nasally, parenterally
venous, intramuscular, or subcutaneous), topically, transdermally, intravaginally,
intravesically, intracistemally, or rectally, in the form of solid, semi-solid, lyophilized
powder, or liquid dosage forms, such as for e, s, suppositories, pills, soft elastic
and hard gelatin dosages (which can be in capsules or tablets), powders, solutions,
suspensions, or aerosols, or the like, specifically in unit dosage forms suitable for simple
administration of precise dosages.
] The compositions will include a conventional pharmaceutical carrier or
excipient and a compound of Formula I as the/an active agent, and, in addition, may include
carriers and adjuvants, etc.
Adjuvants include preserving, wetting, suspending, sweetening, flavoring,
perfuming, emulsifying, and dispensing agents. Prevention of the action of microorganisms
can be ensured by various antibacterial and antifungal agents, for example, parabens,
butanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic
agents, for example sugars, sodium chloride, and the like. Prolonged absorption of the
injectable pharmaceutical form can be brought about by the use of agents delaying
absorption, for example, aluminum monostearate and n.
If desired, a pharmaceutical composition of the compound of Formula I may
also n minor amounts of auxiliary substances such as wetting or emulsifying agents, pH
buffering , antioxidants, and the like, such as, for example, citric acid, sorbitan
monolaurate, triethanolamine oleate, butylalted ytoluene, etc.
The choice of composition depends on various factors such as the mode of
drug administration (e.g., for oral administration, itions in the form of tablets, pills or
capsules) and the bioavailability of the drug substance. Recently, pharmaceutical
compositions have been developed especially for drugs that show poor bioavailability based
upon the principle that bioavailability can be increased by increasing the surface area i.e.,
decreasing particle size. For example, U.S. Pat. No. 4,107,288 describes a pharmaceutical
composition having particles in the size range from 10 to 1,000 nm in which the active
material is supported on a crosslinked matrix of macromolecules. U.S. Pat. No. 5,145,684
describes the production of a pharmaceutical composition in which the drug substance is
pulverized to nanoparticles (average particle size of 400 nm) in the presence of a surface
modifier and then dispersed in a liquid medium to give a pharmaceutical ition that
exhibits ably high bioavailability.
Compositions suitable for parenteral injection may comprise physiologically
acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions,
and sterile powders for reconstitution into sterile injectable solutions or dispersions.
Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include
water, ethanol, polyols leneglycol, polyethyleneglycol, glycerol, and the like), suitable
mixtures thereof, ble oils (such as olive oil) and injectable organic esters such as ethyl
oleate. Proper ty can be maintained, for example, by the use of a coating such as
in, by the maintenance of the required particle size in the case of dispersions and by the
use of surfactants.
One specific route of administration is oral, using a convenient daily dosage
regimen that can be ed according to the degree of severity of the disease-state to be
treated.
Solid dosage forms for oral stration include capsules, tablets, pills,
powders, and granules. In such solid dosage forms, the active nd is admixed with at
least one inert ary ent (or carrier) such as sodium citrate or dicalcium phosphate
or (a) s or extenders, as for example, starches, lactose, sucrose, glucose, mannitol, and
silicic acid, (b) binders, as for example, cellulose derivatives, starch, alignates, gelatin,
polyvinylpyrrolidone, sucrose, and gum acacia, (c) humectants, as for e, glycerol, (d)
disintegrating agents, as for example, agar-agar, m carbonate, potato or tapioca starch,
alginic acid, croscarmellose sodium, complex silicates, and sodium carbonate, (e) solution
retarders, as for example paraffin, (f) tion accelerators, as for example, quaternary
ammonium compounds, (g) wetting agents, as for example, cetyl alcohol, and glycerol
monostearate, magnesium stearate and the like (h) adsorbents, as for example, kaolin and
bentonite, and (i) lubricants, as for example, talc, calcium stearate, magnesium stearate, solid
polyethylene glycols, sodium lauryl sulfate, or mixtures f. In the case of capsules,
s, and pills, the dosage forms may also comprise buffering agents.
Solid dosage forms as described above can be prepared with coatings and
shells, such as enteric coatings and others well known in the art. They may contain pacifying
agents, and can also be of such composition that they release the active compound or
nds in a certain part of the intestinal tract in a delayed manner. Examples of
embedded compositions that can be used are polymeric substances and waxes. The active
compounds can also be in microencapsulated form, if appropriate, with one or more of the
above-mentioned excipients.
Liquid dosage forms for oral administration include pharmaceutically
acceptable ons, solutions, suspensions, syrups, and elixirs. Such dosage forms are
prepared, for example, by dissolving, sing, etc., the compound of Formula I, or a
pharmaceutically acceptable salt thereof, and optional pharmaceutical adjuvants in a carrier,
such as, for example, water, saline, aqueous dextrose, ol, l and the like;
solubilizing agents and emulsifiers, as for example, ethyl alcohol, isopropyl alcohol, ethyl
ate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol,
1,3-butyleneglycol, dimethylformamide; oils, in particular, cottonseed oil, groundnut oil, corn
germ oil, olive oil, castor oil and sesame oil, ol, ydrofurfuryl alcohol,
polyethyleneglycols and fatty acid esters of sorbitan; or mixtures of these substances, and the
like, to thereby form a solution or suspension.
Suspensions, in addition to the active compounds, may n suspending
agents, as for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan
esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and
tragacanth, or mixtures of these substances, and the like.
Compositions for rectal administration are, for e, suppositories that can
be prepared by mixing the compound of Formula I, or a pharmaceutically acceptable salt
thereof, with, for example, suitable non-irritating excipients or carriers such as cocoa butter,
hyleneglycol or a suppository wax, which are solid at ordinary temperatures but liquid
at body temperature and therefore, melt while in a suitable body cavity and release the active
ent therein.
Dosage forms for topical administration of the compound of Formula I, or a
pharmaceutically acceptable salt thereof, e nts, powders, sprays, and inhalants.
The active component is admixed under sterile conditions with a physiologically acceptable
carrier and any preservatives, buffers, or propellants as may be required. Ophthalmic
compositions, eye ointments, powders, and solutions are also contemplated as being within
the scope of this disclosure.
Compressed gases may be used to disperse the compound of Formula I, or a
pharmaceutically acceptable salt thereof, in aerosol form. Inert gases suitable for this e
are nitrogen, carbon e, etc.
] Generally, depending on the intended mode of administration, the
pharmaceutically acceptable compositions will contain about 1% to about 99% by weight of a
compound(s) of Formula I, or a pharmaceutically acceptable salt thereof, and 99% to 1% by
weight of a suitable pharmaceutical excipient. In one example, the composition will be
between about 5% and about 75% by weight of a compound(s) of Formula I, Formula Ia, or
compound 1, or a pharmaceutically acceptable salt thereof, with the rest being suitable
pharmaceutical excipients.
Actual methods of preparing such dosage forms are known, or will be
apparent, to those skilled in this art; for example, see Remington's Pharmaceutical Sciences,
18th Ed., (Mack Publishing Company, Easton, Pa., 1990). The composition to be
administered will, in any event, contain a therapeutically effective amount of a compound of
Formula I, or a pharmaceutically acceptable salt thereof, for treatment of a disease-state in
ance with the teachings of this disclosure.
The compounds of this disclosure, or their pharmaceutically acceptable salts
or solvates, are administered in a therapeutically ive amount which will vary depending
upon a variety of factors including the activity of the specific compound employed, the
metabolic stability and length of action of the compound, the age, body weight, general
, sex, diet, mode and time of administration, rate of excretion, drug combination, the
severity of the ular disease-states, and the host undergoing therapy. The nd of
Formula I, Formula Ia, or compound 1, or a pharmaceutically acceptable salt thereof, can be
stered to a patient at dosage levels in the range of about 0.1 to about 1,000 mg per day.
For a normal human adult having a body weight of about 70 kilograms, a dosage in the range
of about 0.01 to about 100 mg per kilogram of body weight per day is an e. The
ic dosage used, however, can vary. For e, the dosage can depend on a number of
s including the requirements of the patient, the severity of the condition being treated,
and the pharmacological activity of the compound being used. The determination of optimum
dosages for a ular patient is well known to one of ordinary skill in the art.
In other embodiments, the compound of Formula I, Formula Ia, or compound
1, or a pharmaceutically acceptable salt thereof, can be administered to the patient
rently with other cancer treatments. Such treatments include other cancer
chemotherapeutics, hormone replacement therapy, radiation therapy, or immunotherapy,
among others. The choice of other therapy will depend on a number of factors including the
metabolic stability and length of action of the compound, the age, body weight, general
health, sex, diet, mode and time of stration, rate of excretion, drug combination, the
severity of the particular disease-states, and the host undergoing therapy.
Described herein is a method for detecting, diagnosing and treating ROS1
fusions related disease such as SLC34A2-ROS1 fusion-positive NSCLC, CD74-ROS1
fusion-positive NSCLC, and FIG-ROS1 fusion-positive NSCLC, in addition to other ROS1
fusion positive NSCLC. We describe in more detail here methods for the detection and
diagnosing of such disorders. Treating these ers can be better accomplished with the
administering of a therapeutically effective amount of a pharmaceutical composition
comprising a compound of Formula I or the malate salt of a nd of Formula I or
another pharmaceutically acceptable salt of a compound of Formula I, ing in a specific
embodiment, the compound of Formula I is compound 1 or the malate salt of compound 1 to
a patient who has been identified or sed as having a ROS1 fusion related disease such
as SLC34A2-ROS1 fusion-positive NSCLC, CD74-ROS1 fusion-positive NSCLC, and 1
fusion-positive NSCLC.
In another aspect, a compound of Formula I, or a pharmaceutically acceptable
salt thereof, is stered to a patient for preventing or treating a lung cancer.In some of
these ments, the method ses stering to the patient in need thereof, a
composition comprising at least one inhibitor against an ROS1 fusion n, at least one
tor against the ROS1 fusion gene encoding the fusion protein, at least one inhibitor
against a ROS1 coding gene, or a combination thereof, as an active ient.
ROS1 and Fusion Partners SLC34A2, CD74 and FIG
The ROS1 protein, SLC34A2 protein, CD74 protein and FIG n, the
SLC34A2-ROS1 fusion, or the CD74-ROS1 fusion; or the FIG-ROS1 fusion or sometimes
simply called the “ROS1 fusion protein and nucleic acids,” including methods of detection,
diagnosing, kits for detecting and diagnosing, methods of screening, methods of treating and
preventing and various therapy for lung cancer patients, methods to measure the effectiveness
of treatments and other pharmaceutical ingredients can be used in combination with the
various treatments are described below.
The ROS1 n is an orphan transmembrane receptor tyrosine kinase. Human
ROS1 kinase protein (encoded by the ROS1 gene) is a 2347 amino acid long receptor
tyrosine kinase that is prone to aberrant expression leading to cancer. A description of full
length human ROS1 kinase (with the amino acid sequence of the human ROS1 protein) can
be found at UniProt Accession No. P08922 (E.C.- 2.7.10.1). As shown in Table 1, the signal
peptide, extracellular, transmembrane, and kinase domains of ROS1 are found at the
following amino acid residues in SEQ ID NO: 1
Table 1. Amino acid es and domains of ROS1 protein in SEQ ID NO: 1
Signal peptide 1-27 Extracellular domain 28-1859 Transmembrane domain 1860-1882 Kinase
domain 1945-2222
Protein
Domain Amino Acid residues in SEQ ID NO:1
Signal Peptide 1-27
Extracellular domain 28-1859
Transmembrane domain 1860-1882
Kinase domain 1945-2222
The human ROS1 protein may be encoded by a human ROS1 gene d on
human chromosome 6. The C-terminal domain of ROS1 protein may include an amino acid
sequence encoded by a polynucleotide from 31st or 32nd or 34th exon to the last exon (for
example, 32nd or 34th exon) or a fragment thereof of ROS1 gene. The C-terminal domain of
ROS1 protein may include consecutively at least about 100 amino acids from the start
position of 31st or 32nd exon. For e, the C-terminal domain of ROS1 protein may
include consecutively about 100 to about 700 amino acids, consecutively about 200 to about
600 amino acids, or consecutively about 250 to about 500 amino acids, or consecutively
about 270 to about 425 amino acids, or consecutively about 270 to about 450 amino acids, or
consecutively about 475 to about 625 amino acids from the start position of the 32nd exon
(long form) or the 34th exon (short form) toward C-terminus of the ROS1 n. The
inferred breakpoint for the ROS1 protein is 1750, or 1852-1853 aa for SLC34A2-ROS1
fusion ns and CD74-ROS1 fusion proteins and 1880-1881 aa for FIG-ROS1 fusion
proteins.
In one exemplary embodiment, the human SLC34A2 gene encoding the human
SLC34A2 protein (mRNA NM_001177998) is localized to human some 4 (4p15.2)
and contains 13 exons and an amino acid length of about 690 amino acids. The protein
encoded by this gene is a pH-sensitive sodium-dependent phosphate transporter. Defects in
this gene are a cause of pulmonary alveolar microlithiasis. Three transcript variants encoding
two different ms have been found for this gene. The SLC34A2 protein may be derived
from a mammal, such as a human. The N-terminal domain of a SLC34A2-ROS1fusion
protein may include an amino acid sequence encoded by a polynucleotide from the first exon
to the 12th exon, or from the first exon to the fourth exon, or from the first exon to the second
exon of SLC34A2 gene. These last observed exons in the structure of SLC34A2 gene have
inferred breakpoints of 429 and 2076. The N-terminal domain of a SLC34A2-ROS1 fusion
protein may include consecutively at least about 30-250 amino acids from 1st on (that
is, at least amino acid sequence from 1st to 250th positions, or fragments thereof) of the
SLC34A2 protein. The N-terminal domain of SLC34A2-ROS1 fusion protein may include
consecutively about 30 to 250 amino acids, consecutively about 30 to 225 amino acids,
consecutively about 40 to 200 amino acids, or consecutively about 40 to 175 amino acids
from the 1st amino acid position of the SLC34A2 protein.
In one exemplary embodiment, the SLC34A2-ROS1 fusion is a chromosomal
ocation between human chromosomes 6 and 4 that fuses the 3’ region of ROS1 to the 5’
region of SLC34A2. The fusion protein is ed and validated using s s
known to one skilled in the art and or as described herein. In some embodiments, a
compound of a I, or a pharmaceutically acceptable salt thereof, is then administered to
a patient in need thereof for preventing or treating a lung cancer. In some embodiments, a
composition is administered to a patient in need f sing at least one inhibitor
against the SLC34A2-ROS1 fusion protein, at least one inhibitor t the SLC34A2-ROS1
fusion gene ng the fusion protein, at least one inhibitor against a ROS1 coding gene, or
a combination thereof, as an active ingredient.
In the 2-ROS1 fusion protein, the fusion, or fusion region may occur
between various exons of the SLC34A2 gene and the ROS1 gene. Many fusions are known
to one skilled in the art. Examples of such fusions include the 2nd, and/or 4th exon of
SLC34A2 gene and 32nd (Long, L), and/or 34th exon (Short, S) of ROS1 gene, which is called
as a fusion point or breakpoint. Other ROS1 and SLC34A2 fusion or breakpoints are known,
and can be found in the COSMIC-Catalogue of somatic mutations in cancer database v.68 at
cancer.sanger.ac.uk/cancergenome/projects/cosmic/ . The term "a fusion region" may refer to
a polynucleotide fragment (about 10-30 nucleotides) or polypeptide (about 5-30 amino acids)
fragment around the fusion point.
The CD74-ROS1 fusion is a ROS1-involved a chromosomal translocation
between human chromosomes 5 and 6 that fuses the 3’ region of ROS1 to the 5’ region of
CD74. The fusion protein is detected and validated using various methods known to one
skilled in the art and or as described herein. The N-terminal domain of a CD74-ROS1 fusion
protein may include an amino acid sequence encoded by a polynucleotide from the first exon
to the 12th exon, or from the first exon to the fourth exon, or from the first exon to the second
exon of CD74 gene. The N-terminal domain of a CD74-ROS1 fusion n may include
consecutively at least about 30-250 amino acids from 1st position (that is, at least amino
acid sequence from 1st to 250th positions, or fragments thereof) of the CD74 protein. The N-
terminal domain of OS1 fusion protein may include consecutively about 30 to 250
amino acids, consecutively about 30 to 225 amino acids, consecutively about 40 to 200
amino acids, or consecutively about 40 to 210 amino acids or fragments thereof from the 1st
amino acid position of the CD74 protein.
In the fusion protein, the fusion, or fusion region may occur between s
exons of the CD74 gene and the ROS1 gene. Many fusions are known to one skilled in the
art. es of such CD74-ROS1fusions include the 6th exon of CD74 gene fused to the
32nd, or 34th exon of ROS1 gene, which is called as a fusion point or breakpoint. Other
ROS1 and CD74 fusion or breakpoints are known, and can be found in the COSMICCatalogue
of somatic mutations in cancer database v.68 at
cancer.sanger.ac.uk/cancergenome/projects/cosmic/. The term "a fusion region" may refer to a
polynucleotide fragment (about 10-30 nucleotides) or polypeptide (about 5-30 amino acids)
nt around the fusion point.
] The fusion protein FIG-ROS1 results from an intra-chromosomal deletion on
human chromosome 6 fusing the 5’ region of FIG (aka GOPC) to the 3’ region of ROS1.
FIG-ROS1 fusions have been identified in s from cholangiocarcinoma and ovarian
cancer patients at a ncy of 8.7% and 0.5%, respectively. The FIG-ROS1 fusion
protein can be detected and ted using various methods known to one skilled in the art
and or as described herein. The N-terminal domain of a FIG-ROS1 fusion protein may
include utively at least about 150-500 amino acids from 1st position (that is, at least
amino acid sequence from 1st to 500th positions, or fragments thereof) of the FIG protein.
The N-terminal domain of FIG-ROS1 fusion n may include consecutively about 150 to
about 500 amino acids, consecutively about 200 to 450 amino acids, consecutively about 220
to 425 amino acids, or consecutively about 220 to about 420 amino acids or fragments
thereof from the 1st amino acid position of the FIG protein.
In the FIG-ROS1 fusion protein, the fusion, or fusion region may occur between
various exons of the FIG gene and the ROS1 gene. Several S1 s are known to
one skilled in the art. Examples of such fusions e the 4th or 8th exon of FIG gene fused
to the 35th, or 36th exon of ROS1 gene, which is called as a fusion point or breakpoint.
Other ROS1 and FIG fusions or breakpoints are known, and can be found in the COSMICCatalogue
of somatic mutations in cancer database v.68 at
cancer.sanger.ac.uk/cancergenome/projects/cosmic/. The term "a fusion region" may refer to a
polynucleotide fragment (about 10-30 nucleotides) or polypeptide (about 5-30 amino acids)
fragment around the fusion point.
Other ROS1 fusion partners can include TPM3, SDC4, EZR, and LRIG3, in
addition to the SLC34A2, CD74, and FIG fusions described in detail herein. (See Fig. 1
herein, and for example, Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, et
al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012, and Kurtis D. Davies, Anh T.
Le, Mariana F. Theodoro, Margaret C. , Dara L. Aisner, Eamon M. Berge, Luigi M.
Terracciano, Matteo Incarbone, Massimo Roncalli, Federico Cappuzzo, D. Ross Camidge,
Marileila a-Garcia, and Robert C. Doebelet, Identifying and Targeting ROS1 Gene
Fusions in Non-Small Cell Lung Cancer, (2012), Clin Cancer Res. 2012 September 1;
18(17): 579, the contents of these disclosures relating to the ROS1 fusion proteins is
incorporated herein in their entireties.
In one embodiment, the ROS1fusion protein of the present disclosure comprises
the C-terminal domain of human ROS1 protein (for example, human ROS1 as provided in
SEQ ID NO. 1) providing a functional kinase domain, which consists essentially of
consecutive about 50 to 300 amino acids starting from an amino acid ponding to the
start position of 32nd exon of the ROS1 protein and then toward C-terminus of the ROS1
As used herein, the exon number is numbered ing to the exon number
allocated by the National Center for Biotechnology ation (NCBI) hosted by the National
Institutes of Health, Bethesda, Maryland USA. In some exemplary embodiments, the fusion
protein SLC34A2-ROS1 may have any of the amino acid sequence identified as such by
the NCBI. The nucleotide ces of DNA molecules and the amino acid sequences of
ns encoded by the DNA molecules may be determined by an automated DNA
sequencer or an automated peptide sequencer. The otide or amino acid) sequences
ined by such automated sequencing means may include partial error compared with
actual sequences. Generally the sequences determined by automated cing may have
ce identity of at least about 90%, at least 20 about 95%, at least about 99%, or at least
about 99.9% compared with actual sequences. Therefore, the fusion protein, the fusion gene
or the fusion region may have an amino acid sequence or a nucleotide sequence having
sequence identity of at least about 90%, at least about 95%, at least about 99%, or at least
about 99.9% compared with the sequences of identified as such by the NCBI.
For the purpose of simplicity, the following disclosure refers to the ROS1 fusion
protein SLC34A2-ROS1, but may also apply to other ROS1 fusion proteins described herein.
The exemplified SLC34A2-ROS1 fusion protein, in some embodiments may consist of 80-
200 N-terminal amino acid es of 2 and at least 300 C-terminal residues of
ROS1, preferably ranging from 300-500 C-terminal amino acid residues. The fusion gene has
a protein tyrosine kinase domain together with helical s. Without wishing to be bound
by any theory, it is believed that the tertiary conformation of the SLC34A2-ROS1 fusion
protein induces homo-dimerization which will activate the oncogenic protein tyrosine kinase
domain by auto-phosphorylation. Taken together, the SLC34A2-ROS1 fusion gene may be
highly expressed and then dimerized after translation owing to SLC34A2. Then, the dimerized
ROS1 protein tyrosine kinase domain may be stimulated abnormally, thus facilitating the
stimulation of an oncogenic pathway, for example, as seen in a ROS1 fusion related NSCLC
lung cancer.
Once a fusion is detected it will be known as a fusion gene of SLC34A2-ROS1
encoding the fusion protein of SLC34A2-ROS1. A method of providing information for
sing a lung cancer, comprising the step of detecting, in a test sample obtained from a
t, a fusion as described herein. sis would compare a fusion gene ng the
fusion protein; and an overexpression of ROS1 compared to a standard sample from an
individual t a cancer, wherein when at least one element is selected and detected in the
test sample, allowing the subject to be identified as any or all of the following: a cancer
patient, a lung cancer patient, NSCLC lung cancer patient, a ROS1 fusion related NSCLC
patient, and/or a SLC34A2-ROS1 fusion related NSCLC patient.
The deletion, inversion or translocation of some 6 may be detected by
using a polynucleotide (a probe) capable of hybridizing with (complementarily binding to)
the deletion, inversion or translocation region in human chromosome 6 and/or a primer pair
capable of ing the deletion, inversion or translocation of human chromosome 6, for
example, capable of ing a polynucleotide fragment having consecutive 100 to 200
nucleotides including the inversion region in human chromosome 6. The fusion n, the
fusion gene, and the fusion region are described herein. In an exemplary embodiment, the
fusion protein may also be detected by detecting the ce of the fusion protein or the
fusion gene or mRNA ponding to the fusion gene, for example, with the use of ROS1
specific or ROS1 fusion specific antibodies known in the art and described herein.
The presence of the fusion protein may be detected be a general assay that
measures the interaction between the fusion protein and a material (e.g., an antibody or an
aptamer) specifically binding to the fusion protein. The general assay may be
immunochromatography, immunohistochemical staining, enzyme linked immunosorbent
assay (ELISA), radioimmunoassay (RIA), enzyme immunoassay (EIA), florescence
immunoassay (FIA), luminescence immunoassay (LIA), western blotting, FACS, and the like.
In on, the ce of the fusion gene or the mRNA may be detected by a
general assay such as PCR, FISH (fluorescent in situ hybridization), and the like, using a
polynucleotide capable of hybridizing with (complementarily binding to) the fusion gene or
the mRNA. FISH is described in more detail below. The fusion gene may be detected and/or
validated by using the integration techniques of whole-transcriptome (RNA) and/or wholegenome
DNA sequencing through massively parallel sequencing technologies. The
polynucleotide capable of hybridizing with the fusion gene or the mRNA may be a siRNA, an
oligonucleotide, DNA probe, or DNA primer, which can detect the fusion gene or the mRNA
by a direct ization with the fused or truncated gene or transcript in the test sample.
In further embodiments, fluorescence u hybridization (FISH) is ed in
the methods described herein (as described in Verma et al. Human Chromosomes: A Manual
Of Basic Techniques, Pergamon Press, New York, N.Y. (1988)). A FISH assay can be
performed using one or more probe sets, ments are provided such as: (1) A first probe
set, which is a first probe set targeting a somal site which contains the ROS1 gene
(first somal site); it consists of a probe 1A labeled with a first scent substance
and a probe 1B labeled with a second fluorescent substance; probe 1A is complementary to
the first region, which is the 5' region in the aforementioned first chromosomal site, probe 1B
is complementary to the second region, which is present at a distance from the
aforementioned first region and is the 3' region in the aforementioned first chromosomal site,
and the breakpoint in the ROS1 gene when the SLC34A2-ROS1 fusion gene is produced by a
translocation between the SLC34A2 and ROS1 genes is located in the 3' tail of the
aforementioned first region, between the aforementioned first and second regions, or in the 5'
tail of the aforementioned second region; (2) A second probe set, which is a second probe set
targeting a chromosomal site which contains the 2 gene (second chromosomal site);
it consists of a probe 2A labeled with a first fluorescent substance and a probe 2B labeled
with a second fluorescent substance; probe 2A is complementary to the first region, which is
the 5' region in the aforementioned second chromosomal site, probe 2B is complementary to
the second region, which is t at a distance from the aforementioned first region and is
the 3' region in the aforementioned second chromosomal site, and the breakpoint in the
SLC34A2 gene when the SLC34A2-ROS1 fusion gene is produced by a translocation
between the SLC34A2 and ROS1 genes is located in the 3' tail of the aforementioned first
region, between the aforementioned first and second regions, or in the 5' tail of the
aforementioned second region; (3) a third probe set consisting of the aforementioned probe
2A and the aforementioned probe 1B; and (4) a fourth probe set consisting of a probe 4A
which is complementary to the chromosomal site containing the ROS1 gene (the third
chromosomal site), and a probe 4B which is mentary to the chromosomal site
containing the SLC34A2 gene (the fourth chromosomal site).
The length of the aforementioned first chromosomal site can be 0.5–2.0 Mb. The
length of the aforementioned second somal site can be 0.5–2.0 Mb. The length of the
aforementioned third chromosomal site can be 0.5–2.0 Mb. The length of the aforementioned
fourth chromosomal site can be 0.5–2.0 Mb.
] In some embodiments, the FISH assay may be correlated with other physical
chromosome mapping techniques and genetic map data. The FISH technique is well known
(see, e.g., U.S. Pat. Nos. 696; 5,447,841; 5,776,688; and 5,663,319). Examples of
c map data can be found in the 1994 Genome Issue of Science (265: 1981f).
Correlation n the location of the gene encoding ROS1 protein and/or, in the case of
ROS1 fusion polypeptides, the gene encoding the fusion partner of a ROS1 fusion protein
(e.g., the FIG gene, the SLC34A2 gene, or the CD74 gene) on a physical chromosomal map
and a specific disease, or predisposition to a specific disease, may help t the region of
DNA associated with that genetic disease. The nucleotide sequences of the t disclosure
may be used to detect differences in gene sequences between normal, r, or affected
individuals.
In situ hybridization of somal preparations and physical mapping
techniques such as linkage analysis using established chromosomal markers may be used for
extending genetic maps. Often the placement of a gene on the some of another
mammalian species, such as mouse, may reveal associated s even if the number or arm
of a particular human chromosome is not known. New sequences can be assigned to
chromosomal arms, or parts thereof, by physical mapping. This provides valuable
information to investigators searching for e genes using positional cloning or other
gene discovery techniques. Once the disease or syndrome has been crudely localized by
genetic linkage to a particular genomic region, for e, AT to 11q22-23 (Gatti et al.,
Nature 336: 577-580 (1988)), any sequences mapping to that area may represent ated or
regulatory genes for further investigation. The nucleotide sequences encoding the ROS1
fusions of the present disclosure, or portions thereof, may also be used to detect differences in
the somal location due to translocation, inversion, etc., among normal, carrier, or
affected individuals.
It shall be tood that all of the s (e.g., PCR and FISH) that detect
polynucleotides encoding a polypeptide with ROS1 kinase activity (e.g., full-length ROS1 or
an ROS1 fusion polynucleotides such as SLC34A2-ROS1, or CD74-ROS1, or FIGROS1
(S)), may be combined with other methods that detect polypeptides with ROS1 kinase
activity or polynucleotides encoding a polypeptide with ROS1 kinase activity. For example,
detection of a FIG-ROS1 fusion polynucleotide in the genetic material of a biological sample
(e.g., FIG-ROS1 in a circulating tumor cell) may be followed by Western blotting analysis or
immuno-histochemistry (IHC) analysis of the ns of the sample to determine if the FIGROS1
polynucleotide was actually expressed as a S1 fusion polypeptide in the
biological sample. Such Western blotting or IHC analyses may be performed using an
antibody that specifically binds to the polypeptide encoded by the detected S1
polynucleotide, or the es may be performed using antibodies that specifically bind
either to full length FIG (e.g., bind to the N-terminus of the protein) or to full length ROS1
(e.g., bind an epitope in the kinase domain of ROS1). Such assays are known in the art (see,
e.g., U.S. Pat. No. 7,468,252).
In another example, the CISH technology of Dako allows chromatogenic in situ
hybridization with immuno-histochemistry on the same tissue n. See Elliot et al., Br J
Biomed Sci 2008; 65(4): 167- 171, 2008 for a comparison of CISH and FISH.
] Described herein is a method for diagnosing a patient as having a lung cancer or a
suspected lung cancer driven by an ROS1 kinase. The method includes contacting a
biological sample of said lung cancer or a suspected lung cancer (where the biological sample
comprising at least one nucleic acid le) with a probe that hybridizes under stringent
conditions to a nucleic acid molecule ng a polypeptide with ROS1 kinase ty such
as a full length ROS1 polynucleotide or a ROS1 fusion polynucleotide (e.g., a FIG-ROS1
fusion polynucleotide, an SLC34A2-ROS1 fusion polynucleotide, or a CD74-ROS1 fusion
polynucleotide), and wherein hybridization of said probe to at least one nucleic acid molecule
in said biological sample identifies said patient as having a lung cancer or a suspected lung
cancer driven by a ROS1 kinase.
bed herein is a method for sing a patient as having a lung cancer or
suspected of having lung cancer driven by a ROS1 kinase. The method includes contacting a
biological sample of said lung cancer or suspected lung cancer (where said ical sample
comprises at least one polypeptide) with a reagent that specifically binds to a polypeptide
with ROS1 kinase ty (e.g., a S1 fusion polypeptide, an SLC34A2-ROS1 or a
CD74-ROS1 fusion polypeptide), wherein specific binding of said t to at least one
fusion polypeptide in said ical sample identifies said patient as having a lung cancer or
a suspected lung cancer driven by a ROS1 kinase.
In various embodiments, the identification of a lung cancer or suspected lung
cancer as being driven by a ROS1 kinase will identify that patient having that lung cancer or
suspected lung cancer as being likely to respond to a ROS1-inhibiting therapeutic.
] A kit for detecting translocations between SLC34A2 and ROS1 genes can include
one or more probe sets. (1) A first probe set includes a probe 1A labeled with a first
fluorescent substance and a probe 1B labeled with a second fluorescent substance; Probe 1A
is complementary to the first region, which is the 5' region in the aforementioned first
chromosomal site, probe 1B is mentary to the second region, which is present at a
distance from the aforementioned first region and is the 3' region in the aforementioned first
chromosomal site, and the breakpoint in the ROS1 gene when the SLC34A2-ROS1 fusion
gene is produced by a translocation between the SLC32A2 and ROS1 genes is located in the
3' tail of the aforementioned first region, between the aforementioned first and second
regions, or in the 5' tale of the entioned second region; (2) A second probe set, which
is a second probe set targeting a chromosomal site which contains the SLC32A2 gene
(second chromosomal site); it consists of a probe 2A labeled with a first fluorescent substance
and a probe 2B labeled with a second scent substance; probe 2A is complementary to
the first region, which is the 5' region in the aforementioned second chromosomal site, probe
2B is complementary to the second region, which is present at a distance from the
aforementioned first region and is the 3' region in the aforementioned second chromosomal
site, and the oint in the SLC32A2 gene when the SLC34A2-ROS1 fusion gene is
produced by a translocation between the SLC32A2 and ROS1 genes is located in the 3' tail of
the aforementioned first region, n the aforementioned first and second regions, or in
the 5' tale of the aforementioned second region; (3) A third probe set consisting of the
aforementioned probe 2A and the aforementioned probe 1B; and a fourth probe set consisting
of a probe 4A which is complementary to the chromosomal site ning the ROS1 gene
(the third chromosomal site) and a probe 4B which is complementary to the chromosomal site
containing the SLC32A2 gene (the fourth somal site).
A kit useful for identifying patients susceptible to SLC34A2-ROS1 translocation
includes one or more elements selected from a group comprising an explanation of the use of
the probes, a DNA contrast stain, a buffer for hybridization use, an encapsulant, and a control
slide. The kit makes it le to implement conveniently and efficiently the detection
method described herein. The kit can e as required elements (essential ingredients) the
aforementioned first probe set, second probe set, third probe set or fourth probe set. Two or
more types of probe sets can also be included in the kit. For example, the kit can incorporate
first probe set and third probe set. Since the details for each probe set have been described
above, they will not be repeated here.
Detection of the ce or absence of a SLC34A2-ROS1 fusion polynucleotide
can be performed directly using genome DNA that encodes the aforementioned fusion
polypeptide or a transcript from that genome DNA, but it may also be performed indirectly
using a translation product from that transcript (the entioned fusion polypeptide).
Because the genome DNA that encodes the fusion polypeptide is formed by
ion between the 117.61-117.75Mb region of chromosome 6, (6q22) the phenomenon of
the present disclosure may be detected in the “detection of the presence or absence of a
SLC34A2-ROS1 fusion polynucleotide.” In this detection of inversion, for example, a split
n a e region upstream from the kinase domain coding region of the ROS1 gene
and a 3'-side region ream from that coding region of the ROS1 gene may be detected,
or a split between the coding region of part or all of the l domains and 5'-side region
upstream from that coding region of the SLC32A2 gene and a 3'-side region downstream
from the coding region of the helical s of the SLC34A2 gene may be detected.
Techniques known and available to the d practitioner may be used in the
“detection of the presence or absence of a SLC34A2-ROS1 fusion polynucleotide” in the
present disclosure. If “genome DNA that encodes the aforementioned fusion polypeptide” is
the object, for example, in situ hybridization (ISH) using fluorescence or the like, genome
PCR, direct sequencing, southern blotting, or genome microarray analysis may be used. If a
“transcript from the aforementioned genome DNA” is the object, for example, RT-PCR,
direct sequencing, northern ng, dot blotting, or cDNA microarray analysis may be used.
The kit described herein can also include other elements. Examples of these other
elements are the specification for use of the probes, a DNA counterstain such as DAPI, a
hybridization buffer, a wash buffer, solvents, mounting media, control slides, reaction vessels,
and other equipment. Specifications for stic purposes can also be included.
Furthermore, specifications, etc. can also be included that show how the detection (positive
identification) of SLC34A2-ROS1translocation in some samples from cancer ts
should be set up in these patients using an ROS1 kinase inhibitor. Moreover, a plan for
determining the treatment course and an explanation of this plan can also be included.
Comparatively long probes (approximately 200 kb (probe 1A) to approximately
1,370 kb (probe 4B) are plated. Therefore, complementation between the probes and
the target sequences does not need to be highly restrictive, to the extent that specific
hybridization intended in the present disclosure is achieved. An example of similarity
n target sequences is at least 90%, preferably at least 95%, and more preferably at least
98%.
In the case where a first probe set and second probe set are used, the two
fluorescence signals are separated and detected individually in chromosomal samples in
which the translocation between the SLC34A2 gene and the ROS1 gene occurred; in
chromosomal samples in which the translocation did not occur, lly the two fluorescence
signals are observed to be next to each other, or a signal (yellow) that is a combination of the
two scence signals is observed. Thus, the presence or absence of a translocation
between the 2 gene and the ROS1 gene is reflected in the pattern of the fluorescence
. Consequently, a translocation n the SLC34A2 gene and the ROS1 gene can be
determined from the pattern of the fluorescence signal.
The judgment reached above is preferably and typically made based on a
comparison of a result with a control (test sample). Here, the control is a chromosomal
sample derived from a patient with non-small cell lung cancer or a chromosomal sample
derived from a patient exhibiting precancerous lesions. In addition, chromosomal samples
from a t t cerous lesions, chromosomal samples from patients who do not
have cancer, or chromosomal samples taken from normal, healthy subjects can also be used
as the l. Chromosomal samples derived from strains of cells can also be used as a
When the fusion gene is a fusion gene SLC34A2-ROS1encoding the fusion
protein of SLC34A2-ROS1, the fusion gene SLC34A2-ROS1 (or any other ROS1 fusion
gene, e.g. CD74-ROS1, & FIG-ROS1) may be detected by using a polynucleotide (a probe)
capable of hybridizing with (complementarily binding to) the fusion region and/or a primer
pair capable of producing a polynucleotide fragment having consecutive 100 to 200
nucleotides including the fusion region. In addition, in one exemplary ment, the
fusion protein SLC34A2-ROS1may be detected using an antibody or aptamer specifically
binding to the fusion region of the fusion protein SLC34A2-ROS1.
In addition, the detection can be performed by a fusion assay which is a
combination of chromogenic in situ hybridization (CISH) method and silver in situ
hybridization (SISH) method. The "fusion point" in the present ication refers to a
point where a portion derived from the respective genes of SLC34A2 is fused with a
portion derived from the ROS1 gene.
The term “capable of hybridizing with the fusion region (or the inversion region)”
may refer to having a complementary sequence or a sequence having sequence identity of at
least 90% with that of the fusion region (or the inversion region). Another embodiment
provides a composition for diagnosing a cancer, including one or more selected from the
group consisting of a polynucleotide capable of hybridizing with the fusion region, a primer
pair e of producing a polynucleotide fragment having consecutive 100 to 200
nucleotides ing the fusion . Also a polynucleotide capable of izing with
the inversion region in human chromosome 6, a primer pair capable of producing a
polynucleotide fragment having consecutive 100 to 200 nucleotides including the inversion
region of human chromosome 6, and an antibody or aptamer binding to the fusion region.
Another embodiment provides a use of the fusion protein and/or the fusion gene for
diagnosing a cancer. The patient may be any mammal, for example, a primate such as a
human or monkey, a rodent such as a mouse or a rat, in particular a human. The test sample,
suitable for use in any assays mentioned, may be a cell (e.g., a lung cell); a tissue (e.g., a lung
tissue); body fluid (e.g., blood); circulating tumor DNA, ating tumor cells. The samples
may be ted in any manner known to one skilled in the art, including collection from the
surgical biopsy of tumor, a core biopsy of tumor, a fine needle aspirate of tumor, pleural
on, and other known methods of separating cells and tissues from ts. For
example, a FISH assay ibed ) could be performed on ating tumor cells.
The patient may be receiving treatments or have plans to be treated with a kinase
inhibitor. The test sample may e a cell derived from a human cancer cell or an t
thereof.
Another embodiment provides a fusion gene encoding the fusion protein, where a
gene encoding the N-terminal domain of the fusion partner positions at 5' end and a gene
encoding the C-terminal domain of the ROS1 protein positions at 3' end. In one ary
embodiment, when the fusion protein is the SLC34A2-ROS1protein, the fusion gene may be
represented as SLC34A2-ROS1gene, where a gene encoding the N-terminal domain of
SLC34A2 ons at 5' end and a gene encoding the C-terminal domain of the ROS1 protein
positions at 3' end.
Another ment provides an expression vector including the fusion gene and
optionally ription elements (e.g., a promoter and the like) operably linked to the fusion
gene. Another embodiment provides a transformant cell transformed with the expression
vector.
Biological specimens obtained in the course of treatment or diagnosis (biopsy
samples, etc.) are often formalin fixed, but in this case, the use of in situ hybridization is
advantageous because the DNA genome which is the ion object is stable under formalin
fixing and because detection sensitivity is high.
In in situ hybridization, the genomic DNA that encodes a SLC34A2-ROS1fusion
ptide in the biological specimen can be detected by hybridizing the polynucleotide of
(a) or (b) stated below having a chain length of at least 15 nucleotide bases:
(a) a polynucleotide that is at least one probe selected from the group made up of
probes that hybridize to a polynucleotide that encodes the 2 protein and probes that
hybridize to a polynucleotide that encodes the ROS1 protein
(b) a polynucleotide that is a probe that hybridizes to a fusion site of a
polynucleotide that encodes the SLC34A2 protein and a polynucleotide that encodes the
ROS1 protein.
] In in situ ization, the genome DNA that encodes a CD74-ROS1fusion
polypeptide in the biological specimen can be detected by hybridizing the polynucleotide of
(a) or (b) stated below having a chain length of at least 15 bases:
(a) a polynucleotide that is at least one probe selected from the group made up of
probes that hybridize to a polynucleotide that encodes the CD74 protein and probes that
hybridize to a polynucleotide that encodes the ROS1 protein
(b) a polynucleotide that is a probe that hybridizes to a fusion site of a
polynucleotide that encodes the CD74 n and a polynucleotide that encodes the ROS1
In in situ hybridization, the genome DNA that encodes a FIG-ROS1fusion
polypeptide in the biological en can be detected by hybridizing the polynucleotide of
(a) or (b) stated below having a chain length of at least 15 bases:
(a) a polynucleotide that is at least one probe selected from the group made up of
probes that ize to a polynucleotide that s the FIG protein and probes that
ize to a polynucleotide that encodes the ROS1 protein
(b) a polynucleotide that is a probe that hybridizes to a fusion site of a
polynucleotide that encodes the FIG protein and a polynucleotide that encodes the ROS1
protein.
However, the DNA sequence of a gene may mutate in the natural world (that is,
non-artificially). Accordingly, such natural variants may also be contemplated (similarly
hereinafter).
The polynucleotide stated in (a) of the present sure may be any, provided
that it can detect the presence of genome DNA that encodes the aforementioned ROS1 fusion
n in the biological specimen by hybridizing to a polynucleotide that s the ROS1
binding partner, i.e. SLC34A2, CD74 or FIG protein or a polynucleotide that encodes the
ROS1 protein, which are the target base sequences of that polynucleotide. It is ably a
polynucleotide stated in (a1) through (a4) below.
(a1) A combination of a polynucleotide that hybridizes to the coding region of
part or all of the helical domain of exons 1-2 and 5'-side region upstream from that coding
region of the SLC34A2 gene (also ed to as "5' SLC34A2 probe 1" hereinafter) and a
polynucleotide that hybridizes to the coding region of the kinase domain and 3'-side region
downstream from that coding region of the ROS1 gene (also referred to as "3' ROS1 probe 1"
hereinafter.)
(a2) A combination of a polynucleotide that hybridizes to the 5'-side region
upstream from the coding region of the kinase domain of the ROS1 gene (also referred to as
"5' ROS1 probe 1" hereinafter) and a polynucleotide that hybridizes to coding region of the
kinase domain and 3'-side region downstream from that coding region of the ROS1 gene
(also referred to as "3' ROS1 probe 1" hereinafter.)
] (a3) A combination of a polynucleotide that hybridizes to the coding region of the
ectin type-III 9 and 5'-side region upstream from that region of the ROS1 gene (also
referred to as "5' ROS1 probe 2" hereinafter) and a polynucleotide that hybridizes to the
coding region of the transmembrane domain and 3'-side region downstream from that coding
region of the ROS1 gene (also referred to as "3' ROS1 probe 2" hereinafter.)
(a4) A combination of a polynucleotide that hybridizes to the coding region of
part or all of the l domain and 5'-side region upstream from that coding region of the
SLC34A2 gene (also referred to as "5' SLC34A2 probe 1" hereinafter) and a polynucleotide
that hybridizes to the coding region of the coiled coil domain and 3'-side region downstream
from that coding region of the SLC34A2 gene (also referred to as "3' SLC34A2 probe 1"
hereinafter.)
The region (target base sequence) to which the polynucleotide of (a1) used in in
situ hybridization izes is preferably a region within 000 bases from the fusion
site of the SLC34A2 gene and ROS1 gene, for reasons of specificity to the target base
sequence and detection sensitivity, and the region to which the polynucleotides of (a2)
through (a4) used in in situ hybridization hybridize is preferably a region within 1,000,000
bases from the oint in the SLC34A2 gene or ROS1 gene, for the same reasons.
The polynucleotide stated in (a) or (b) above used in in situ hybridization is
preferably a collection made up of a plurality of types of polypeptide that can cover all of the
entioned target base sequences, for reasons of specificity to the target base sequence
and detection sensitivity. In this case, the length of the polynucleotides that constitute the
collection is at least 15 bases, and preferably 100 to 1000 bases.
The polynucleotide stated in (a) or (b) above used in in situ hybridization is
preferably labeled by fluorescent dye or the like for detection. Examples of such a fluorescent
dye include DEAC, FITC, R6G, TexRed and Cy5, but are not d to these. Other than a
fluorescent dye, the aforementioned polynucleotide may also be labeled with a dye
(chromogen) such as DAB, or silver and the like based on enzymatic metal deposition.
In in situ ization, if 5' SLC34A2 probe 1 and 3' ROS1 probe 1 are used, or if
' ROS1 probe 1 and 3' ROS1 probe 1 are used, or if 5' ROS1 probe 2 and 3' ROS1 probe 2
are used, or if 5' SLC34A2 probe 1 and 3' SLC34A2 probe 1 are used, it is preferred that
these probes are labeled with mutually different dyes. When in situ hybridization is
performed using a combination of probes labeled with ent dyes in this manner, when the
signal produced by the label of 5' SLC34A2 probe 1 (for example, scence) and the
signal produced by the label of 3' ROS1 probe 1 overlap, it can be determined that genome
DNA that encodes a SLC34A2-ROS1 fusion polypeptide has been detected. On the other
hand, when the signal produced by the label of 5' ROS1 probe 1 and the signal produced by
the label of 3' ROS1 probe 1 are split, or the signal produced by the label of 5' ROS1 probe 2
and the signal produced by the label of 3' ROS1 probe 2 are split, or the signal ed by
the label of 5' SLC34A2 probe 1 and the signal produced by the label of 3' 2 probe 1
are split, it can be determined that genome DNA that encodes a SLC34A2-ROS1 fusion
polypeptide has been detected.
Polynucleotide labeling may be performed by a known que. For example, a
substrate base labeled with fluorescent dye or the like by nick ation or random priming
may be integrated in a polynucleotide, thereby labeling that polynucleotide. In in situ
hybridization, the conditions used when hybridizing the polynucleotide stated in (a) or (b)
above and the aforementioned biological specimen may be varied depending on various
factors such as the length of the relevant polynucleotide, but an example of high-stringency
ization conditions is 0.2xSSC, 65°C, and an example of low-stringency hybridization
conditions is 2.0xSSC, 50°C. Note that hybridization conditions of the same stringency as the
aforementioned ions can be ed by a person skilled in the art appropriately
selecting the various conditions such as salt concentration (dilution ratio of SSC) and
temperature, as well as concentration of surfactant (NP-40, etc.), concentration of formamide,
and pH. For example, for general hybridization conditions for screening, polynucleotide
compositions are provided that are capable of hybridizing under moderate to high stringency
conditions to a polynucleotide sequence provided herein, or a fragment thereof, or a
complementary sequence thereof. Hybridization techniques are well known in the art of
molecular biology. For purposes of ration, suitable moderately stringent conditions for
testing the hybridization of a polynucleotide of the present disclosure with other
polynucleotides include prewashing in a solution of 5.times.SSC, 0.5% SDS, 1.0 mM EDTA
(pH 8.0); hybridizing at 50°C-60°C, 5X SSC, overnight; followed by washing twice at 65°C
for 20 minutes with each of 2X, 0.5X and 0.2X SSC containing 0.1% SDS. One skilled in the
art will understand that the stringency of ization can be readily manipulated, such as by
altering the salt content of the hybridization solution and/or the temperature at which the
hybridization is performed. For e, in another ment, suitable highly ent
hybridization conditions include those described above, with the exception that the
temperature of hybridization is increased, e.g., to 60-65°C or 65-70°C.
Examples of methods for detecting genome DNA that encodes a SLC34A2-
ROS1fusion polypeptide using the polynucleotide stated in (a) or (b) above other than the
aforementioned in situ hybridization are rn blotting, rn blotting and dot ng.
In these methods, the aforementioned fusion gene is detected by hybridizing under moderate
to high ency ions the polynucleotide stated in (a) or (b) above to a membrane on
which a nucleic acid extract obtained from the aforementioned biological specimen has been
transcribed. When using the polynucleotide of (a), it can be determined that genome DNA
that encodes a SLC34A2-ROS1fusion polypeptide has been detected when a polypeptide that
hybridizes to a cleotide that encodes the SLC34A2 protein and a polypeptide that
hybridizes to a cleotide that encodes the ROS1 protein recognize the same band
developed on the membrane.
Genome microarray analysis and DNA microarray analysis are additional methods
for ing genome DNA that encodes a SLC34A2-ROS1fusion polypeptide using the
polynucleotide of (b) above. In these methods, an array of polynucleotides of (b) is fixed on a
substrate, and the relevant genome DNA is detected by putting the biological specimen in
contact with the polynucleotides on the array. In PCR or cing, the polynucleotide of
(c) stated below may be used to specifically amplify part or all of a SLC34A2-ROS1fusion
polynucleotide, using DNA (genome DNA, cDNA) or RNA prepared from the biological
specimen as a template. (c) A polynucleotide that is a pair of primers designed to sandwich a
fusion site of a polynucleotide that encodes the SLC34A2 n and a polynucleotide that
encodes the ROS1 protein. The "polynucleotide that is a pair of primers" is a primer set of
which one primer hybridizes to a polynucleotide that encodes the SLC34A2 protein and the
other primer hybridizes to a polynucleotide that encodes the ROS1 protein in a base sequence
such as the entioned fusion polynucleotide that serves as a target. The length of these
polynucleotides is normally 15 to 100 bases, and preferably 17 to 30 bases.
] From the viewpoints of precision and sensitivity of detection by PCR, the
polynucleotide stated in (c) of the present disclosure is preferably a complementary sequence
to the base sequence of the aforementioned fusion polynucleotide within 5000 bases from the
fusion site of the polynucleotide that encodes the SLC34A2 protein and the polynucleotide
that encodes the ROS1 protein.
The ucleotide that is a pair of primers” can be appropriately designed by
known techniques based on the base sequence of the SLC34A2-ROS1fusion polynucleotide
that serves as a target. Advantageous examples of the "polynucleotide that is a pair of
s" are primer sets made up of one primer selected from the group made up of
SLC34A2-ROS1-F1, SLC34A2-int15-F1, SLC34A2-int15-F2, SLC34A2-ex16-F1,
SLC34A2-ex23-F1, SLC34A2-ex24-F1, SLC34A2-F-orf2438 and SLC34A2-int15-F3.5, and
one primer selected from the group made up of SLC34A2-ROS1-R1, ROS1-int11-R3, ROS1-
int7-R1, nt11-R0.5, nt11-R1, nt7-R2 and ROS1-R-orf2364. More
preferably, it is SLC34A2-ROS1-F1 and SLC34A2-ROS1-R1, SLC34A2-int15-F1 and
SLC34A2-ROS1-R1, 2-int15-F2 and ROS1-int11-R3, SLC34A2-ex16-F1 and
SLC34A2-ROS1-R1, SLC34A2-ex23-F1 and 2-ROS1-R1, or SLC34A2-ex24-F1
primer and ROS1-int7-R1 primer.
Described herein are methods of: identifying, assessing or detecting a
2-ROS1 fusion; methods of identifying, assessing, ting, and/or treating a
t having a cancer, e.g., a cancer having a SLC34A2-ROS1, a CD74-ROS1, or a FIGROS1
fusion; isolated SLC34A2-ROS1, CD74-ROS1, or a FIG-ROS1 nucleic acid
molecules, c acid constructs, host cells containing the nucleic acid les; purified
SLC34A2-ROS1, CD74-ROS1, or S1 ptides and g agents; detection
reagents (e.g., probes, primers, antibodies, kits, capable, e.g., of specific detection of
SLC34A2-ROS1, CD74-ROS1, or FIG-ROS1 nucleic acids or proteins); screening assays for
identifying les that interact with, e.g., inhibit, 5'SLC34A2-3'ROS1, 5’CD74-3’ROS1,
or a 5‘FIG-3’ROS1fusions, e.g., novel kinase inhibitors; as well as assays and kits for
evaluating, identifying, assessing and/or treating a subject having a cancer, e.g., a cancer
having one or more of a SLC34A2-ROS1, CD74-ROS1, or FIG-ROS1 fusion. The
compositions and methods identified herein can be used, for example, to identify new
SLC34A2-ROS1, CD74-ROS1, or FIG-ROS1 inhibitors; to evaluate, identify or select
subject, e.g., a patient, having a cancer; and to treat or prevent a cancer.
SLC34A2-ROS1, CD74-ROS1, and FIG-ROS1 Nucleic Acid Molecules.
Described herein is a nucleic acid molecule (e.g., an isolated or purified) nucleic acid
molecule that es a fragment of a SLC34A2, or a CD74, or a FIG gene and a fragment
of a ROS1 proto-oncogene. In one embodiment, the nucleic acid molecule includes a fusion,
e.g., an in-frame fusion, of at least one exon of SLC34A2, CD74, or FIG and an exon of
ROS1 (e.g., one or more exons encoding a ROS1 ne kinase domain or a fragment
thereof).
In an illustrative embodiment, the 5'SLC34A2-3'ROS1 nucleic acid molecule
comprises ient SLC34A2 and sufficient ROS1 ce such that the encoded
'SLC34A2-3'ROS1 fusion has constitutive kinase activity, e.g., has elevated activity, e.g.,
kinase ty, as compared with wild type ROS1, e.g., in a cell of a cancer referred to
herein. In an embodiment the encoded 5'SLC34A2-3'ROS1 fusion comprises at least 1, 2, 3,
4, 5, 6, 7, 9, 10, or 11 exons from SLC34A2 and at least 1, 2, 3, 4, 5, 6, 7, 9,10, 11, 12, or 13
ROS1 exons. In one embodiment, the encoded 4A2-3'ROS1 fusion polypeptide
includes a helical domain, or a functional fragment thereof, and a ROS1 tyrosine kinase
domain or a functional nt thereof.
In an illustrative embodiment, the 5'CD74-3'ROS1 nucleic acid molecule
comprises sufficient CD74 and sufficient ROS1 sequence such that the encoded 5'CD74-
3'ROS1 fusion has constitutive kinase activity, e.g., has elevated activity, e.g., kinase activity,
as compared with wild type ROS1, e.g., in a cell of a cancer referred to . In an
embodiment, the encoded 5'CD74-3'ROS1 fusion comprises at least 1, 2, 3, 4, 5, 6, exons
from CD74 and at least 1, 2, 3, 4, 5, 6, 7, 9,10, 11, 12, or 13 ROS1 exons. In one
embodiment, the encoded 5'CD74-3'ROS1 fusion polypeptide includes a helical; anchor
for type II membrane protein domain, or a functional fragment thereof, and a ROS1
tyrosine kinase domain or a functional fragment thereof.
In an illustrative embodiment, the 5'FIG-3'ROS1 c acid molecule
comprises sufficient FIG and sufficient ROS1 sequence such that the encoded 5'FIG-3'ROS1
fusion has constitutive kinase activity, e.g., has elevated activity, e.g., kinase activity, as
compared with wild type ROS1, e.g., in a cell of a cancer referred to herein. In an
embodiment the encoded 5'FIG-3'ROS1 fusion comprises at least 1, 2, 3, 4, 5, 6, 7, or 8 exons
from FIG and at least 1, 2, 3, 4, 5, 6, 7, 9,10, 11, 12, or 13 ROS1 exons. In one embodiment,
the encoded 3'ROS1 fusion polypeptide includes a coiled coil domain, or a functional
fragment thereof, and a ROS1 tyrosine kinase domain or a functional nt thereof.
In one embodiment, the SLC34A2-ROS1 fusion nucleic acid molecule
includes a nucleotide ce that has an in-frame fusion of exon 2 and/or 4 of SLC34A2
with exon 32, and/or 34, and/or 35 of ROS1. In another embodiment, the c acid
molecule includes a nucleotide sequence that includes a breakpoint. For example, the
SLC34A2-ROS1 fusion can include an in-frame fusion of at least exon 4 of SLC34A2 or a
nt thereof (e.g., exons 1-4 of 2 or a fragment thereof) with at least exon 32
and/or 34 of ROS1 or a fragment thereof (e.g., exons 30-43 of ROS1 or a fragment thereof).
In certain ments, the 2-ROS1 fusion is in a 5'-SLC34A2 to 3'-ROS1
configuration. In one ment, the nucleic acid molecule includes the nucleotide
sequence of exons 1-4 of the SLC34A2 gene, or a fragment thereof. In another embodiment,
the nucleic acid molecule includes the nucleotide sequence of exons 30-43 e.g. 32, and/or 34,
and/or 35 of the ROS1 gene, or a fragment thereof, or a sequence substantially identical there
In one embodiment, the CD74-ROS1 fusion c acid molecule includes a
nucleotide sequence that has an in-frame fusion of exons 1-6 of CD74 with exon 32, and/or
34 of ROS1. In another embodiment, the nucleic acid molecule includes a tide
sequence that includes a breakpoint. For example, the CD74-ROS1 fusion can include an inframe
fusion of at least exon 6 of CD74 or a fragment thereof (e.g., exons 1-6 of CD74 or a
fragment f) with at least exon 32 and/or 34, and/or 35 of ROS1, or a fragment thereof
(e.g., exons 30-43 of ROS1 or a fragment thereof). In certain embodiments, the CD74-ROS1
fusion is in a 5'-CD74 to 3'-ROS1 configuration. In one embodiment, the nucleic acid
molecule includes the nucleotide ce of exons 1-6 of the CD74 gene, or a fragment
thereof. In r embodiment, the nucleic acid molecule includes the nucleotide sequence
of exons 30-43 e.g. 32, and/or 34 and/or 35 of the ROS1 gene, or a nt f, or a
sequence substantially identical there to.
In one embodiment, the FIG-ROS1 fusion nucleic acid molecule includes a
nucleotide sequence that has an in-frame fusion of exons 1-8, e.g. 1-4, or 1-8 of FIG with
exon 32, and/or 34, and/or 35 of ROS1. In another embodiment, the nucleic acid molecule
includes a nucleotide sequence that includes a breakpoint. For example, the S1
fusion can include an in-frame fusion of at least exon 4 and/or exon 8 of FIG or a fragment
thereof (e.g., exons 1-4, or 1-8, of FIG or a fragment thereof) with at least exon 32 and/or 34,
and/or 35 of ROS1 or a fragment thereof (for example, exons 30-43 of ROS1 or a fragment
thereof). In certain embodiments, the FIG-ROS1 fusion is in a 5'-CD74 to 3'-ROS1
configuration. In one embodiment, the nucleic acid molecule includes the nucleotide
sequence of exons 1-6 of the CD74 gene, or a fragment thereof. In another embodiment, the
c acid molecule includes the nucleotide sequence of exons 30-43 e.g. 32, and/or 34,
and/or 35 of the ROS1 gene, or a fragment thereof, or a sequence substantially identical there
In other embodiments, the SLC34A2-ROS1 fusion nucleic acid molecule
includes a nucleotide sequence encoding a 2-ROS1 fusion ptide that includes
a fragment of a SLC34A2 gene and a fragment of a ROS1 proto-oncogene. In one
embodiment, the nucleotide sequence encodes a SLC34A2-ROS1 fusion polypeptide that
includes a helical domain or a functional fragment thereof, and a ROS1 tyrosine kinase
domain or a functional fragment thereof.
In another embodiment, the CD74-ROS1 fusion nucleic acid molecule
includes a OS1 fusion that includes a fusion junction between the ROS1 transcript
and the CD74 transcript. In another embodiment, the c acid molecule includes a
fusion, e.g., an me fusion, of at least exon 32, or 34, or 35 of ROS1 or a fragment
f (e.g., exons 30-43 of ROS1 or a fragment thereof), and at least exon 1 or a nt
thereof (e.g., exons 1-6 of CD74 or a fragment thereof). In certain embodiments, the CD74-
ROS1 fusion is in a 5'- CD74 to 3'- ROS1 configuration. In one ment, the nucleic
acid molecule includes the nucleotides corresponding to exons 30-43 of a ROS1 gene, e.g.
exons 32, 34, or 35 or a fragment thereof, or a sequence substantially identical there to.
In another ment, the S1 fusion nucleic acid molecule includes
a FIG-ROS1 fusion that includes a fusion junction between the ROS1 transcript and the FIG
transcript. In r embodiment, the nucleic acid molecule includes a fusion, e.g., an inframe
fusion, of at least exon 32, or 34, or 35 of ROS1 or a fragment thereof (e.g., exons 30-
43 of ROS1 or a fragment thereof), and at least exon 4 or 8 a fragment thereof (e.g., exons 1-
8 of FIG or a nt f). In certain ments, the FIG-ROS1 fusion is in a 5'- FIG
to 3'- ROS1 configuration. In one ment, the nucleic acid molecule includes the
nucleotides corresponding to exons 30-43 of a ROS1 gene, e.g. exons 32, 34, or 35 or a
fragment thereof, or a sequence substantially identical there to.
Described herein are nucleic acid constructs that include the SLC34A2-ROS1,
CD74-ROS1, and FIG-ROS1fusion nucleic acid molecules bed herein. In certain
embodiments, the nucleic acid molecules are operatively linked to a native or a heterologous
regulatory sequence. Also included are vectors and host cells that include the SLC34A2-
ROS1 nucleic acid molecules described herein, e.g., vectors and host cells suitable for
producing the nucleic acid les and ptides described herein.
] Described herein are nucleic acid molecules that s or inhibits the
expression of a nucleic acid molecule that s a SLC34A2-ROS1 fusion described
herein. Examples of such c acid molecules include, for example, antisense molecules,
ribozymes, RNAi, triple helix molecules that hybridize to a nucleic acid encoding SLC34A2-
ROS1, CD74-ROS1, and FIG-ROS1 or a transcription regulatory region of SLC34A2-ROS1,
CD74-ROS1, and FIG-ROS1and blocks or reduces mRNA expression of SLC34A2-ROS1,
CD74-ROS1, or FIG-ROS1.
Described herein is a nucleic acid molecule, e.g., nucleic acid fragment,
suitable as probe, primer, bait or y member that includes, flanks, hybridizes to, which
are useful for identifying, or are otherwise based on, the ROS1 fusions described herein. In
certain embodiments, the probe, primer or bait le is an oligonucleotide that allows
capture, detection or isolation of a ROS1 fusion nucleic acid molecule described herein. The
oligonucleotide can comprise a nucleotide sequence substantially complementary to a
nt of the ROS1 fusion nucleic acid molecules described herein. The sequence identity
between the nucleic acid fragment, e.g., the oligonucleotide, and the target ROS1fusion
sequence need not be exact, so long as the sequences are sufficiently complementary to allow
the capture, detection or isolation of the target sequence. In one embodiment, the nucleic acid
fragment is a probe or primer that includes an oligonucleotide between about 5 and 25, e.g.,
between 10 and 20, or 10 and 15 tides in length. In other embodiments, the nucleic
acid fragment is a bait that includes an oligonucleotide between about 100 to 300 tides,
130 to 230 tides, 150 to 200 nucleotides, 200 to 350, 350 to 950, 300 to 600, 500-
1000, 750- 2000, nucleotides 00 nucleotides, in length and do not necessarily include the
ROS1 fusion nucleic acids.
In one embodiment, the nucleic acid fragment can be used to identify or capture,
e.g., by hybridization, a SLC34A2-ROS1 fusion, or a CD74-ROS1 fusion, or a S1
fusion. In an illustrative example, the c acid fragment can be a probe, a primer, for use
in identifying or capturing, e.g., by hybridization under moderate to high stringency
conditions, a SLC34A2-ROS1 fusion or a CD74-ROS1 fusion, or a FIG-ROS1 fusion
described herein. In one embodiment, the nucleic acid fragment can be useful for identifying
or capturing a SLC34A2-ROS1, or a CD74-ROS1, or a FIG-ROS1 breakpoint. In one
exemplary embodiment, the nucleic acid fragment hybridizes to a nucleotide sequence within
a chromosomal ngement that creates an in-frame fusion of exon 4 or 13 of SLC34A2
with exon 32, 34, or 35 of ROS1 (e.g., a sequence within a translocation on chromosome 6).
The probes or primers described herein can be used, for example, for FISH
detection or PCR amplification, or for RT-PCT confirmation of ROS1 rearrangements and
identification of binding partners. In one ary embodiment where detection is based on
PCR, amplification of the SLC34A2-ROS1, or CD74-ROS1, or FIG-ROS1 fusion junctions
can be performed using a primer or a primer pair, e.g., for amplifying a sequence flanking the
2-ROS1, or OS1, or FIG-ROS1 fusion junctions described herein, e.g., the
mutations or the junction of a somal rearrangement described herein. In one
embodiment, a pair of isolated oligonucleotide primers can amplify a region ning or
adjacent to a on in the SLC34A2-ROS1 fusion. For example, forward primers can be
designed to hybridize to a nucleotide sequence within SLC34A2, CD74, or FIG c or
mRNA ce. In various embodiments, primers to ROS1, SLC34A2, and FIG (various
species including human) are commercially available from Qiagen (Cat. Nos. QF0018545,
QF00449078, and QF00278992 Qiagen, Gaithersburg, MD, USA). In other embodiments,
confirmation of the presence of ROS1 fusion polynucleotides can be performed on patient’s
tumor samples using a panel of PCR primers including SLC34A2 exon 4 and CD74 exon 6
forward primers paired each with a ROS1 exon 32 and exon 34 reverse primer. RNA from
the tumor sample can be extracted from FFPE tissue using the Agencourt Formapure method
(Agencourt Biosciences, Beverly, MA, USA) and reverse transcribed using the Superscript
III cDNA sis kit commercially available from Invitrogen, ad, CA, USA. The
following s can be used to determine SLC34A2-ROS1 or CD74-ROS1 breakpoints:
SLC34A2 exon 4 forward, TCGGATTTCTCTACTTTTTCGTG (SEQ ID NO:3); CD74 exon
6 forward, CTCCTGTTTGAAATGAGCAGG (SEQ ID NO:4); ROS1 exon 32 reverse,
GGAATGCCTGGTTTATTTGG (SEQ ID NO:5); and ROS1 exon 34 reverse,
TGAAACTTGTTTCTGGTATCCAA (SEQ ID NO:6) . PCR amplifications can be
performed in any PCR l cycler, for example, a Eppendorf Mastercycler Gradient
(Eppendorf, Hamburg, Germany), using um Taq polymerase (Invitrogen) under
standard conditions with 40 ng of cDNA. cDNA was sequenced using the BigDye 3.0 kit
(Life Technologies, Carlsbad, CA).
The nucleic acid fragment can be detectably labeled with, e.g., a radiolabel, a
fluorescent label, a inescent label, a chemiluminescent label, an enzyme label, a
g pair label, or can include an affinity tag; a tag, or identifier (e.g., an adaptor, barcode
or other sequence identifier).
In another exemplary embodiment, a method of determining the presence of a
SLC34A2-ROS1, or CD74-ROS1, or FIG-ROS1 fusion comprising: directly acquiring
knowledge that a SLC34A2-ROS1, or CD74-ROS1, or FIG-ROS1 fusion nucleic acid
molecule or polypeptide is present in a sample from a subject. The sample can be a sample
comprised of fluid, cells, tissue, e.g., a tumor tissue, it can include a nucleic acid sample, a
n sample, a tumor biopsy or a circulating tumor cell or nucleic acid, it can be chosen
from a lung , including a NSCLC, a SCLC, a SCC, or a combination thereof and an
adenocarcinoma or a ma.
The method of detecting the SLC34A2-ROS1, or CD74-ROS1, or S1
fusion in a nucleic acid molecule, and by the use of any of the following methods: nucleic
acid hybridization assay, amplification-based assays, PCR-RFLP assay, real-time PCR,
sequencing, screening is, FISH, spectral karyotyping or MFISH, comparative genomic
hybridization), in situ hybridization, SSP, HPLC or mass-spectrometric genotyping.
The method detecting a SLC34A2-ROS1, or OS1, or FIG-ROS1
fusion polypeptide or protein is described including the method of contacting a protein
sample with a reagent which specifically binds to a 2-ROS1, or OS1, or
FIG-ROS1 fusion polypeptide; and detecting the formation of a complex of the SLC34A2-
ROS1, or OS1, or FIG-ROS1 fusion polypeptide and the reagent. Methods of
polypeptide ion include using a reagent labeled with a detectable group to facilitate
detection of the bound and d reagent, wherein the reagent is an antibody molecule,
wherein the level or activity the SLC34A2-ROS1, or CD74-ROS1, or FIG-ROS1 fusion is
evaluated, wherein the SLC34A2-ROS1, or CD74-ROS1, or FIG-ROS1 fusion is detected
prior to initiating, , or after, a treatment in a subject, wherein the SLC34A2-ROS1, or
CD74-ROS1, or FIG-ROS1 fusion is detected at the time of diagnosis with a cancer, wherein
the SLC34A2-ROS1, or CD74-ROS1, or FIG-ROS1 fusion is detected at a predetermined
interval, e.g., a first point in time and at least at a subsequent point in time.
] Responses to treatment are also included, ically where, responsive to a
determination of the presence of the SLC34A2-ROS1, or CD74-ROS1, or FIG-ROS1 fusion,
one or more of the following are used: (1) stratifying a patient population; (2) identifying or
selecting the subject as likely or unlikely to respond to a treatment; (3) selecting a treatment
option; and/or (4) prognosticating the time course of the disease in the subject.
An isolated or purified nucleic acid molecule that encodes a SLC34A2-ROS1, or
CD74-ROS1, or FIG-ROS1 fusion or a breakpoint comprising fragment thereof can be used
for confirmatory purpose and direct specific ent of NSCLC and lung adenocarcinoma
ROS1 fusion ve cancer using the compounds of the present invention. Other constructs
can be used to direct ic treatment of ROS1 fusion positive cancers, for example, ROS1-
rearranged NSCLC, including: an isolated or purified nucleic SLC34A2-ROS1, or CD74-
ROS1, or S1 fusion nucleic acid molecule operatively linked to a native or a
logous regulatory ce. An isolated or purified vector sing a nucleic acid
molecule that encodes a SLC34A2-ROS1, or CD74-ROS1, or FIG-ROS1 fusion or a
oint comprising fragment thereof. A host cell comprising a vector. A nucleic acid
molecule that specifically reduces or inhibits the expression of a nucleic acid molecule that
encodes a SLC34A2-ROS1, or CD74-ROS1, or FIG-ROS1 fusion, which can be selected
from an antisense molecule, ribozyme, siRNA, or triple helix molecule. An isolated or
purified SLC34A2-ROS1, or CD74-ROS1, or FIG-ROS1 fusion polypeptide or breakpoint
containing nt thereof. The isolated or purified SLC34A2-ROS1, or CD74-ROS1, or
FIG-ROS1 fusion polypeptide having a ROS1 kinase activity, and/or a dimerizing or
multimerizing activity. An isolated or purified antibody molecule that specifically binds a
SLC34A2-ROS1, or CD74-ROS1, or FIG-ROS1 fusion polypeptide. The antibody le,
wherein said antibody molecule is a monospecific antibody molecule to the SLC34A2-ROS1,
or CD74-ROS1, or FIG-ROS1 fusion polypeptide.
Examples of the method for detecting the translation product of the SLC34A2-
ROS1, or CD74-ROS1, or FIG-ROS1 fusion polynucleotide in the present disclosure are
immunostaining, western blotting, ELISA, flow cytometry, precipitation and
antibody array analysis. In these methods, an antibody that binds to a SLC34A2-ROS1, or
OS1, or FIG-ROS1 fusion polypeptide is used. Examples of such an antibody are an
antibody specific to a polypeptide containing a fusion site of the SLC34A2, or CD74, or FIG
protein and ROS1 protein (also referred to as "fusion pecific antibody" hereinafter), an
antibody that binds to a polypeptide made up of a region on the C terminal side from the
aforementioned fusion site of the ROS1 protein (also ed to as "ROS1-C terminal
antibody" hereinafter), and an antibody that binds to a polypeptide made up of a region on the
N terminal side from the aforementioned fusion site of the SLC34A2, or CD74, or FIG
protein (also referred to as " SLC34A2, or CD74, or FIG -N terminal antibody" hereinafter).
Here, "fusion site-specific antibody" means an antibody that specifically binds to a
polypeptide ning the aforementioned fusion site but does not bind to either wild-type
(normal-type) SLC34A2, or CD74, or FIG protein or wild-type (normal-type) ROS1 protein.
A SLC34A2-ROS1, or CD74-ROS1, or FIG-ROS1 fusion polypeptide can be
detected by the aforementioned fusion site-specific antibody or a combination of the
aforementioned ROS1-C terminal antibody and SLC34A2, or CD74, or FIG -N terminal
antibody. However, since almost no expression of the ROS1 n, for example, is detected
in normal lung cells, the presence of a SLC34A2-ROS1, or CD74-ROS1, or FIG-ROS1
fusion polypeptide in lung adenocarcinoma tissue can be detected even if the ROS1-C
terminal dy alone is used in immunostaining.
In various ments, immunohistochemical staining (IHC) and western
blotting applications for the identification of ROS1 fusion polypeptides of the present
disclosure can be med using o-ROS1, ROS1antibodies that are commercially
available from Cell ing Technology (Danvers, MA, USA). In one embodiment,
identification of ROS1 fusion ve cancer cells, for example NSCLC ROS1 rearranged
lung cancer cells can be made with rabbit anti-ROS1monoclonal antibody D4D6, Cat. No.
3287 (Cell Signaling Technology, Danvers, MA, USA).
In some embodiments, the "antibody that binds to a SLC34A2-ROS1, or CD74-
ROS1, or FIG-ROS1 fusion polypeptide" can be prepared by a person skilled in the art
selecting an appropriate known method. An example of such known methods is a method in
which an immune animal is inoculated with the aforementioned polypeptide made up of a C
al portion of the ROS1 protein, a SLC34A2-ROS1, or CD74-ROS1, or FIG-ROS1
fusion polypeptide, the aforementioned polypeptide made up of an N terminal portion of the
SLC34A2, or CD74, or FIG protein, etc. thereby ting the immune system of the animal,
and then the blood serum of the animal is recovered (polyclonal antibody), and methods for
producing monoclonal dies such as the oma method, recombinant DNA method
and phage display method. If an antibody to which a labeled substance is bound is used, the
target protein can be directly detected by detecting the label. The labeled substance is not
particularly limited provided that it can bind to the antibody and can be ed. Examples
include peroxidase, β-D-galactosidase, microperoxidase, horseradish peroxidase (HRP),
fluorescein isothiocyanate (FITC), rhodamine isothiocyanate (RITC), alkali phosphatase,
, and radioactive substances. Furthermore, in on to s that directly detect a
target protein using an antibody to which a labeled substance is bound, methods that
ctly detect the target protein using protein G, protein A or a secondary antibody to
which a labeled substance is bound may also be used.
If the presence of a SLC34A2-ROS1, or OS1, or FIG-ROS1 fusion
polynucleotide or polypeptide is detected in a specimen isolated from a subject by the
aforementioned methods, it is judged that efficacy of cancer treatment by a ROS1 tyrosine
kinase inhibitor such as a compound of Formula I, Ia or compound 1, or a pharmaceutically
acceptable salt thereof, will be high in that patient, whereas if the presence of a SLC34A2-
ROS1, or CD74-ROS1, or FIG-ROS1 fusion polynucleotide is not detected, it is judged that
efficacy of cancer treatment by a ROS1 tyrosine kinase inhibitor will be low in that patient.
As bed above, any of the polynucleotides stated in (a) through (c) below
having a chain length of at least 15 bases may be advantageously used in detecting the
presence or absence of a SLC34A2-ROS1, or CD74-ROS1, or FIG-ROS1 fusion
polynucleotide;
(a) a cleotide that is at least one probe selected from the group made up of
probes that ize to a polynucleotide that encodes the SLC34A2, or CD74, or FIG protein
and probes that hybridize to a polynucleotide that encodes the ROS1 n.;
(b) a polynucleotide that is a probe that hybridizes to a fusion site of a
polynucleotide that encodes the SLC34A2, or CD74, or FIG protein and a polynucleotide that
encodes the ROS1 protein;
(c) a polynucleotide that is a pair of primers designed to sandwich a fusion site of
a polynucleotide that encodes the SLC34A2, or CD74, or FIG protein and a polynucleotide
that encodes the ROS1 protein.
These cleotides have a base sequence complementary to the specific base
sequence of the target gene. Here, "complementary" may mean not completely
complementary, provided that it hybridizes, for example, under mopderate to high stringency
conditions. For example, these polypeptides have 80% or , preferably 90% or higher,
more preferably 95% or higher, and most preferably 100% homology with the ied base
sequence.
In the polynucleotides of (a) through (c), in part or all of DNA or RNA,
nucleotides may be substituted with artificial nucleic acids such as PNA (polyamide nucleic
acid, peptide nucleic acid), LNA (trademark, locked nucleic acid, bridged nucleic acid), ENA
mark, 2'-O, 4'-C-ethylene-bridged nucleic acids), GNA (glycerol nucleic acid) and TNA
(threose c acid).
Further, as described above, an antibody that binds to a SLC34A2-ROS1, or
CD74-ROS1, or S1 fusion polypeptide is advantageously used in detecting the
translation product of a SLC34A2-ROS1, or CD74-ROS1, or FIG-ROS1 fusion
polynucleotide. Accordingly, described herein is a drug for determining the effectiveness of
cancer treatment by a ROS1 tyrosine kinase inhibitor, comprising this antibody.
The detection method of a fusion gene described herein includes a step of
detecting the presence of polynucleotides of the present specification in a sample obtained
from a test subject. As the sample obtained from a test t, substances collected from a
test subject (samples isolated from a living body), specifically, any types of body fluid
(preferably blood) collected, alveolar and bronchial washings, samples having undergone
biopsy, and phlegm samples are used. Preferably, a biopsy sample or a phlegm sample from
an ed area in the lung of a test subject is used. From the sample, genome DNA can be
ted and used. In addition, transcripts thereof (products produced as a result of
ription and translation of a ; for example, mRNA, cDNA and proteins) can be
used. Particularly, it is preferable to e and use mRNA or cDNA.
Genome DNA can be extracted by known methods, and the extraction can be
easily med using a commercially available DNA extraction kit.
The step of detection can be performed according to known gene analysis
methods (for example, known methods that are commonly used as gene detection methods
such as PCR, LCR (Ligase chain reaction), SDA (Strand displacement amplification),
NASBA (Nucleic acid sequence-based amplification), ICAN (Isothermal and chimeric
primer-initiated ication of c acids), LAMP (Loop-mediated isothermal
ication) method, TMA (Gen-Probe' s TMA system) method, in situ hybridization
method, and microar-rays). For example, a hybridization technology in which a c acid
hybridized with a polynucleotide to be detected is used as a probe, a gene ication
technology in which DNA hybridized with a polynucleotide to be detected is used as a
primer, or the like is used.
Specifically, the detection is performed using nucleic acids derived from a sample
obtained from a test subject, for example, mRNA and the like. The amount of mRNA is
measured by a method of gene amplification reaction by using primers that are designed so as
to be able to specifically amplify the ce of a polynucleotide to be detected. The
primers used in the ion method bed herein, or the primers included in the
detection kit are not ularly limited as long as the primers can specifically amplify the
sequence of a cleotide to be detected, and designed based on the base sequence of a
cleotide to be detected. Primers used in the PCR amplification monitor method can be
designed using primer design software (for example, Primer Express manufactured by PE
tems) and the like. In addition, since the larger the size of a PCR product is, the more
the amplification efficiency worsens, it is appropriate for a sense primer and an antisense
primer to be designed such that the size of amplification products obtained when mRNA or
cDNA is amplified becomes 1 kb or less.
More specifically, a sense primer (5'-primer) is designed from a portion encoding
SLC34A2, and an antisense primer (3'-primer) is designed from a portion ng ROS1. It
is able to use the primer included in the detection kit described herein, and it is more
preferable to use the primer that is most suitably included in the detection kit. In the PCR
amplification monitor method, it is also possible to design multiplex PCR for detecting all
fusion polynucleotides in a single reaction liquid, by mixing the above sense primers
corresponding to respective genes. By the method suitable for each amplification
technology, it is possible to confirm r or not a target gene (whole gene or a specific
portion thereof) has been amplified. For example, in the PCR method, PCR products are
analyzed by agarose gel ophoresis and subjected to ethidium bromide staining and the
like, whereby it is possible to confirm whether or not amplified nts having a target
size have been obtained. When the amplified fragments having a target size have been
obtained, this indicates that a polynucleotide to be detected is present in the sample
obtained from a test subject. The presence of a polynucleotide to be detected can be
detected in this manner.
The detection method of a fusion gene described herein preferably includes a step
of detecting the presence of a specific polynucleotide in a sample obtained from a test subject
by a gene amplification reaction and a step of detecting whether or not amplified fragments
having a target size have been obtained.
The detection using a hybridization technology is med using, for example,
northern hybridization, dot blotting method, DNA microarray method, and RNA protection
method. As probes used for hybridization, it is possible to use a probe which comprises
sequences consisting of 16 bases respectively upstream and downstream of the fusion point
as a center of a nucleic acid molecule consisting of at least 32 consecutive bases hybridizing
with a polynucleotide to be ed or with a complementary strand thereof under a
moderate to high stringency conditions (preferably under a high ency condition), or
comprises complementary strands thereof.
It is also possible to use a gene amplification technology such as RT-PCR. In
the RT-PCR method, the PCR amplification monitor (real time PCR) method is med
during the process of gene amplification, whereby the presence of a polynucleotide to be
detected can be more quantitatively analyzed. PCR amplification monitor methods can be
used. Real time PCR is a known method, and can be simply performed using cially
available instruments and kits for this method.
The detection method of a fusion protein of some of the embodiments described
herein includes a step of detecting the presence of a specific polypeptide in a sample
obtained from a test subject, that is, a polypeptide encoded by a polynucleotide to be
detected (hereinafter, called a polypeptide to be detected). Such a detection step can be
performed by immunoassay method or enzyme activity assay method that is conducted by
preparing a solubilized liquid derived from a sample ed from a test t (for
e, a cancer tissue or cells obtained from a test t) and ing a polypeptide
to be detected contained in the liquid with an anti-SLC34A2, or an anti-CD74, or an anti-
FIG antibody and an anti-ROS1 antibody. Preferably, it is possible to use techniques using
a monoclonal antibody or a polyclonal dy specific to a polypeptide to be detected,
such as enzymatic immunoassay method, double antibodies sandwich ELISA ,
scence immunoassay method, radioimmunoassay method, and western blotting
method.
When the polynucleotide to be detected or polypeptide to be detected in the
detection method described herein is detected from a sample obtained from a test subject, the
test t is a subject (patient) who has cancer with the polynucleotide positive and is to be
provided with ent using ROS1 inhibitors.
The detection kit described herein comprises at least sense and antisense primers
that are designed so as to be able to specifically amplify a polynucleotide to be detected in the
detection method described herein. The sense and antisense primer set is a set of
polynucleotides functioning as primers for ying a polynucleotide to be detected.
In one embodiment, the primer set described herein for the detection of a fusion
gene comprises (1) a primer set which comprises a sense primer designed from a portion
encoding SLC34A2, or CD74, or FIG and an antisense primer designed from a portion
encoding ROS1 and is for detecting a fusion gene of SLC34A2, or CD74, or FIG and ROS1
gene, wherein the anti-sense primer consists of a nucleic acid molecule (preferably a
c acid le consisting of at least 16 bases) hybridizing with a “polynucleotide to
be detected” under moderate to high stringencyconditions (preferably under high stringency
conditions), and the sense primer consists of a nucleic acid molecule rably a nucleic
acid molecule consisting of at least 16 bases) izing with a complementary strand of
the “polynucleotide to be detected” under a stringent condition (preferably under high
stringency conditions).
The following primer sets (2) and (3) are included in the primer set as more
specific variants of primer set (1).
(2) A primer set of a sense primer that consists of an oligonucleotide consisting of
at least any 16 consecutive bases.
] (3) A primer set of a sense primer that consists of an oligonucleotide consisting of
at least any 16 consecutive bases.
In these primer sets (1) to (3), an interval between the ons where the sense
primer and the anti-sense primer are selected is preferably 1 kb or less, or the size of an
amplification product amplified by the sense primer and the antisense primer is ably 1
kb or less.
In addition, the primer has a strand length consisting of 15 to 40 bases in general,
preferably consisting of 16 to 24 bases, more preferably consisting of 18 to 24 bases, and
particularly preferably consisting of 20 to 24 bases.
The primer set can be used for amplifying and ing a polynucleotide to be
detected. er, though not particularly limited, the respective primers included in the
primer set of the present disclosure can be prepared by, for example, al synthesis.
Exemplary ROS1, SLC34A2, or CD74 primers operable to detect ROS1 fusion
polynucleotides are provided in Table 2.
Table 2. Exemplary primer set for fying various ROS1 fusion proteins in accordance
with the present disclosure.
Primer name Primer Sequence (5’-3’)
ROS1 InvPCR F1 GTCTGGCATAGAAGATTAAAG (SEQ ID NO: 7)
ROS1 InvPCR F2 AAACGAAGACAAAGAGTTGG (SEQ ID NO: 8)
ROS1 InvPCR R1 GTCAGTGGGATTGTAACAAC (SEQ ID NO: 9)
ROS1 InvPCR R2 AAACTTGTTTCTGGTATCC (SEQ ID NO: 10)
ROS1 Break Rev1 AGCCAACTCTTT (SEQ ID NO: 11)
TCTATTTCCCAAACAACGCTATTAATCAGACCC (SEQ
ROS1 E43R1
ID NO: 12)
ROS1 E34R TTGTTTCTGGTATCCAA (SEQ ID NO: 13)
CD74 E5F CCTGAGACACCTTAAGAACACCA (SEQ ID NO: 14)
SLC34A2 E4F TCGGATTTCTCTACTTTTTCGTG (SEQ ID NO: 15)
A method of screening an anticancer drug includes: contacting a sample
compound to a cell expressing the fusion protein; and ing the fusion protein
expression level in the cell, n the fusion protein expression level in the cell d with
the sample compound is decreased compared with that before the treatment with the sample
compound or that in a eated cell, the sample compound is determined as a candidate
compound for the anticancer drug.
The method of screening an anticancer drug may further include the step of
measuring the fusion protein expression level in the cell before the treatment of the sample
compound. In this case the sample compound may be determined as a candidate compound
for the anticancer drug when the fusion protein expression level after treatment of the sample
compound is decreased compared with that before the treatment with the sample compound
in the same cell. Alternatively, the method of screening an anticancer drug may include
providing cells expressing the fusion protein, and contacting a sample compound to a part of
the provided cells. In this case the sample compound may be determined as a ate
compound for the anticancer drug when the fusion protein expression level in the cell
contacted with the sample compound is decreased compared with that in the cells which are
not contacted with the sample compound.
The cell used in the screening method may be a cell d from a cancer cell
where the fusion gene or the fusion protein is expressed and/or activated, an extract of the cell,
or a culture of the cell. The cancer cell may be a solid cancer cell, in particular a lung cancer,
for e a non-small cell lung cancer such as a lung adenocarcinoma, as described above.
Still another embodiment provides a method of screening an anticancer drug
against lung cancer including: treating a cell expressing the fusion protein with a sample
compound; measuring the fusion protein expression level in the cell, n the fusion
protein expression level in the cell d with the sample compound is decreased compared
with that before the treatment with the sample compound or that in a non-treated cell, the
sample compound is determined as a candidate nd for the ncer drug against lung
cancer.
The ROS1 fusion proteins (i.e. SLC34A2-ROS1, CD74-ROS1, and FIGROS1
) can be used as a marker for diagnosing a lung cancer or for treating or preventing or
treating a lung . The treatment or prevention of lung cancer comprises the step of
administering a therapeutically effective amount of at least one inhibitor against the fusion
protein, at least one inhibitor t the fusion gene encoding the fusion protein, at least one
inhibitor against a ROS1 coding gene, or .a combination thereof, to a patient in need thereof.
The inhibitor can be such as Formula I, Ia or compound 1, or a pharmaceutically acceptable
salt thereof.
] Another embodiment provides a method of preventing and/or treating a cancer,
comprising administering a pharmaceutically (therapeutically) effective amount of at least
one inhibitor against the fusion protein, at least one inhibitor against the fusion gene encoding
the fusion protein, at least one inhibitor against a ROS1 coding gene, or a combination
thereof, to a patient in need thereof, any of which may be the compounds of Formula 1 and
the other specific compounds disclosed herein. The method may further comprise the step of
identifying the patient who needs the prevention and/or treatment of a cancer, prior to the step
of administering such treatment. Another ment provides a composition for preventing
and/or treating a cancer, sing administering at least one inhibitor against the fusion
protein, including a 1, either alone or with at least one inhibitor against the fusion
gene encoding the fusion protein, at least one inhibitor against a ROS1 coding gene, or a
combination thereof. Another embodiment provides a use of an inhibitor against the fusion
protein, an inhibitor against the fusion gene encoding the fusion protein, an inhibitor against a
ROS1 coding gene, or a combination thereof, for ting and/or treating a cancer. The
inhibitor can be such as Formula I, Ia or nd 1, or a ceutically acceptable salt
thereof.
In the present sure, the cancer may be a lung , in particular a small
cell lung cancer (SCLC) or a non-small cell lung cancer (NSCLC) such as a lung
adenocarcinoma, a squamous cell lung carcinoma, or a large cell lung carcinoma.
The composition wherein the inhibitor against the ROS1 fusion n is at least
one ed from the group consisting of an aptamer specifically binding to the fusion
protein, an antibody specifically binding to the fusion protein and the inhibitor against the
fusion gene or the ROS1 coding gene is at least one selected from the group consisting of
siRNA, shRNA, miRNA, and an r, which are capable of specifically binding to the
fusion gene or the ROS1 coding gene.
Any ROS1 kinase inhibitor that inhibits the sion of ROS1 and/or ROS1
kinase activity (e.g., transcription, translation, or stability) may be used alone or in
combination with the compound of Formula I, Ia, or compound 1, or a pharmaceutically
able salt thereof.
The inhibiting agent may be ROS1-specific, or it may be non-specific (e.g., nonspecific
kinase inhibitors, multi-target inhibitors). Several ROS1 kinase inhibitors have been
developed, and their al applications are being investigated. Downstream of the ROS1
kinase activity, there are kinases such as phosphatidylinositol 3 kinases (PI3K) and
extracellular signal kinases 1/2 (ERK) (Wixted JH et al. J Biol Chem 2011), and STAT3
(Hwang JH et al. Mol Endocrinol 2003; 17: 1155-1166). A drug that inhibits such
downstream signal transmission routes can also be used as an alternative to an ROS1 kinase
inhibitor or as an adjuvant, alone or in combination with the compounds of Formula 1.
In one mode, subjects judged to have a SLC34A2-ROS1, or CD74-FIG
translocation or a FIG-ROS1 deletion, are also judged as having an ROS1 mutation at a site
beyond the ocation site. An example of an ROS1 mutation is an activating mutation,
which enables constitutive kinase activity. The ROS1 activating mutation is an arbitrary
on that causes an increase in activation in comparison with the wild type mutation. For
example, an ROS1 activating mutation may bring about permanent ROS1 activation. There
may even be a secondary ROS1 ting mutation t that is associated with or is due to
the use of an ROS1 inhibitor. Mutations that give rise to an increase in ROS1 signal activity
occur because of, for example, a kinase domain point mutation, deletion, insertion,
duplication, or inversion, or combination of two or more of those, which give rise to an
increase in the ROS1 signal. For subjects who are judged to have both a ROS1 fusion
translocation or deletion as provided herein, and an ROS1 mutation, the on can also be
made to treat them with an ROS1 kinase tor. In addition, treatment/therapy may be
carried out on them based on that decision.
As described above, the effectiveness of cancer treatment by a ROS1 tyrosine
kinase inhibitor is considered to be high in a patient in whom a SLC34A2-ROS1, or a CD74-
ROS1, or a FIG-ROS1 fusion polynucleotide is detected by the method described herein. For
this reason, cancer treatment can be efficiently performed by administering a ROS1 ne
kinase inhibitor ively to those cancer patients who possess the 2-ROS1, or a
CD74-ROS1, or a FIG-ROS1 fusion gene and the ROS1 gene. Accordingly, described herein
is a method for treating cancer, comprising a step of administering a ROS1 tyrosine kinase
inhibitor which is Formula I, Ia or compound 1, or a pharmaceutically acceptable salt thereof,
to a patient in whom the effectiveness of cancer treatment by that ROS1 tyrosine kinase
inhibitor was determined to be high by the aforementioned diagnostic method described
herein.
] In the present disclosure, a men" is not only a biological specimen (for
example, cells, tissue, organ, fluid (blood, lymph fluid, etc.), digestive fluid, sputum,
alveolar/bronchial lavage fluid, urine, stools), but also includes c acid extracts e
DNA extract, mRNA extract, or cDNA preparation or cRNA preparation prepared from
mRNA extract) or protein extracts obtained from these ical specimens. This specimen
may also be one that has undergone formalin fixing treatment, l fixing treatment,
freezing treatment or paraffin embedding treatment.
Furthermore, the genome DNA, mRNA, cDNA or protein may be prepared by a
person skilled in the art after selected a suitable known technique considering the type, state
and so forth of the specimen.
In addition to the aforementioned substances (polynucleotides, antibodies) as
active ingredients, the drug of the present invention may contain other pharmaceutically
acceptable ingredients. Examples of such ingredients include buffering , emulsifiers,
suspending agents, stabilizers, preservatives, physiological saline and so forth. As buffering
agents, ates, citrates, acetates and so forth may be used. As emulsifiers, gum arabic,
sodium alginate, tragacanth and so forth may be used. As suspending agents, glycerol
monostearate, aluminum monostearate, methylcellulose, carboxymethylcellulose,
hydroxymethylcellulose, sodium lauryl sulfate and so forth may be used. As stabilizers,
propylene , diethyl e, ascorbic acid and so forth may be used. As vatives,
sodium azide, benzalkonium chloride, paraoxybenzoic acid, chlorobutanol and so forth may
be used.
Furthermore, in addition to the preparation that contains polynucleotides and
dies, preparations such as a substrate, a ve control (for example, SLC34A2-
ROS1, CD74-ROS1, or FIG-ROS1 fusion polynucleotides, SLC34A2-ROS1, CD74-ROS1,
or FIG-ROS1 fusion polypeptides, or cells that possess them, etc.) and a negative control
necessary for detection of the label appended to the polynucleotides and antibodies, a
counterstaining reagent (DAPI, etc.) used in in situ hybridization or the like, a molecule
required in detecting the antibody (for e, a secondary antibody, protein G, protein A),
and buffer solution used in dilution or washing of the dy may be combined as a kit for
use in the method described herein. This kit may include instructions for use of the kit.
Described herein is the aforementioned kit for use in the method described .
The methods of detection described herein are particularly useful when a fusion
protein is detected which consists essentially of N-terminal domain of a fusion partner and C-
terminal domain of ROS1 n encoding a kinase domain. The fusion protein may be
SLC34A2-ROS1 fusion protein consisting essentially of N-terminal domain of SLC34A2
protein or fragment thereof and C-terminal domain of ROS1 protein encoding a kinase
domain. The fusion protein may be CD74-ROS1 fusion protein consisting essentially of N-
terminal domain of CD74 protein or a fragment thereof and C-terminal domain of ROS1
protein encoding a kinase domain. The fusion protein may be FIG-ROS1 fusion protein
consisting ially of N-terminal domain of FIG protein or a fragment thereof and C-
terminal domain of ROS1 protein encoding a kinase domain. The method can be used for
diagnosing a lung cancer, ularly non small cell lung cancer and includes: detecting at
least one of a ROS1-involved chromosomal ngement including inversion,
translocation, or deletion in chromosome 6; a fusion protein wherein protein is fused with
other protein; a fusion gene encoding the fusion protein; and the pression of ROS1
compared to a standard sample from an individual without a cancer. When one of the
chromosomal rearrangements described above selected from the above group is detected in
the test , the individual for ent of a ROS1 inhibitor, such as a a I, Ia or
compound 1, or a ceutically acceptable salt thereof.
ation of Compound 1
Preparation of N-(4-{[6,7-bis(methyloxy)quinolinyl]oxy}phenyl)-N'-(4-
fluorophenyl)cyclopropane-1,1-dicarboxamide and the (L)-malate salt thereof.
The synthetic route used for the preparation of N-(4-[6,7-bis(methyloxy)quinolin
yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide and the (L)-malate salt
thereof is depicted in Scheme 1:
Scheme 1
OH Cl
O O
POCl3/CH3CN O
O N O N
O N
2,6-Lutidine
H H
N N
Pd/C
HCO2H, HCO2K O O
K2CO3,H2O, THF
O O F
EtO H
O (L)-Malic acid
F Acetone
O N O O THF
O N
Cl N
Oxalyl de H H
THF N N
1) SO2Cl2, Et3N DMF
O O THF F O O
O O O F
HO OH O .C4H6O5
F HO N
H2N O N Compound (I)
Preparation of ro–6,7–dimethoxy–quinoline
A reactor was charged sequentially with 6,7-dimethoxy-quinolineol (10.0 kg)
and acetonitrile (64.0 L). The resulting mixture was heated to approximately 65 °C and
orus oxychloride (POCl3, 50.0 kg) was added. After the addition of POCl3, the
temperature of the reaction mixture was raised to approximately 80 °C. The reaction was
deemed complete (approximately 9.0 hours) when less than 2 percent of the starting material
remained (in process high-performance liquid chromotography [HPLC] analysis). The
reaction mixture was cooled to approximately 10 °C and then quenched into a d on
of dichloromethane (DCM, 238.0 kg), 30% NH4OH (135.0 kg), and ice (440.0 kg). The
resulting mixture was warmed to approximately 14 °C, and phases were separated. The
organic phase was washed with water (40.0 kg) and concentrated by vacuum distillation to
remove the solvent (approximately 190.0 kg). Methyl-t-butyl ether (MTBE, 50.0 kg) was
added to the batch, and the mixture was cooled to approximately 10 °C, during which time
the product llized out. The solids were recovered by centrifugation, washed with n
heptane (20.0 kg), and dried at approximately 40 °C to afford the title compound (8.0 kg).
Preparation of 6,7–Dimethyl–4–(4-nitro–phenoxy)–quinoline
A reactor was sequentially charged with 4-chloro-6,7-dimethoxy-quinoline (8.0
kg), 4 nitrophenol (7.0 kg), 4 dimethylaminopyridine (0.9 kg), and 2,6 ne (40.0 kg). The
reactor contents were heated to approximately 147 °C. When the reaction was complete (less
than 5 percent starting material remaining as determined by in process HPLC analysis,
approximately 20 hours), the reactor contents were allowed to cool to approximately 25 °C.
Methanol (26.0 kg) was added, followed by potassium carbonate (3.0 kg) dissolved in water
(50.0 kg). The reactor contents were stirred for approximately 2 hours. The resulting solid
precipitate was filtered, washed with water (67.0 kg), and dried at 25 °C for approximately 12
hours to afford the title compound (4.0 kg).
Preparation of 4–(6,7 –Dimethoxy–quinoline–4–yloxy)–phenylamine
A solution containing potassium formate (5.0 kg), formic acid (3.0 kg), and water
(16.0 kg) was added to a mixture of methoxy(4-nitro-phenoxy)-quinoline (4.0 kg),
percent palladium on carbon (50 percent water wet, 0.4 kg) in ydrofuran (THF, 40.0
kg) that had been heated to imately 60 °C. The addition was carried out such that the
ature of the on mixture remained approximately 60 °C. When the reaction was
deemed complete as determined using in-process HPLC analysis (less than 2 t starting
material remaining, lly 1 5 hours), the reactor contents were filtered. The filtrate was
concentrated by vacuum distillation at approximately 35 °C to half of its original volume,
which resulted in the itation of the product. The t was recovered by filtration,
washed with water (12.0 kg), and dried under vacuum at approximately 50 °C to afford the
title compound (3.0 kg; 97 percent area under curve (AUC)).
Preparation of 1-(4-Fluoro-phenylcarbamoyl)-cyclopropanecarboxylic acid
Triethylamine (8.0 kg) was added to a cooled (approximately 4 °C) solution of
commercially available cyclopropane-1,1-dicarboxylic acid (2 1, 10.0 kg) in THF (63.0 kg) at
a rate such that the batch temperature did not exceed 10 °C. The solution was stirred for
approximately 30 minutes, and then thionyl chloride (9.0 kg) was added, g the batch
temperature below 10 °C. When the on was te, a solution of 4–fluoroaniline (9.0
kg) in THF (25.0 kg) was added at a rate such that the batch temperature did not exceed 10
°C. The mixture was stirred for approximately 4 hours and then diluted with isopropyl acetate
(87.0 kg). This solution was washed sequentially with aqueous sodium hydroxide (2.0 kg
dissolved in 50.0 L of water), water (40.0 L), and aqueous sodium chloride (10.0 kg dissolved
in 40.0 L of water). The organic solution was concentrated by vacuum distillation followed
by the addition of e, which resulted in the precipitation of solid. The solid was
recovered by centrifugation and then dried at approximately 35 °C under vacuum to afford
the title compound. (10.0 kg).
Preparation of 1-(4-Fluoro-phenylcarbamoyl)-cyclopropanecarbonyl chloride
] Oxalyl chloride (1.0 kg) was added to a solution of 1-(4-fluoro-phenylcarbamoyl)-
cyclopropanecarboxylic acid (2.0 kg) in a mixture of THF (11 kg) and N, N-
dimethylformamide (DMF; 0.02 kg) at a rate such that the batch temperature did not exceed
°C. This on was used in the next step without further processing.
Preparation of N-(4-{[6,7-bis(methyloxy)quinolinyl]oxy}phenyl)-N'-(4-
fluorophenyl)cyclopropane-1,1-dicarboxamide
The solution from the previous step containing 1-(4-fluoro-phenylcarbamoyl)-
cyclopropanecarbonyl chloride was added to a mixture of 4-(6,7-dimethoxy-quinoline
yloxy)-phenylamine (3.0 kg) and potassium carbonate (4.0 kg) in THF (27.0 kg) and water
(13.0 kg) at a rate such that the batch temperature did not exceed 30 °C. When the reaction
was complete (in typically 10 minutes), water (74.0 kg) was added. The mixture was stirred
at 15-30 °C for approximately 10 hours, which resulted in the precipitation of the t.
The product was recovered by filtration, washed with a pre-made solution of THF (11.0 kg)
and water (24.0 kg), and dried at approximately 65 °C under vacuum for imately 12
hours to afford the title compound (free base, 5.0 kg). 1H NMR (400 MHz, d6-DMSO): δ 10.2
(s, 1H), 10.05 (s, 1H), 8.4 (s, 1H), 7.8 (m, 2H), 7.65 (m, 2H), 7.5 (s, 1H), 7.35 (s, 1H), 7.25
(m, 2H), 7.15(m, 2H), 6.4 (s, 1H), 4.0 (d, 6H), 1.5 (s, 4H). LC/MS: M+H= 502.
Preparation of N-(4-{[6,7-bis(methyloxy)quinolinyl]oxy}phenyl)-N'-(4-
fluorophenyl)cyclopropane-1,1-dicarboxamide, (L) malate salt
A solution of L-malic acid (2.0 kg) in water (2.0 kg) was added to a solution of
Cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinolineyloxy)-phenyl]-amide (4-
fluoro-phenyl)-amide free base (1 5, 5.0 kg) in ethanol, maintaining a batch temperature of
approximately 25 °C. Carbon (0.5 kg) and thiol silica (0.1 kg) were then added, and the
resulting mixture was heated to imately 78 °C, at which point water (6.0 kg) was
added. The reaction mixture was then ed, followed by the addition of isopropanol (38.0
kg), and was allowed to cool to approximately 25 °C. The product was red by filtration
and washed with isopropanol (20.0 kg), and dried at approximately 65 °C to afford the title
compound (5.0 kg).
Alternative ation of N-(4-{[6,7-Bis(methyloxy)quinolinyl]oxy}phenyl)-N’-(4-
fluorophenyl)cyclopropane-1,1-dicarboxamide and the (L)-malate salt thereof.
An alternative synthetic route that can be used for the preparation of N-(4-{[6,7-
bis(methyloxy)quinolinyl]oxy}phenyl)-N’-(4-fluorophenyl)cyclopropane-1,1-
dicarboxamide and the (L)-malate salt thereof is depicted in Scheme 2, as described in
, the entire contents of which is incorporated by reference.
Scheme 2
Preparation of 4–Chloro–6,7–dimethoxy–quinoline
] A reactor was charged sequentially with 6,7-dimethoxy-quinolineol (47.0 kg)
and acetonitrile (318.8 kg). The resulting mixture was heated to approximately 60 °C and
phosphorus oxychloride (POCl3, 130.6 kg) was added. After the on of POCl3, the
temperature of the on mixture was raised to approximately 77 °C. The reaction was
deemed complete (approximately 13 hours) when less than 3% of the starting material
remained (in-process high-performance liquid chromatography [HPLC] analysis). The
reaction mixture was cooled to approximately 2-7 °C and then quenched into a d
solution of dichloromethane (DCM, 482.8 kg), 26 t NH4OH (251.3 kg), and water (900
L). The resulting mixture was warmed to approximately 20-25 °C, and phases were
separated. The organic phase was filtered h a bed of AW hyflo super-cel NF (Celite;
.4 kg) and the filter bed was washed with DCM (118.9 kg). The combined organic phase
was washed with brine (282.9 kg) and mixed with water (120 L). The phases were separated
and the organic phase was concentrated by vacuum distillation with the removal of solvent
(approximately 95 L residual volume). DCM (686.5 kg) was charged to the reactor
containing organic phase and concentrated by vacuum distillation with the removal of solvent
(approximately 90 L residual volume). Methyl t-butyl ether (MTBE, 226.0 kg) was then
charged and the temperature of the mixture was adjusted to -20 to -25 °C and held for 2.5
hours ing in solid precipitate which was then filtered and washed with n-heptane (92.0
kg), and dried on a filter at approximately 25 °C under en to afford the title nd.
(35.6 kg).
Preparation of 4–(6, 7 –Dimethoxy–quinoline–4–yloxy)–phenylamine
4-Aminophenol (24.4 kg) dissolved in methylacetamide (DMA, 184.3 kg)
was charged to a reactor containing 4-chloro-6,7-dimethoxyquinoline (35.3 kg), sodium tbutoxide
(21.4 kg) and DMA (167.2 kg) at 20-25 °C. This e was then heated to 100-
105 °C for approximately 13 hours. After the reaction was deemed complete as determined
using cess HPLC analysis (less than 2 percent starting material remaining), the r
contents were cooled at 15-20 °C and water (pre-cooled, 2-7 °C, 587 L) charged at a rate to
maintain 15-30 °C temperature . The resulting solid precipitate was filtered, washed with a
mixture of water (47 L) and DMA (89.1 kg) and finally with water (214 L). The filter cake
was then dried at approximately 25 °C on filter to yield crude 4-(6, 7-dimethoxy-quinoline
yloxy)-phenylamine (59.4 kg wet, 41.6 kg dry calculated based on LOD). Crude 4-(6, 7-
dimethoxy-quinolineyloxy)-phenylamine was refluxed (approximately 75 °C) in a mixture
of ydrofuran (THF, 211.4 kg) and DMA (108.8 kg) for approximately 1hour and then
cooled to 0–5 °C and aged for approximately 1 hour after which time the solid was filtered,
washed with THF (147.6 kg) and dried on a filter under vacuum at approximately 25 °C to
yield 4-(6,7-dimethoxy-quinolineyloxy)-phenylamine (34.0 kg).
Alternative Preparation of 4–(6, thoxy-quinolineyloxy)-phenylamine
4-chloro-6,7-dimethoxyquinoline (34.8 kg) and 4-aminophenol (30.8 kg) and
sodium tert pentoxide (1.8 equivalents) 88.7 kg, 35 weight percent in THF) were charged to a
reactor, followed by N,N-dimethylacetamide (DMA, 293.3 kg). This mixture was then
heated to 105–115 °C for approximately 9 hours. After the reaction was deemed complete as
determined using in-process HPLC analysis (less than 2 percent starting al remaining),
the reactor contents were cooled at 15-25 °C and water (315 kg) was added over a two hour
period while maintaining the temperature n 20-30 °C. The reaction mixture was then
agitated for an additional hour at 20-25 °C. The crude product was collected by filtration and
washed with a mixture of 88kg water and 82.1 kg DMA, followed by 175 kg water. The
t was dried on a filter drier for 53 hours. The LOD showed less than 1 percent w/w.
In an alternative procedure, 1.6 equivalents of sodium tert-pentoxide were used
and the reaction temperature was increased from 0 °C. In addition , the cool down
temperature was increased to 35-40 °C and the starting temperature of the water addition was
adjusted to 35-40 °C, with an allowed exotherm to 45 °C.
Preparation of 1–(4–Fluoro–phenylcarbamoyl)–cyclopropanecarboxylic acid
Triethylamine (19.5 kg) was added to a cooled ximately 5 °C) solution of
cyclopropane–1,1–dicarboxylic acid (24.7 kg) in THF (89.6 kg) at a rate such that the batch
temperature did not exceed 5 °C. The solution was stirred for approximately 1.3 hours, and
then thionyl chloride (23.1 kg) was added, keeping the batch temperature below 10 °C. When
the addition was complete, the solution was stirred for imately 4 hours keeping
temperature below 10 °C. A on of 4–fluoroaniline (18.0 kg) in THF (33.1 kg) was then
added at a rate such that the batch temperature did not exceed 10 °C. The mixture was stirred
for approximately 10 hours after which the reaction was deemed complete. The reaction
mixture was then diluted with isopropyl acetate (218.1 kg). This on was washed
sequentially with aqueous sodium hydroxide (10.4 kg, 50 percent dissolved in 119 L of
water) further diluted with water (415 L), then with water (100 L) and finally with aqueous
sodium chloride (20.0 kg dissolved in 100 L of water). The organic solution was concentrated
by vacuum distillation (100 L residual volume) below 40 °C followed by the addition of nheptane
(171.4 kg), which resulted in the precipitation of solid. The solid was recovered by
filtration and washed with n-heptane (102.4 kg), resulting in wet, crude 1-(4-fluorophenylcarbamoyl
)-cyclopropanecarboxylic acid (29.0 kg). The crude, 1-(4-fluorophenylcarbamoyl
)-cyclopropanecarboxylic acid was dissolved in ol (139.7 kg) at
approximately 25 ºC followed by the addition of water (320 L) resulting in slurry which was
recovered by filtration, washed sequentially with water (20 L) and n-heptane (103.1 kg) and
then dried on the filter at approximately 25 °C under nitrogen to afford the title compound
(25.4 kg).
Preparation of luoro-phenylcarbamoyl)-cyclopropanecarbonyl chloride
Oxalyl chloride (12.6 kg) was added to a on of luoro-phenylcarbamoyl)-
ropanecarboxylic acid (22.8 kg) in a mixture of THF (96.1 kg) and N, N-
dimethylformamide (DMF; 0.23 kg) at a rate such that the batch temperature did not exceed
°C. This solution was used in the next step without further processing.
Alternative Preparation of 1-(4-Fluoro-phenylcarbamoyl)-cyclopropanecarbonyl
chloride
A r was charged with luoro-phenylcarbamoyl)-
cyclopropanecarboxylic acid (35 kg), 344 g DMF, and 175kg THF. The reaction mixture
was adjusted to 12-17 °C and then to the reaction mixture was charged 19.9 kg of oxalyl
de over a period of 1 hour. The reaction e was left stirring at 12-17 °C for 3 to 8
hours. This solution was used in the next step without further processing.
Preparation of cyclopropane-1,1-dicarboxylic acid 7-dimethoxy-quinoline
yloxy)-phenyl]-amide (4-fluoro-phenyl)-amide
The solution from the previous step containing 1-(4-fluoro-phenylcarbamoyl)-
cyclopropanecarbonyl chloride was added to a mixture of compound 4-(6,7-dimethoxyquinolineyloxy
)-phenylamine (23.5 kg) and potassium carbonate (31.9 kg) in THF (245.7
kg) and water (116 L) at a rate such that the batch temperature did not exceed 30 °C. When
the reaction was complete (in approximately 20 minutes), water (653 L) was added. The
mixture was stirred at 20-25 °C for approximately 10 hours, which resulted in the
precipitation of the product. The product was recovered by filtration, washed with a pre-made
solution of THF (68.6 kg) and water (256 L), and dried first on a filter under nitrogen at
imately 25 °C and then at approximately 45 °C under vacuum to afford the title
compound (41.0 kg, 38.1 kg, calculated based on LOD).
ative Preparation of cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxyquinolineyloxy
)-phenyl]-amide (4-fluoro-phenyl)-amide
A reactor was d with 4-(6,7-dimethoxy-quinolineyloxy)-phenylamine
(35.7 kg, 1 equivalent), followed by 412.9 kg THF. To the reaction mixture was charged a
solution of 48.3 K2CO3 in 169 kg water. The acid de solution of described in the
ative Preparation of 1-(4-Fluoro-phenylcarbamoyl)-cyclopropanecarbonyl chloride
above was transferred to the reactor containing 4-(6,7-dimethoxy-quinolineyloxy)-
phenylamine while maintaining the temperature between 20-30 °C over a minimum of two
hours. The reaction mixture was stirred at 20-25 °C for a minimum of three hours. The
reaction temperature was then adjusted to 30-25 °C and the mixture was agitated. The
agitation was stopped and the phases of the mixture were allowed to separate. The lower
aqueous phase was removed and discarded. To the remaining upper organic phase was added
804 kg water. The reaction was left stirring at 15-25 °C for a minimum of 16 hours.
The product precipitated. The t was filtered and washed with a mixture of
179 kg water and 157.9 kg THF in two portions. The crude product was dried under a
vacuum for at least two hours. The dried product was then taken up in 285.1 kg THF. The
resulting suspension was transferred to reaction vessel and agitated until the suspension
became a clear (dissolved) solution, which required heating to 30-35 °C for approximately 30
minutes. 456 kg water was then added to the solution, as well as 20 kg SDAG-1 ethanol
(ethanol denatured with methanol over two hours. The mixture was ed at 15-25 °C fir
at least 16 hours. The product was filtered and washed with a mixture of 143 kg water and
126.7 THF in two portions. The product was dried at a maximum temperature set point of 40
In an alternative procedure, the on temperature during acid chloride
formation was adjusted to 10-15 °C. The recrystallization temperature was d from 15-
°C to 45-50 °C for 1 hour and then cooled to 15-25 °C over 2 hours.
Preparation of cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinoline
-phenyl]-amide (4-fluoro-phenyl)-amide, malate salt
Cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinolineyloxy)–
phenyl]–amide (4-fluoro-phenyl)-amide (1-5; 13.3 kg), L-malic acid (4.96 kg), methyl ethyl
ketone (MEK; 188.6 kg) and water (37.3 kg) were charged to a reactor and the mixture was
heated to reflux (approximately 74 °C) for approximately 2 hours. The r temperature
was d to 50 to 55 °C and the reactor contents were filtered. These sequential steps
described above were repeated two more times starting with similar amounts of starting
material (13.3 kg), L-Malic acid (4.96 kg), MEK (198.6 kg) and water (37.2 kg). The
combined filtrate was azeotropically dried at atmospheric pressure using MEK (1133.2 kg)
(approximate residual volume 711 L; KF < 0.5 % w/w) at approximately 74 °C. The
temperature of the reactor contents was reduced to 20 to 25 °C and held for approximately 4
hours resulting in solid precipitate which was filtered, washed with MEK (448 kg) and dried
under vacuum at 50 °C to afford the title compound (45.5 kg).
Alternative Preparation of cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxyquinolineyloxy
)-phenyl]-amide (4-fluoro-phenyl)-amide, (L) malate salt
Cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinolineyloxy)-
phenyl]-amide (4-fluoro-phenyl)-amide (47.9 kg), L-malic acid (17.2), 658.2 kg methyl ethyl
ketone, and 129.1 kg water (37.3 kg) were charged to a reactor and the mixture was heated
50-55 °C for approximately 1-3 hours, and then at 55-60 °C for an on al 4-5 hours. The
e was clarified by filtration through a 1 μm cartridge. The reactor temperature was
adjusted to 20-25 oC and vacuum led with a vacuum at 150-200 mm Hg with a
maximum jacket ature of 55 °C to the volume range of 558-731 L.
The vacuum lation was med two more times with the charge of 380 kg
and 380.2 kg methyl ethyl ketone, respectively. After the third lation, the volume of the
batch was adjusted to 18 v/w of cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxyquinolineyloxy
)-phenyl]-amide (4-fluoro-phenyl)-amide by charging 159.9 kg methyl
ethyl ketone to give a total volume of 880L. An addition al vacuum distillation was carried
out by adjusting 245.7 methyl ethyl ketone. The reaction e was left with moderate
agitation at 20-25 °C for at least 24 hours. The product was filtered and washed with 415.1
kg methyl ethyl ketone in three portions. The product was dried under a vacuum with the
jacket temperature set point at 45 °C.
In an alternative procedure, the order of addition was changed so that a solution of
17.7 kg L-malic acid dissolved in 129.9 kg water was added to cyclopropane-1,1-
dicarboxylic acid [4-(6,7-dimethoxy-quinolineyloxy)-phenyl]-amide (4-fluoro-phenyl)-
amide (48.7 kg) in methyl ethyl ketone (673.3 kg).
Biological Example
Growth of HCC-78 and NCI-H2228 cells
Both HCC-78 and NCI-H2228 cells were received from DSMZ and ATCC
tively as a frozen ical sample thawed into a T-75 flask (Nunc) and grown until
80 to 90% confluent for adherent cells or until cells were at a density of 1 - 2 x 106 cells/mL
for suspension cells.
NCI-H2228, a human lung NSCLC adenocarcinoma cell line (ATCC, CRL 5935)
harboring the activating EML4-ALK fusions, were seeded at a density of 3.5 x 104 cells/well
and 2.5 x 104 well for 48 hours or 72 hours respectively, in 0.1 ml in RPMI 1640
(ATCC 30-2001), 10 % FBS, 1 % penicillin-streptomycin onto black 96-well plates (Costar,
3904).
HCC-78, a human lung NSCLC adenocarcinoma cell line (DSMZ, ACC 563)
harboring the activating SLC34A2-ROS1 fusions and or-Met, were seeded at a density
of 2.5 x 104 cells/well and 2 x 104 cells/well for 48 hours or 72 hours respectively, in 0.1 ml
in RPMI 1640 (ATCC 30-2001), 10 % FBS (heat-inactivated, Cellgro), 1 % penicillinstreptomycin
onto black 96-well plates (Costar, 3904).
Cells were grown at 37°C in a humidified, 5% CO2 atmosphere for 16 hours.
DMSO or serial dilutions of nd 1 in fresh serum free medium or serum containing
medium were added to the cells and incubated for 48 hours or 72 hours at 37°C in a
humidified, 5% CO2 atmosphere prior to the addition of 5’-bromo-2’-deoxy ne (BrdU)
labelling solution (Roche) for 2 to 4 hours. Suspension cells were transferred to filter plates
(Corning, 3504) before performing the assay. Cells were assayed for eration by
monitoring BrdU incorporation. Reagents from the Cell Proliferation ELISA, BrdU
(chemiluminescence) kit (Roche ences, 11 669 915 001) were used ing to the
manufacturer’s instructions. After BrdU labelling, cells were fixed with FixDenat solution.
rdU peroxidase (POD) conjugate was added and plates were washed with 1x PBS.
Substrate solution was added, and luminescence measurements were taken on a Victor
Wallac V plate reader (Perkin Elmer). The tage inhibition of proliferation was
ated by ing cell eration with compound 1 treatment to DMSO treated
samples. tage inhibition values at 5 to 8 compound 1 concentrations were used to
ate IC50 values.
Biological Example
Inhibition of ROS1 phosphorylation
HCC-78 cells, a human lung NSCLC adenocarcinoma cell line (DSMZ, ACC
563) harboring the activating SLC34A2-ROS1 fusion and phosphor-Met, were seeded at 3
x105 well onto 6-well plates (Nunclon, 152795), RPMI 1640 (ATCC, 30-2001)
containing 10% FBS (heat-inactivated, Cellgro) and 1% penicillin-streptomycin (Cellgro).
DMSO or serial dilutions of compound 1 in fresh medium with 10% FBS in a final
concentration of 0.3% DMSO (vehicle) were added to the cells and incubated for 3 hour.
After treatment, cells were collected and washed with cold PBS and immediately lysed with
0.15 mL of cold lysis buffer (50 mM Tris HCl, pH 8.0, 150 mM NaCl, 1% NP 40, 0.1% SDS,
0.5% sodium deoxycholate, 1 mM EDTA, 50 mM NaF, 1 mM sodium pyrophosphate, 1 mM
Na3VO4, 2 mM PMSF, 10 μg/mL aprotinin, 5 μg/mL leupeptin and 5 µg/mL pepstatin A).
Lysates were collected, and protein concentrations were measured by the BCA method
(Pierce). Lysates were collected and protein concentrations were measured by the BCA
method (Pierce). Lysates were mixed with NuPage LDS sample buffer (Invitrogen NP0007)
and Reducing Agent (Invitrogen 4), then heated at 70°C for 10 min. 20 µg protein
was loaded onto NuPage 10% Bis Tris gels (Invitrogen, NP0302). Proteins were transferred
to nitrocellulose membranes (Invitrogen, LC2001), blocked for 1 hr. in Odyssey Blocking
Buffer (Li-Cor,927 40000), and incubated at 4°C overnight with the anti-ROS1 mouse
monoclonal antibody (1:1000) (Cell Signaling Technology, 3266) and Anti-phospho ROS1
(Y2274) rabbit antibody (1:1000) (Cell Signaling Technology, 3077) diluted in Odyssey
Blocking Buffer containing 0.1% Tween 20. Membranes were washed four times for 10 min
each with TBS T buffer (50 mM Tris HCl, pH7.2; 150 mM NaCl; 0.1% Tween 20) and
blotted with Goat anti Mouse IRDye680 (Li-Cor, 926 32220) and Goat anti Rabbit IRDye800
(Li-Cor, 926 32211) secondary antibodies in y Blocking buffer containing 0.1%
Tween 20 and 0.01% SDS for 60 min at room temperature. Membranes were washed four
times for 10 min each with TBS-T buffer and rinsed with PBS twice. The membranes were
scanned using the Odyssey Scanner (Li-Cor) and the signal intensity of each band was
quantified using ImageQuant (Molecular s). IC50 values were calculated based on the
signal with compound treatment compared to the vehicle (DMSO) control.
Inhibition of SLC34A2-ROS1mediated kinase activity in HCC-78 NSCLC cells
administered with single escalating doses of compound 1, or 3-[(1R)(2,6-dichloro
fluorophenyl)ethoxy](1-piperidinylpyrazolyl)pyridinamine (Crizotinib;
XALKORI®) is shown in Fig. 1. Fig. 1 clearly illustrates the potent inhibitory activity of
nd 1 against ROS1 fusion kinase, and is more potent than the comparator control, 3-
[(1R)(2,6-dichlorofluorophenyl)ethoxy](1-piperidinylpyrazolyl)pyridin
amine (Crizotinib) at the concentrations tested in vitro.
Biological Example
ROS1-Dependent Proliferation of HCC-78 NSCLC Cells
IC50 values were ated for compound 1 and comparator l, 3-[(1R)
(2,6-dichlorofluorophenyl)ethoxy](1-piperidinylpyrazolyl)pyridinamine
(Crizotinib) after incubation of active agents with HCC-78 NSCLC cells for 48 or 72 hours at
various concentrations. tation of proliferation of HCC-78 NSCLC cells was performed
using BrdU ELISA (chemiluminescence, Roche Biosciences, Cat. No. 11 669 915 001) in
ance with manufacturer’s recommendations. Determination of IC50 values (A-E)
ntration at 50% inhibition) were determined as provided above, and computationally
determined using GraphPad Prism software.
Table 3. ROS1-Dependent Proliferation of HCC-78 NSCLC Cells in the presence
of compound 1 of the t invention and 3-[(1R)(2,6-dichlorofluorophenyl)ethoxy]-
-(1-piperidinylpyrazolyl)pyridinamine (Crizotinib).
NCI-H2228 HCC-78
Tissue Type Lung
ogy NSCLC Adenocarcinoma
Genotype Information EML4-ALK fusion SLS34A2-ROS1 fusion
TP53 Q331*
CDKN2A M1 *157 del, ?fs:
RB1 E204fs*10
Compound Name 48 hr Prolif. 72 hr Prolif. 48 hr Prolif. 72 hr Prolif.
IC50 (nM) IC50 (nM) IC50 (nM) IC50 (nM)
Compound 1 D E A A
3-[(1R)(2,6-dichloro C C B A
fluorophenyl)ethoxy](1-
piperidinylpyrazol
yl)pyridinamine
(Crizotinib)
IC50 data ed: E- 5,000 – 10,000 nM; D- 1,000-5,000 nM; C- 500-1000 nM; B- 100-500
nM; A- 10-100 nM.
Other Embodiments
The foregoing disclosure has been described in some detail by way of illustration
and example, for purposes of clarity and tanding. The invention has been described
with reference to various specific and preferred embodiments and techniques. However, it
should be understood that many variations and modifications can be made while remaining
within the spirit and scope of the invention. It will be obvious to one of skill in the art that
changes and modifications can be practiced within the scope of the appended .
Therefore, it is to be understood that the above description is intended to be illustrative and
not restrictive.
The scope of the invention , therefore, be determined not with reference to
the above description, but should instead be determined with reference to the following
ed , along with the full scope of equivalents to which such claims are entitled.
Claims (23)
1. Use of a compound of Formula I: Formula I or a ceutically acceptable salt thereof, wherein: R1 is halo; R2 is halo; R3 is (C1-C6)alkyl; R4 is (C1-C6)alkyl; and Q is CH or N, in the manufacture of a medicament for the treatment of lung adenocarcinoma, wherein the lung adenocarcinoma is SLC34A2-ROS1, CD74-ROS1, or FIG-ROS1 fusionpositive all cell lung .
2. The use of claim 1, wherein the compound of Formula I is a compound of Formula Ia Formula Ia, or a pharmaceutically acceptable salt thereof, wherein: R1 is halo; R2 is halo; and Q is CH or N.
3. The use of claim 1 or 2, wherein the compound of Formula I is nd 1: H H N N O O CH3 O F H3C O N compound 1 or a pharmaceutically acceptable salt thereof.
4. The use of any one of claims 1-3, n the pharmaceutically acceptable salt of the compound of Formula I, Formula Ia and compound 1 is the (L)- or (D)-malate salt.
5. The use of claim 3, wherein the pharmaceutically acceptable salt of the nd 1 is the (L)-malate salt.
6. The use of claim 3, wherein the pharmaceutically acceptable salt of the compound 1 is the (L) malate salt and/or the (D) malate salt, which is in the lline N-1 form or N-2 form.
7. The use of any one of claims 1-6 wherein the medicament comprises a pharmaceutically acceptable carrier, excipient, or diluent.
8. The use of any one of claims 1-7, wherein the medicament is formulated for administration subsequent to another form of treatment.
9. The use of any one of claims 1-7, wherein the medicament is formulated for administration post-cisplatin and/or gemcitabine treatment.
10. The use of any one of claims 1-7, wherein the medicament is formulated for administration post-carboplatin treatment.
11. The use of any one of claims 1-7, wherein the medicament is formulated for administration arboplatin and/or gemcitabine treatment.
12. The use of any one of claims 1-7, wherein the medicament is formulated for administration post-cisplatin and/or carboplatin treatment.
13. The use of any one of claims 1-7, wherein the medicament is formulated for administration post-docetaxel treatment.
14. The use of any one of claims 1-7, wherein the medicament is formulated for administration post-crizotinib treatment.
15. The use of any one of claims 1-7, wherein the medicament is formulated for stration post-crizotinib and/or abine treatment.
16. The use of any one of claims 1-7, wherein the medicament is formulated for administration rizotinib and/or gemcitabine and/or docetaxel treatment.
17. The use of any one of claims 1-7, wherein the medicament is formulated for administration post-cisplatin and/or gemcitabine and/or docetaxel treatment.
18. Use of compound 1 H H N N O O CH3 O F H3C O N compound 1 or a ceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of ROS1 fusion-positive nonsmall cell lung .
19. The use of claim 18, wherein the medicament comprises at least one pharmaceutically acceptable carrier.
20. The use of claim 18 or 19, wherein the pharmaceutically acceptable salt of compound 1 is the (L)- or (D)-malate salt.
21. The use of any one of claims 18-20, wherein the ceutically acceptable salt of compound 1 is the (L)-malate salt.
22. The use of claim 20, wherein the pharmaceutically acceptable salt of compound 1 is the (L) malate salt and/or the (D) malate salt, which is in the crystalline N-1 form or N-2 form.
23. Use of any one of claims 1-22 substantially as herein described with reference to any e thereof and with or without reference to the accompanying drawings. W0
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461984599P | 2014-04-25 | 2014-04-25 | |
US61/984,599 | 2014-04-25 | ||
PCT/US2015/027800 WO2015164869A1 (en) | 2014-04-25 | 2015-04-27 | Method of treating lung adenocarcinoma |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ725576A NZ725576A (en) | 2021-03-26 |
NZ725576B2 true NZ725576B2 (en) | 2021-06-29 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2015249232B2 (en) | Method of treating lung adenocarcinoma | |
EP2892532B1 (en) | Inhibitors of met, vegfr and ret for use in the treatment of lung adenocarcinoma | |
US20150057335A1 (en) | Novel fusion genes identified in lung cancer | |
EP3030577B1 (en) | Novel nrg1 fusion genes in cancer | |
US20160058777A1 (en) | Identification and treatment of cancer subsets | |
NZ725576B2 (en) | Method of treating lung adenocarcinoma | |
JP5119546B2 (en) | Diagnosis of malignant transformation of gastrointestinal stromal tumor originating in the stomach | |
WO2022192232A1 (en) | Ep300 degrader and uses thereof in neuroblastoma |